DDI-DrugBank.d676.s2	Because IN 0	Matulane NNP B-noun.person	exhibits VBZ B-verb.communication	some DT 0	monoamine NN 0	oxidase NN 0	inhibitory JJ B-adj.all	activity NN B-noun.process	, , 0	sympathomimetic_drugs NNS B-noun.body	, , 0	tricyclic_antidepressant JJ B-adj.all	drugs NNS B-noun.artifact	( ( 0	e.g. UH 0	, , 0	amitriptyline_HCl NNP B-noun.person	, , 0	imipramine_HCl NNP B-noun.location	) ) 0	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	and CC 0	foods NNS B-noun.person	with IN 0	known VBN B-verb.cognition	high JJ B-adj.all	tyramine NN B-noun.substance	content NN I-noun.substance	, , 0	such JJ 0	as IN 0	wine NN B-noun.artifact	, , 0	yogurt NN B-noun.person	, , 0	ripe JJ B-adj.all	cheese NN B-noun.communication	and CC 0	bananas NNS B-noun.artifact	, , 0	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d757.s0	Usage NN 0	with IN 0	Alcohol NNP B-noun.person	, , 0	Due JJ 0	to TO 0	the DT 0	potential NN B-noun.person	for IN 0	increased VBN B-verb.change	CNS NNP 0	depressants NNS B-noun.animal	effects NNS B-noun.phenomenon	, , 0	alcohol NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	who WP 0	are VBP 0	currently RB B-adv.all	receiving VBG B-verb.communication	pentazocine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d181.s4	The DT 0	authors NNS B-noun.person	report VBP B-verb.communication	the DT 0	case NN B-noun.state	of IN 0	an DT 0	infant NN B-noun.person	with IN 0	confirmed VBN B-verb.cognition	congenital JJ B-adj.all	hypothyroidism NN B-noun.artifact	on IN 0	levothyroxine NN B-noun.person	who WP 0	experienced VBD B-verb.perception	a DT 0	possible JJ B-adj.all	drug NN B-noun.artifact	interaction NN 0	with IN 0	simeticone NN B-noun.person	. . 0	. . 0
DDI-MedLine.d199.s4	Based VBN B-verb.cognition	on IN 0	this DT 0	experience NN B-noun.event	, , 0	we PRP 0	suggest VBP B-verb.communication	that IN 0	low JJ 0	- : 0	dose NN 0	ketamine NN 0	added VBD B-verb.communication	to TO 0	propofol VB B-verb.social	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	prevention NN B-noun.person	of IN 0	EA NNP 0	in IN 0	children NNS B-noun.animal	with IN 0	a DT 0	history NN B-noun.cognition	of IN 0	EA NNP 0	with IN 0	propofol NN B-noun.person	TIVA NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s1	This DT 0	interaction NN B-noun.act	should MD 0	be VB 0	given VBN B-verb.possession	consideration NN B-noun.attribute	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	NSAIDs NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	ACE_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d781.s5	Potassium NNP B-noun.person	Supplements NNPS I-noun.person	and CC 0	Potassium NNP B-noun.person	- : 0	Sparing_Diuretics NNS B-noun.person	, , 0	ACEON NNP B-noun.group	___ NNP I-noun.group	Tablets NNPS I-noun.group	may MD 0	increase VB B-verb.body	serum NN 0	potassium NN 0	because IN 0	of IN 0	its PRP$ 0	potential NN B-noun.person	to TO 0	decrease VB B-verb.change	aldosterone JJ B-adj.all	production NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d653.s2	Drugs NNS B-noun.person	such JJ 0	as IN 0	troleandomycin NN B-noun.person	and CC 0	ketoconazole NN B-noun.group	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	corticosteroids NNS B-noun.food	and CC 0	thus RB B-adv.all	decrease VB B-verb.change	their PRP$ 0	clearance NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d661.s4	There EX 0	are VBP B-verb.stative	no DT 0	controlled JJ B-adj.all	studies NNS B-noun.group	documenting VBG B-verb.social	the DT 0	use NN 0	of IN 0	ZEMURON NNP B-noun.group	___ CC 0	before IN 0	or CC 0	after IN 0	other JJ B-adj.all	nondepolarizing_muscle_relaxants NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d169.s3	Our PRP$ 0	objective NN B-noun.cognition	was VBD B-verb.stative	to TO 0	establish VB B-verb.cognition	potential JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	calcium NN B-noun.artifact	on IN 0	absorption NN B-noun.act	of IN 0	nonheme NN B-noun.person	and CC 0	heme_iron NNP B-noun.person	and CC 0	the DT 0	dose NN B-noun.communication	response NN B-noun.communication	for IN 0	this DT 0	effect NN B-noun.cognition	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	a DT 0	meal NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d776.s17	Depending VBG B-verb.motion	on IN 0	clinical JJ B-adj.all	circumstances NNS B-noun.state	, , 0	consideration NN B-noun.group	should MD 0	be VB 0	given VBN B-verb.possession	to TO 0	increasing VBG B-verb.change	the DT 0	dose NN B-noun.quantity	of IN 0	DIFLUCAN JJ B-noun.group	when WRB 0	it PRP 0	is VBZ 0	administered VBN B-verb.possession	with IN 0	rifampin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d677.s1	as RB 0	well RB 0	as IN 0	atropine JJ B-adj.all	and CC 0	phosphorous_insecticides NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d220.s1	The DT 0	hepatic JJ B-adj.all	clearance NN B-noun.person	and CC 0	drug NN B-noun.person	- : 0	drug NN B-noun.person	interactions NNS I-noun.person	of IN 0	luteolin NN B-noun.substance	and CC 0	apigenin NN B-noun.person	were VBD 0	studied VBN B-verb.cognition	by IN 0	using VBG B-verb.consumption	primary JJ B-adj.all	cultured JJ B-adj.all	rat NN B-noun.person	hepatocytes NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s10	Pravastatin NNP B-noun.person	, , 0	In IN 0	a DT 0	2-way JJ B-adj.all	crossover NN B-noun.artifact	study NN B-noun.artifact	of IN 0	24 CD B-adj.all	normal JJ B-adj.all	- : 0	weight NN B-noun.attribute	, , 0	mildly RB B-adv.all	hypercholesterolemic JJ B-adj.all	patients NNS B-noun.person	receiving VBG B-verb.communication	XENICAL NNP B-noun.group	120 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	6 CD B-adj.all	days NNS B-noun.time	, , 0	XENICAL NNP B-noun.group	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	pravastatin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d761.s11	Warfarin NNP B-noun.person	, , 0	In IN 0	12 CD B-adj.all	normal JJ B-adj.pert	- : 0	weight NN B-noun.artifact	subjects NNS B-noun.artifact	, , 0	administration NN B-noun.person	of IN 0	XENICAL NNP B-noun.group	120 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	16 CD B-adj.all	days NNS B-noun.person	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	any DT 0	change NN B-noun.possession	in IN 0	either DT 0	warfarin NN B-noun.location	pharmacokinetics NNS B-noun.person	( ( 0	both DT 0	R- : 0	and CC 0	S NNP 0	- : 0	enantiomers NNS B-noun.person	) ) 0	or CC 0	pharmacodynamics NNS B-noun.person	( ( 0	prothrombin NN B-noun.person	time NN B-noun.person	and CC 0	serum NN B-noun.person	Factor NNP B-noun.group	VII NNP I-noun.group	) ) 0	. . 0	. . 0
DDI-MedLine.d178.s0	[ CC 0	Ticagrelor NNP B-noun.group	, , 0	a DT 0	novel JJ B-adj.all	antiplatelet_agent NN B-noun.act	for IN 0	patients NNS B-noun.person	with IN 0	acute JJ B-adj.all	coronary JJ B-adj.all	syndrome NN B-noun.person	] : 0	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d657.s0	Interactions NNS B-noun.person	for IN 0	Dronabinol NNP B-noun.person	, , 0	_ '' 0	In IN 0	studies NNS B-noun.act	involving VBG B-verb.stative	patients NNS B-noun.person	with IN 0	AIDS NNP B-noun.group	and/or CC 0	cancer NN B-noun.state	, , 0	MARINOL NNP B-noun.group	( ( 0	Dronabinol NNP B-noun.person	) ) I-noun.person	Capsules NNP I-noun.person	has VBZ 0	been VBN B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	a DT 0	variety NN B-noun.cognition	of IN 0	medications NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	cytotoxic JJ B-adj.all	agents NNS B-noun.person	, , 0	anti NNS B-noun.person	- : 0	infective JJ B-adj.all	agents NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	or CC 0	opioid_analgesics NNS B-noun.group	) ) 0	without IN 0	resulting VBG B-verb.stative	in IN 0	any DT 0	clinically RB B-adj.all	significant JJ B-adj.all	drug NN B-noun.attribute	/ : 0	drug NN B-noun.act	interactions NNS I-noun.act	. . 0	. . 0
DDI-DrugBank.d776.s2	These DT 0	are VBP 0	described VBN B-verb.communication	in IN 0	greater JJR B-adj.all	detail NN B-noun.group	below IN 0	, , 0	_ : 0	Oral JJ B-adj.all	hypoglycemics NNS B-noun.person	, , 0	Coumarin NNP B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	, , 0	Phenytoin NNP B-noun.person	, , 0	Cyclosporine NNP B-noun.person	, , 0	Rifampin NNP B-noun.person	, , 0	Theophylline PRP 0	, , 0	Terfenadine NNP B-noun.person	, , 0	Cisapride NNP B-noun.location	, , 0	Astemizole NNP B-noun.location	, , 0	Rifabutin NNP B-noun.person	, , 0	Tacrolimus NNP B-noun.person	, , 0	Short NNP B-noun.person	- : 0	acting_benzodiazepines NNS B-noun.person	, , 0	_ : 0	Oral JJ B-adj.all	hypoglycemics NNS B-noun.person	, , 0	Clinically RB B-adv.all	significant JJ B-adj.all	hypoglycemia NN B-noun.state	may MD 0	be VB 0	precipitated VBN B-verb.creation	by IN 0	the DT 0	use NN 0	of IN 0	DIFLUCAN JJ 0	with IN 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	, , 0	. . 0
DDI-MedLine.d174.s0	[ SYM 0	Cyclooxygenase_inhibitors NNS B-noun.person	and CC 0	antiplatelet JJ B-adj.all	effect NN B-noun.cognition	of IN 0	acetylsalicylic_acid NNP B-noun.person	. . 0	selective VB B-verb.cognition	approach NN B-noun.person	to TO 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_drugs NNS B-noun.cognition	in IN 0	cardiological JJ B-adj.all	practice NN B-noun.person	] : 0	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d756.s4	Exert NNP B-noun.person	particular JJ B-adj.all	caution NN B-noun.communication	in IN 0	combining VBG B-verb.creation	levomepromazine NN I-verb.creation	with IN 0	other JJ B-adj.all	anticholinergic_drugs NNS B-noun.object	( ( 0	tricyclic_antidepressants NNS B-noun.person	and CC 0	antiparkinsonian JJ B-adj.pert	- : 0	agents NNS B-noun.person	) ) 0	, , 0	Particularly RB 0	the DT 0	elderly JJ B-noun.group	may MD 0	develop VB B-verb.cognition	delirium NN B-noun.person	, , 0	high JJ B-adj.all	fever NN B-noun.person	, , 0	severe JJ B-adj.all	obstipation NN B-noun.act	, , 0	even RB B-adv.all	ileus JJ B-adj.all	and CC 0	glaucoma NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d776.s5	When WRB 0	DIFLUCAN NNP B-noun.group	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	these DT 0	or CC 0	other JJ B-adj.all	sulfonylurea_oral_hypoglycemic_agents NNS B-noun.person	, , 0	blood NN B-noun.act	glucose NN B-noun.act	concentrations NNS B-noun.artifact	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	and CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	the DT 0	sulfonylurea NN B-noun.artifact	should MD 0	be VB 0	adjusted VBN B-verb.change	as RB 0	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d700.s8	Therefore RB 0	, , 0	do VBP 0	not RB B-adv.all	administer VB B-verb.communication	Myfortic NNP B-noun.person	with IN 0	cholestyramine NN B-noun.act	or CC 0	other JJ 0	agents NNS B-noun.person	that WDT 0	may MD 0	interfere VB B-verb.stative	with IN 0	enterohepatic JJ B-adj.all	recirculation NN B-noun.act	or CC 0	drugs NNS B-noun.artifact	that WDT 0	may MD 0	bind VB B-verb.social	bile JJ B-adj.all	acids NNS B-noun.person	, , 0	for IN 0	example NN B-noun.person	bile NN B-noun.group	acid NN B-noun.act	sequestrates NNS B-noun.artifact	or CC 0	oral JJ B-adj.all	activated_charcoal NN B-noun.person	, , 0	because IN 0	of IN 0	the DT 0	potential NN B-noun.person	to TO 0	reduce VB B-verb.change	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	Myfortic NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d751.s0	AGGRASTAT NNP B-noun.group	has VBZ 0	been VBN 0	studied VBN B-verb.cognition	on IN 0	a DT 0	background NN B-noun.event	of IN 0	aspirin NN B-noun.food	and CC 0	heparin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d781.s6	Use NNP B-noun.person	of IN 0	potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	( ( 0	spironolactone NN 0	, , 0	amiloride IN 0	, , 0	triamterene NN B-noun.person	and CC 0	others NNS 0	) ) 0	, , 0	potassium NN B-noun.person	supplements NNS B-noun.artifact	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	capable JJ B-adj.all	of IN 0	increasing VBG B-verb.change	serum NN B-noun.group	potassium NN B-noun.person	( ( 0	indomethacin NN 0	, , 0	heparin NN B-noun.person	, , 0	cyclosporine NN B-noun.person	and CC 0	others NNS 0	) ) 0	can MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	hyperkalemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s16	Studies NNS B-noun.person	with IN 0	furosemide JJ B-adj.all	agents NNS B-noun.person	and CC 0	meloxicam NN B-noun.person	have VBP 0	not RB B-adv.all	demonstrated VBN B-verb.perception	a DT 0	reduction NN B-noun.act	in IN 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-MedLine.d224.s10	Adding VBG B-verb.communication	0.01 CD 0	% NN 0	manganese_gluconate NN 0	to TO 0	10 CD B-adj.all	% NN 0	carbamide_peroxide NN 0	bleaching VBG B-verb.body	gel NN I-verb.body	increased VBD B-verb.change	the DT 0	degree NN B-noun.communication	of IN 0	tooth NN 0	bleaching VBG B-verb.contact	after IN 0	a DT 0	seven CD 0	- : 0	day NN 0	treatment NN B-noun.group	and CC 0	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	resulting VBG B-adj.all	shade NN B-noun.communication	after IN 0	14 CD B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d585.s1	Anticholinergics NNS B-noun.person	antagonize VBP B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	antiglaucoma_agents NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d720.s2	MAO NNP B-noun.group	- : 0	A_inhibitors NNS B-noun.person	reduce VB B-verb.change	sumatriptan NN 0	clearance NN B-noun.person	, , 0	significantly RB B-adv.all	increasing VBG B-verb.change	systemic JJ B-adj.all	exposure NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d649.s0	Sulfamethizole NNP B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	barbiturates NNS B-noun.location	, , 0	tolbutamide NN 0	, , 0	and CC 0	uricosurics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d631.s2	Folinic_acid JJ 0	( ( 0	leucovorin NN 0	) ) 0	should MD 0	be VB 0	administered VBN B-verb.possession	until IN 0	normal JJ B-adj.all	hematopoiesis NN B-noun.cognition	is VBZ 0	restored VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d597.s25	In IN 0	vitro NN B-noun.animal	, , 0	methotrexate NN B-noun.person	did VBD 0	not RB B-adv.all	displace VB B-verb.communication	meloxicam NN B-noun.person	from IN 0	its PRP$ 0	human JJ B-adj.all	serum NN B-noun.body	binding NN B-verb.contact	sites NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d670.s0	Potential NNP B-noun.person	for IN 0	INVEGA NNP B-noun.person	___ NNP I-noun.person	to TO 0	Affect VB B-verb.competition	Other JJ 0	Drugs NNP B-noun.person	Paliperidone NNP I-noun.person	is VBZ B-verb.stative	not RB B-adv.all	expected VBN B-verb.cognition	to TO 0	cause VB B-verb.communication	clinically RB B-adv.all	important JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	with IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	cytochrome JJ B-noun.person	P450 NN I-noun.person	isozymes NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d573.s1	If IN 0	at IN 0	all DT 0	possible JJ B-adj.all	guanethidine NN B-noun.location	should MD 0	be VB 0	discontinued VBN B-verb.stative	well RB 0	before IN 0	minoxidil NN B-noun.time	is VBZ 0	begun VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d584.s3	Warfarin NNP B-noun.person	, , 0	A DT 0	multidose JJ B-adj.all	study NN B-noun.artifact	of IN 0	oxandrolone NN 0	, , 0	given VBN B-verb.possession	as IN 0	5 CD B-adj.all	or CC 0	10 CD B-adj.all	mg IN 0	BID NNP B-noun.group	in IN 0	15 CD B-adj.all	healthy JJ B-adj.all	subjects NNS B-noun.person	concurrently RB B-adv.all	treated VBN B-verb.change	with IN 0	warfarin NN B-noun.act	, , 0	resulted VBD B-verb.stative	in IN 0	a DT 0	mean JJ B-adj.all	increase NN B-noun.event	in IN 0	S NNP 0	- : 0	warfarin NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.time	from IN 0	26 CD B-adj.all	to TO 0	48 CD 0	hours NNS B-noun.person	and CC 0	AUC NNP B-noun.group	from IN 0	4.55 CD 0	to TO 0	12.08 CD 0	ng FW 0	hr FW 0	/ FW 0	mL FW 0	, , 0	similar JJ B-adj.all	increases NNS B-noun.event	in IN 0	R SYM 0	- : 0	warfarin NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.person	and CC 0	AUC NNP B-noun.group	were VBD B-verb.stative	also RB B-adv.all	detected VBD B-verb.perception	. . 0	. . 0
DDI-DrugBank.d617.s3	isosorbide_dinitrate JJ B-adj.all	, , 0	nitroglycerin NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d597.s28	In IN 0	these DT 0	subjects NNS B-noun.person	, , 0	meloxicam NN B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	warfarin NN B-noun.act	pharmacokinetics NNS I-noun.act	and CC 0	the DT 0	average JJ B-adj.all	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	as IN 0	determined VBN B-verb.communication	by IN 0	prothrombin NN B-noun.person	time NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d645.s4	Terbinafine NN B-noun.person	decreases VBZ B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	caffeine NN B-noun.phenomenon	by IN 0	19 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d166.s0	Improved VBN B-verb.change	parathyroid JJ B-adj.all	hormone NN 0	control NN B-noun.act	by IN 0	cinacalcet NN B-noun.person	is VBZ 0	associated VBN B-verb.cognition	with IN 0	reduction NN B-noun.act	in IN 0	darbepoetin NN 0	requirement NN B-verb.stative	in IN 0	patients NNS B-noun.person	with IN 0	end NN B-noun.person	- : 0	stage NN B-noun.communication	renal JJ B-adj.all	disease NN B-noun.state	. . 0	_ PRP 0	. . 0
DDI-MedLine.d213.s4	The DT 0	latter JJ B-adj.all	displayed JJ B-adj.all	midazolam NN B-noun.body	clearances NNS B-verb.weather	similar JJ B-adj.all	to TO 0	those DT 0	in IN 0	two CD 0	larger JJR B-adj.all	cohorts NNS B-noun.relation	of IN 0	nonmatched JJ B-adj.all	tacrolimus NN B-noun.person	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	( ( 0	n UH 0	= $ 0	58 CD 0	and CC 0	n PRP 0	= $ 0	80 CD B-adj.all	) ) 0	and CC 0	to TO 0	those DT 0	receiving VBG B-verb.perception	a DT 0	calcineurin_inhibitor NN B-noun.person	- : 0	free JJ B-noun.person	regimen NNS I-noun.person	( ( 0	n UH 0	= $ 0	6 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-MedLine.d142.s1	To TO 0	research VB B-verb.social	the DT 0	influence NN B-noun.cognition	of IN 0	glycyrrhiza_extract NN B-noun.state	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	characteristic JJ B-adj.all	parameters NNS B-noun.event	of IN 0	daphnetin NN B-noun.person	, , 0	which WDT 0	was VBD 0	aimed VBN B-verb.cognition	to TO 0	explore VB B-verb.communication	the DT 0	rationality NN B-noun.time	of IN 0	concert NN B-noun.food	application NN B-noun.act	of IN 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d189.s10	Furafylline NN B-noun.artifact	and CC 0	sulfaphenazole NN B-noun.person	had VBD B-verb.perception	no DT 0	effect NN B-noun.cognition	, , 0	while IN 0	quinidine NN B-noun.communication	appeared VBD B-verb.communication	to TO 0	augment VB B-verb.change	precocene_I JJ B-adj.all	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d776.s27	The DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	fluconazole NN B-noun.shape	with IN 0	cisapride NN 0	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d189.s7	ABT NNP 0	decreased VBD B-verb.change	the DT 0	toxicity NN B-noun.location	of IN I-noun.location	precocene_I NNP I-noun.location	, , 0	increased VBN B-verb.change	exposure NN I-verb.change	to TO 0	parent NN B-noun.person	compound NN B-noun.person	, , 0	and CC 0	decreased VBD B-verb.change	metabolite NN B-noun.food	levels NNS B-noun.attribute	in IN 0	a DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	manner NN B-noun.person	. . 0	. . 0
DDI-MedLine.d230.s7	There EX 0	were VBD B-verb.stative	no DT 0	significant JJ B-adj.all	differences NNS B-noun.cognition	between IN 0	the DT 0	pharmacokinetics NNS B-noun.person	parameters NNS B-noun.person	of IN 0	amiodarone NN 0	administered VBN B-verb.possession	intravenously RB B-adv.all	or CC 0	intragastrically RB B-adv.all	and CC 0	the DT 0	control NN B-noun.act	( ( 0	without IN 0	neferine NN B-noun.location	) ) 0	group NN 0	( ( 0	with IN 0	ratios NNS B-noun.time	of IN 0	0.7 CD 0	- : 0	1.4 CD 0	in IN 0	all DT 0	experimental JJ B-adj.all	groups NNS B-noun.group	) ) 0	, , 0	suggesting VBG B-verb.communication	that IN 0	neferine NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	amiodarone JJ B-adj.all	plasma NN B-noun.plant	pharmacokinetics NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d650.s0	Dopamine_antagonists NNS B-noun.person	, , 0	such JJ 0	as IN 0	the DT 0	neuroleptics NNS B-noun.person	( ( 0	phenothiazines NNS B-noun.animal	, , 0	butyrophenones NNS 0	, , 0	thioxanthines NNS 0	) ) 0	or CC 0	metoclopramide NN B-noun.attribute	, , 0	ordinarily RB 0	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	Permax NNP B-noun.person	( ( 0	a DT 0	dopamine_agonist NN 0	) ) 0	, , 0	. . 0
DDI-DrugBank.d619.s4	Severe JJ B-adj.all	toxicity NN B-noun.state	has VBZ 0	also RB B-adv.all	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	the DT 0	combination NN B-noun.event	of IN 0	tricyclic_antidepressants NNS B-noun.plant	and CC 0	ELDEPRYL NNP B-noun.group	and CC 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	and CC 0	ELDEPRYL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d632.s5	No DT 0	formal JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	been VBN 0	performed VBN B-verb.social	to TO 0	assess VB B-verb.cognition	the DT 0	effect NN B-noun.cognition	of IN 0	SYMLIN NNP B-noun.other	on IN 0	the DT 0	kinetics NNS B-noun.cognition	of IN 0	oral JJ B-adj.all	antidiabetic_agents NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d698.s0	Interactions NNS B-noun.person	for IN 0	Vitamin_B2 NNP B-noun.person	( ( I-noun.person	Riboflavin NNP I-noun.person	) ) 0	, , 0	_ '' 0	Alcohol NNP B-noun.person	; : 0	impairs VBZ B-verb.communication	the DT 0	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	riboflavin NN B-noun.body	. . 0
DDI-MedLine.d216.s6	The DT 0	findings NNS B-noun.act	suggest VBP B-verb.communication	that IN 0	the DT 0	dosage NN B-noun.quantity	of IN 0	S NNP 0	- : 0	ketamine NN B-noun.person	should MD 0	be VB 0	reduced VBN B-verb.change	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ticlopidine NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d161.s7	The DT 0	3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ B-adj.all	treatment NN B-noun.attribute	also RB B-adv.all	had VBD B-verb.perception	a DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine JJ B-noun.other	- : 0	induced JJ B-verb.creation	loss NN B-noun.process	of IN 0	norepinephrine JJ B-adj.all	neurons NNS B-noun.person	in IN 0	the DT 0	locus NN B-noun.body	coeruleus NN I-noun.body	and CC 0	adjoining VBG B-verb.change	A5 : 0	and CC 0	A7 : 0	noradrenaline JJ B-adj.all	cell NN B-noun.body	groups NNS B-noun.group	. . 0	. . 0
DDI-MedLine.d212.s7	Finally RB B-adv.all	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	eugenol NN B-noun.food	in IN 0	colchicine NN 0	nanoemulsion NN 0	to TO 0	enhance VB B-verb.change	the DT 0	colchicine NN B-noun.phenomenon	bioavailability NN B-noun.phenomenon	was VBD 0	investigated VBN B-verb.creation	by IN 0	an DT 0	oral JJ B-adj.all	administration NN B-noun.time	method NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d758.s0	The DT 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	oxycodone_hydrochloride NN B-noun.group	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	with IN 0	that DT 0	of IN 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	.. . 0	. . 0
DDI-MedLine.d189.s11	These DT 0	results NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	rat NN 0	liver NN 0	slices NNS 0	do VBP 0	not RB B-adv.all	reproduce VB B-verb.change	the DT 0	reported VBN B-verb.communication	in IN 0	vivo JJ B-adj.all	biotransformation NN B-noun.cognition	of IN 0	precocene_I NNP B-noun.person	and CC 0	therefore RB 0	may MD 0	not RB 0	be VB B-verb.stative	an DT 0	appropriate JJ B-adj.all	model NN B-noun.person	for IN 0	precocene_I JJ B-adj.all	metabolism NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d149.s1	To TO 0	observe VB B-verb.perception	the DT 0	injury NN B-noun.person	in IN 0	rat NN 0	primary NN B-noun.person	cultured VBD B-verb.communication	neurons NNS B-noun.person	induced VBN B-verb.creation	by IN 0	Abeta(1 SYM 0	- : 0	40 LS 0	) ) 0	and CC 0	the DT 0	protective JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	combination NN B-noun.event	of IN 0	ginseng NN B-noun.person	and CC 0	ginko NN B-noun.person	extracts NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d583.s1	Remifentanil VB B-verb.change	clearance NN B-noun.act	is VBZ B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	thiopental JJ 0	, , 0	isoflurane NN B-noun.person	, , 0	propofol NN B-noun.person	, , 0	or CC 0	temazepam NN B-noun.artifact	during IN 0	anesthesia NN 0	. . 0	. . 0
DDI-DrugBank.d585.s5	Anticholinergic_drugs NNS B-noun.animal	may MD 0	antagonize VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	drugs NNS B-noun.artifact	that WDT 0	alter VBP B-verb.change	gastrointestinal JJ B-adj.all	motility NN B-noun.motive	, , 0	such JJ 0	as IN 0	metoclopramide NN 0	. . 0	. . 0
DDI-DrugBank.d578.s9	Aspirin NNP B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	conjunction NN 0	with IN 0	corticosteroids NNS B-noun.food	in IN 0	patients NNS B-noun.person	suffering VBG B-verb.body	from IN 0	hypoprothrombinemia NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d710.s6	Aspirin NNP B-noun.person	, , 0	Rimantadine_HCl NNP B-noun.person	, , 0	100 CD 0	mg NN B-noun.quantity	, , 0	was VBD 0	given VBN B-verb.possession	twice RB B-adv.all	daily RB 0	fro RB 0	13 CD B-adj.all	days NNS B-noun.person	to TO 0	12 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d142.s0	[ SYM 0	Effects NNS B-noun.phenomenon	of IN 0	glycyrrhiza_extract NN B-noun.state	on IN 0	pharmacokinetics NNS B-noun.person	property NN B-noun.person	of IN 0	daphnetin NN B-noun.food	in IN 0	rats NNS B-noun.animal	] : 0	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d648.s6	Caution NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	EVISTA NNP B-noun.group	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	other JJ 0	highly RB B-adv.all	protein VBP B-verb.cognition	- : 0	bound NN B-noun.person	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	clofibrate NN B-noun.person	, , 0	indomethacin NN B-noun.person	, , 0	naproxen NN B-noun.person	, , 0	ibuprofen NN B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	and CC 0	diazoxide NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d780.s7	Sulfonamides NNS B-noun.person	, , 0	Concurrent JJ 0	use NN 0	of IN 0	procaine_hydrochloride JJ B-noun.other	and CC 0	sulfonamides NNS B-noun.animal	may MD 0	result VB B-verb.stative	in IN 0	a DT 0	reduction NN B-noun.act	of IN 0	the DT 0	antibacterial JJ B-adj.all	action NN B-noun.process	of IN 0	the DT 0	sulfonamide NN 0	. . 0	. . 0
DDI-DrugBank.d652.s0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	metoclopramide NN B-noun.attribute	on IN 0	gastrointestinal JJ B-adj.all	motility NN B-noun.motive	are VBP 0	antagonized VBN B-verb.cognition	by IN 0	anticholinergic_drugs NNS B-noun.object	and CC 0	narcotic_analgesics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d212.s1	The DT 0	effect NN B-noun.cognition	of IN 0	eugenol NN B-noun.act	on IN 0	colchicine NN 0	transport NN 0	across IN 0	an DT 0	isolated JJ B-adj.all	rat NN 0	intestinal JJ B-adj.all	membrane NN B-noun.person	was VBD 0	studied VBN B-verb.cognition	using VBG B-verb.consumption	an DT 0	in IN 0	vitro NN 0	diffusion JJ 0	chamber NN 0	system NN 0	. . 0	. . 0
DDI-MedLine.d190.s1	To TO 0	determine VB B-verb.communication	whether IN 0	the DT 0	co SYM 0	- : 0	injection NN B-noun.act	of IN 0	extracellular JJ B-adj.all	matrix NN B-noun.person	degrading VBG B-verb.communication	enzymes NNS B-noun.person	improves VBZ B-verb.change	retinal JJ B-adj.all	transduction NN B-noun.act	following VBG B-verb.stative	intravitreal JJ B-adj.all	delivery NN B-noun.group	of IN 0	adeno JJ B-noun.person	- : 0	associated_virus-2 NN B-noun.person	( ( 0	AAV2 NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d743.s8	Due JJ 0	to TO 0	the DT 0	chemical NN B-noun.body	similarity NN B-noun.attribute	of IN 0	other JJ 0	azole JJ B-adj.all	- : 0	type_antifungal_agents NNS B-noun.person	( ( 0	including VBG B-verb.change	fluconazole NN B-noun.attribute	, , 0	metronidazole NN B-noun.attribute	, , 0	and CC 0	miconazole NN B-noun.location	) ) 0	to TO 0	ketoconazole VB B-verb.social	, , 0	and CC 0	itraconazole NN B-noun.artifact	, , 0	concomitant JJ B-adj.all	use NN 0	of IN 0	these DT 0	products NNS B-noun.person	with IN 0	terfenadine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	pending VBG B-verb.body	full JJ B-adj.all	examination NN 0	of IN 0	potential JJ B-adj.all	interactions NNS B-noun.possession	. . 0	. . 0
DDI-MedLine.d185.s12	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	panobinostat NN B-noun.person	with IN 0	CYP3A NNP B-noun.person	inhibitors NNS I-noun.person	is VBZ B-verb.stative	feasible JJ B-adj.all	as IN 0	the DT 0	observed JJ B-adj.all	increase NN B-noun.act	in IN 0	panobinostat NN 0	PK NNP 0	parameters NNS B-noun.person	was VBD B-verb.stative	not RB B-adv.all	considered VBN B-verb.cognition	clinically RB B-adv.all	relevant JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d637.s1	Use NNP B-noun.person	of IN 0	neuroleptics NNS B-noun.person	in IN 0	conjunction NN 0	with IN 0	oral JJ B-adj.all	morphine NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	respiratory JJ B-adj.pert	depression NN B-noun.person	, , 0	hypotension NN B-noun.person	and CC 0	profound JJ B-adj.all	sedation NN B-noun.act	or CC 0	coma NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d704.s1	However RB 0	, , 0	interactions NNS B-noun.possession	may MD 0	be VB 0	expected VBN B-verb.cognition	and CC 0	FLOMAX NNP B-noun.group	capsules NNS B-noun.artifact	should MD 0	NOT RB 0	be VB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	other JJ B-adj.all	alpha NN B-noun.person	- : 0	adrenergic_blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s5	The DT 0	effect NN B-noun.cognition	of IN 0	orlistat NN B-noun.Tops	on IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	supplemental JJ B-adj.all	vitamin_D NNP B-noun.person	, , 0	vitamin_A NNP B-noun.person	, , 0	and CC 0	nutritionally RB B-adv.all	- : 0	derived VBN B-verb.cognition	vitamin_K NNP B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	at IN 0	this DT 0	time NN B-noun.time	. . 0	. . 0
DDI-MedLine.d166.s6	The DT 0	primary JJ B-adj.all	objective NN B-noun.cognition	of IN 0	the DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	ascertain VB B-verb.possession	the DT 0	difference NN B-noun.cognition	in IN 0	darbepoetin JJ B-adj.all	responsiveness NN B-noun.act	before IN 0	and CC 0	after IN 0	12 CD B-adj.all	months NNS B-noun.quantity	of IN 0	cinacalcet NN B-noun.phenomenon	therapy NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d610.s3	Ethanol NNP B-noun.person	decreases VBZ B-verb.communication	the DT 0	elimination NN B-noun.act	of IN 0	abacavir NN B-noun.person	causing VBG B-verb.communication	an DT 0	increase NN B-noun.act	in IN 0	overall JJ B-adj.all	exposure NN B-noun.person	. . 0	The DT 0	addition NN 0	of IN 0	methadone NN B-noun.attribute	has VBZ B-verb.possession	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetic JJ B-adj.all	properties NNS B-noun.attribute	of IN 0	abacavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d700.s16	Interference NNP B-noun.person	of IN 0	MPAG NNP B-noun.group	hydrolysis NN 0	may MD 0	lead VB B-verb.cognition	to TO 0	less JJR B-verb.motion	MPA NNP 0	available JJ 0	for IN 0	absorption NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d761.s13	Therefore RB 0	, , 0	as IN 0	vitamin_K JJ B-adj.all	absorption NN B-noun.artifact	may MD 0	be VB 0	decreased VBN B-verb.change	with IN 0	XENICAL NNP B-noun.group	, , 0	patients NNS B-noun.person	on IN 0	chronic JJ B-adj.all	stable JJ B-adj.all	doses NNS B-noun.event	of IN 0	warfarin NN B-noun.person	who WP 0	are VBP 0	prescribed VBN B-verb.communication	XENICAL NNP B-noun.group	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	for IN 0	changes NNS B-noun.relation	in IN 0	coagulation NN B-adj.all	parameters NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d735.s3	Sirolimus NNP B-noun.person	AUC NNP I-noun.person	was VBD 0	increased VBN B-verb.change	by IN 0	21 CD B-adj.all	% NN 0	with IN 0	no DT 0	effect NN B-noun.cognition	on IN 0	Cmax NNP B-noun.person	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	MYCAMINE NN 0	compared VBN B-verb.change	with IN 0	sirolimus NN 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d572.s5	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	ZETIA NNP B-noun.group	with IN 0	fibrates NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	until IN 0	use NN 0	in IN 0	patients NNS B-noun.person	is VBZ 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d662.s3	Following VBG 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	NOVANTRONE NNP B-noun.group	___ CC 0	with IN 0	corticosteroids NNS B-noun.food	, , 0	no DT 0	evidence NN B-noun.attribute	of IN 0	drug NN B-noun.person	interactions NNS I-noun.person	has VBZ 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-MedLine.d201.s9	CRM197 NN 0	induced VBN B-verb.creation	apoptosis NN B-noun.artifact	, , 0	and CC 0	furthermore RB B-adv.all	, , 0	the DT 0	combination NN B-noun.event	of IN 0	CRM197 JJ B-noun.cognition	plus CC 0	doxorubicin RB 0	enhanced JJ B-adj.all	cytotoxicity NN B-noun.state	in IN 0	a DT 0	T NNP 0	- : 0	ALL DT 0	cell NN B-noun.communication	line NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d776.s33	Tacrolimus NN B-noun.person	, , 0	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	nephrotoxicity NN B-noun.state	in IN 0	patients NNS B-noun.person	to TO 0	whom WP 0	fluconazole NN B-noun.person	and CC 0	tacrolimus NN B-noun.person	were VBD 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d231.s3	Being VBG 0	moxifloxacin NN B-noun.substance	and CC 0	lomefloxacin NN B-noun.person	fluoroquinolones VBZ B-verb.emotion	the DT 0	interaction NN B-noun.act	study NN B-noun.artifact	of IN 0	was VBD 0	carried VBN B-verb.change	out RP 0	with IN 0	sucralfate NN B-noun.person	, , 0	gelusil NN B-noun.artifact	, , 0	erythromycin NN B-noun.person	and CC 0	multi_minerals NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s20	In IN 0	a DT 0	study NN B-noun.artifact	conducted VBN B-verb.communication	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	, , 0	mean JJ B-adj.all	pre NN B-noun.person	- : 0	dose NN 0	lithium NN 0	concentration NN B-noun.cognition	and CC 0	AUC NNP B-noun.group	were VBD 0	increased VBN B-verb.change	by IN 0	21 CD B-adj.all	% NN 0	in IN 0	subjects NNS B-noun.artifact	receiving VBG B-verb.perception	lithium NN I-verb.perception	doses NNS B-noun.artifact	ranging VBG B-verb.stative	from IN 0	804 CD 0	to TO 0	1072 CD 0	mg IN 0	BID NNP 0	with IN 0	meloxicam NN B-noun.communication	15 CD 0	mg IN 0	QD NNP 0	as IN 0	compared VBN 0	to TO 0	subjects NNS B-noun.person	receiving VBG B-verb.social	lithium NN I-verb.social	alone RB 0	. . 0	. . 0
DDI-DrugBank.d604.s5	John's_Wort NN B-noun.act	with IN 0	hormonal_contraceptive_agents NNS B-noun.artifact	may MD 0	reduce VB B-verb.change	the DT 0	effectiveness NN B-noun.cognition	of IN 0	the DT 0	contraception NN B-noun.act	and CC 0	up RB 0	to TO 0	one CD 0	month NN B-noun.person	after IN 0	discontinuation NN B-noun.act	of IN 0	these DT 0	concomitant JJ B-adj.all	therapies NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d146.s3	Post SYM 0	- : 0	exposure NN B-noun.person	prophylaxis NN B-noun.person	of IN 0	H1N1 NN 0	with IN 0	oseltamivir NN B-noun.person	was VBD B-verb.stative	safe JJ B-adj.all	, , 0	effective JJ B-adj.all	and CC 0	well RB 0	tolerated VBN 0	to TO 0	prevent VB B-verb.stative	H1N1 JJ B-adj.all	influenza NN B-noun.cognition	A DT 0	virus NN B-noun.process	infection NN I-noun.process	in IN 0	newly RB B-adv.all	transplanted VBN B-verb.change	renal JJ B-adj.all	allograft NN B-noun.act	recipient NN B-noun.artifact	receiving VBG B-verb.perception	triple JJ B-adj.all	immunosuppression NN B-noun.act	without IN 0	any DT 0	interaction NN B-noun.act	with IN 0	tacrolimus NN B-noun.attribute	level NN I-noun.attribute	. . 0	. . 0
DDI-DrugBank.d588.s7	Lithium NNP B-noun.person	, , 0	Serum NNP B-noun.person	lithium NN I-noun.person	levels NNS B-noun.state	may MD 0	increase VB B-verb.change	. . 0	. . 0
DDI-DrugBank.d696.s0	Methysergide NNP B-noun.person	may MD 0	reverse VB B-verb.communication	the DT 0	analgesic JJ B-adj.all	activity NN B-noun.state	of IN 0	narcotic_analgesics NNS B-noun.group	. . 0	. . 0
DDI-MedLine.d206.s2	In IN 0	the DT 0	present JJ B-adj.all	study NN B-noun.artifact	, , 0	the DT 0	antidepressant NN B-noun.location	like IN 0	activity NN B-noun.process	of IN 0	curcumin NN B-noun.communication	and CC 0	its PRP$ 0	combination NN B-noun.event	with IN 0	fluoxetine NN B-noun.person	and CC 0	imipramine NN B-noun.act	was VBD 0	studied VBN B-verb.cognition	in IN 0	acute JJ B-adj.all	model NN B-noun.person	( ( 0	three CD 0	doses NNS B-noun.communication	24 CD B-adj.all	, , 0	5 CD B-adj.all	and CC 0	1 CD 0	h PRP 0	before IN 0	test NN 0	) ) 0	of IN 0	forced JJ 0	swimming NN 0	test NN 0	( ( 0	FST NNP 0	) ) 0	in IN 0	glass NN B-noun.artifact	jar NN I-noun.artifact	and CC 0	tail JJ B-noun.body	suspension NN 0	test NN 0	( ( 0	TST NNP 0	) ) 0	in IN 0	mice NNS B-noun.animal	and CC 0	in IN 0	chronic JJ B-adj.all	model NN B-noun.person	( ( 0	14 CD B-adj.all	day NN 0	study NN B-noun.artifact	) ) 0	of IN 0	FST NNP 0	with IN 0	water NN 0	wheel NN 0	in IN 0	rats NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d653.s7	The DT 0	effect NN B-noun.cognition	of IN 0	corticosteroids NNS B-noun.shape	on IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	is VBZ B-verb.stative	variable JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d633.s7	In IN 0	a DT 0	large JJ B-adj.all	compassionate JJ B-adj.all	use NN B-noun.person	program NN B-noun.person	Mexitil NNP I-noun.person	___ NNP I-noun.person	has VBZ 0	been VBN 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	commonly RB B-adv.all	employed VBN B-verb.consumption	antianginal JJ I-verb.consumption	, , 0	antihypertensive JJ B-adj.all	, , 0	and CC 0	anticoagulant_drugs NNS B-noun.object	without IN 0	observed JJ B-verb.perception	interactions NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d631.s0	Pyrimethamine NN 0	may MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	sulfonamides NNS B-noun.food	, , 0	quinine NN B-noun.location	and CC 0	other JJ 0	antimalarials NNS B-noun.person	, , 0	and CC 0	with IN 0	other JJ 0	antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d772.s0	TERAZOL NN B-noun.communication	7 CD B-adj.all	Vaginal NNP B-noun.person	Cream NNP I-noun.person	0.4 CD 0	% NN 0	and CC 0	TERAZOL NNP B-noun.communication	3 CD B-adj.all	Vaginal NNP B-noun.other	Suppositories NNPS I-noun.other	80 CD 0	mg IN 0	The DT 0	therapeutic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	these DT 0	products NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	oral JJ B-adj.all	contraceptive JJ B-adj.all	usage NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d154.s3	In IN 0	experiment NN B-noun.communication	1 CD 0	, , 0	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	GSLS NNP B-noun.group	at IN 0	a DT 0	dose NN B-noun.quantity	of IN 0	5 CD 0	mg RB 0	/ JJ 0	kg NN 0	of IN 0	BW NNP B-noun.act	for IN 0	7 CD 0	d NN 0	on IN 0	the DT 0	immune JJ B-adj.all	response NN B-noun.communication	in IN 0	chickens NNS B-noun.animal	intramuscularly RB B-adv.all	injected VBN B-verb.change	with IN 0	inactivated_ND_vaccine JJ 0	was VBD 0	evaluated VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d707.s0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	a DT 0	loop_diuretic JJ B-noun.person	had VBD B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	calcium NN B-noun.person	- : 0	lowering VBG B-verb.motion	action NN B-noun.process	of IN 0	Aredia NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d633.s13	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	cimetidine NN B-noun.act	and CC 0	Mexitil NNP B-noun.person	___ NNP I-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	, , 0	decrease VB B-verb.cognition	, , 0	or CC 0	leave VB B-verb.cognition	unchanged JJ B-noun.person	Mexitil NNP I-noun.person	___ NNP I-noun.person	plasma NN I-noun.person	levels NNS B-noun.state	, , 0	. . 0
DDI-DrugBank.d676.s4	No DT 0	cross NN B-noun.person	- : 0	resistance NN B-noun.person	with IN 0	other JJ B-adj.all	chemotherapeutic_agents NNPS B-noun.person	, , 0	radiotherapy NN B-noun.act	or CC 0	steroids NNS B-noun.communication	has VBZ 0	been VBN 0	demonstrated VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d577.s6	Sulfonamides NNS B-noun.person	can MD 0	also RB B-adv.all	displace VB B-verb.contact	methotrexate NN B-noun.person	from IN 0	plasma NN B-noun.person	protein NN B-noun.person	- : 0	binding JJ B-verb.contact	sites NNS B-noun.location	, , 0	thus RB 0	increasing VBG B-verb.change	free JJ B-adj.all	methotrexate NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d179.s0	Synergistic JJ B-adj.all	interaction NN B-noun.act	between IN 0	sunitinib NN B-noun.person	and CC 0	docetaxel NN B-noun.act	is VBZ B-verb.stative	sequence NN B-adj.ppl	dependent NN B-noun.person	in IN 0	human JJ B-adj.all	non NN B-noun.person	- : 0	small JJ B-adj.all	lung NN B-noun.artifact	cancer NN I-noun.artifact	with IN 0	EGFR NNP B-noun.group	TKIs NNP I-noun.group	- : 0	resistant JJ B-adj.all	mutation NN B-noun.act	. . 0	. . 0
DDI-MedLine.d214.s2	and/or CC 0	antibiotic_drug JJ B-adj.all	doxycycline NN B-noun.attribute	( ( 0	100 CD 0	mg NN B-noun.quantity	/ : 0	kg PRP 0	, , 0	p. : 0	o. LS 0	) ) 0	, , 0	as RB 0	well RB 0	as IN 0	that DT 0	of IN 0	neurotoxin NN B-noun.phenomenon	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine JJ 0	( ( 0	MPTP NNP B-noun.group	) ) 0	( ( 0	4 CD 0	x RB 0	20 CD 0	mg FW 0	/ FW 0	kg FW 0	, , 0	i. NN B-noun.quantity	p. '' 0	) ) 0	. . 0
DDI-MedLine.d146.s0	Post SYM 0	- : 0	exposure NN B-noun.person	prophylaxis NN B-noun.person	for IN 0	H1N1 NN 0	with IN 0	oseltamivir NN B-noun.person	in IN 0	renal JJ B-adj.all	allograft NN B-noun.act	recipient NN B-noun.act	-- : 0	safe JJ B-noun.person	and CC 0	effective JJ B-adj.all	without IN 0	any DT 0	immunosuppresive_drug JJ B-adj.all	interaction NN B-noun.act	. . 0	_ PRP 0	. . 0
DDI-MedLine.d214.s1	The DT 0	effects NNS B-noun.phenomenon	of IN 0	anti NNS B-noun.person	- : 0	parkinsonian_drug NN B-noun.group	hemantane NN B-noun.attribute	[ '' 0	( ( 0	2-adamantyl)hexamethylenimine JJ 0	] PRP 0	( ( 0	10 CD B-adj.all	mg FW B-noun.quantity	/ FW 0	kg FW 0	, , 0	p. : 0	o. LS 0	) ) 0	. . 0
DDI-DrugBank.d711.s1	Since IN 0	bacteriostatic JJ B-adj.all	drugs NNS B-noun.artifact	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	bactericidal JJ B-adj.all	action NN B-noun.process	of IN 0	penicillin NN B-noun.food	, , 0	it PRP 0	is VBZ B-verb.stative	advisable JJ B-adj.all	to TO 0	avoid VB B-verb.social	giving VBG B-verb.possession	tetracycline_class_drugs NNS B-noun.artifact	in IN 0	conjunction NN 0	with IN 0	penicillin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d166.s1	Uncontrolled JJ B-adj.all	hy SYM 0	- : 0	per SYM 0	- : 0	parathyroidism NN B-noun.attribute	causes VBZ B-verb.stative	bone NN 0	marrow NN 0	fibrosis NN 0	, , 0	leading VBG B-verb.motion	to TO 0	erythropoietin VB B-verb.consumption	( ( 0	EPO NNP 0	) ) 0	resistance NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d739.s6	Phenobarbital JJ B-adj.all	, , 0	which WDT 0	induces VBZ B-verb.stative	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	, , 0	decreased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	montelukast NN B-noun.person	approximately RB B-adv.all	40 CD B-adj.all	% NN 0	following VBG B-verb.stative	a DT 0	single JJ B-adj.all	10-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	montelukast NN B-noun.person	. . 0	. . 0
DDI-MedLine.d199.s0	Prevention NNP B-noun.person	of IN 0	emergence NN B-noun.phenomenon	agitation NN I-noun.phenomenon	in IN 0	seven CD 0	children NNS B-noun.person	receiving VBG B-verb.communication	low JJ I-verb.communication	- : 0	dose NN B-noun.quantity	ketamine NN B-noun.artifact	and CC 0	propofol VB B-verb.change	total JJ B-adj.all	intravenous JJ B-adj.all	anesthesia NN B-noun.location	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d686.s1	Therefore RB 0	, , 0	when WRB 0	concomitant JJ B-adj.all	use NN 0	of IN 0	thiabendazole NN B-noun.communication	and CC 0	xanthine_derivatives NNPS B-noun.person	is VBZ 0	anticipated VBN B-verb.cognition	, , 0	it PRP 0	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	to TO 0	monitor VB B-verb.perception	blood NN I-verb.perception	levels NNS B-noun.state	and/or CC 0	reduce VB B-verb.change	the DT 0	dosage NN B-noun.quantity	of IN 0	such JJ B-adj.all	compounds NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d591.s6	Coadministration NN B-noun.person	of IN 0	a DT 0	selective JJ B-noun.person	and CC 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	ketoconazole NN B-noun.person	( ( 0	100 CD 0	mg NN B-noun.quantity	bid NN B-noun.food	for IN 0	2 CD B-adj.all	days NNS B-noun.person	with IN 0	ropivacaine NN B-noun.person	infusion NN B-noun.person	administered VBD B-verb.possession	1 CD B-adj.all	hour NN B-noun.communication	after IN 0	ketoconazole NN B-noun.artifact	) ) 0	caused VBD B-verb.creation	a DT 0	15 CD B-adj.all	% NN 0	reduction NN B-noun.act	in IN 0	in SYM 0	- : 0	vivo JJ B-adj.all	plasma NN B-noun.phenomenon	clearance NN B-noun.attribute	of IN 0	ropivacaine NN B-noun.act	. . 0	. . 0
DDI-MedLine.d192.s7	Single JJ B-noun.act	- : 0	unit NN B-noun.group	in IN 0	vivo JJ B-adj.all	extracellular JJ B-adj.all	recordings NNS B-noun.artifact	performed VBN B-verb.social	in IN 0	neurons NNS B-noun.act	of IN 0	the DT 0	NAc NNP B-noun.other	confirmed VBD B-verb.cognition	an DT 0	opiate NN B-noun.person	- : 0	state NN B-noun.person	- : 0	dependent JJ B-adj.all	role NN B-noun.attribute	for IN 0	BLA NNP B-noun.group	D1/D2 NNP I-noun.group	transmission NN B-noun.communication	in IN 0	NAc NNP B-noun.location	neuronal JJ B-adj.all	response NN B-noun.act	patterns NNS B-noun.artifact	to TO 0	morphine VB B-verb.change	. . 0	. . 0
DDI-DrugBank.d741.s0	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	of IN 0	18 CD B-adj.all	chronic JJ B-adj.pert	hepatitis NN B-noun.group	C NNP 0	patients NNS B-noun.person	concomitantly RB B-adv.all	receiving VBG B-verb.communication	methadone NN B-noun.attribute	, , 0	treatment NN B-noun.plant	with IN 0	PEG NNP B-noun.group	- : 0	Intron NNP B-noun.person	once RB B-adv.all	weekly RB I-adv.all	for IN 0	4 CD B-adj.all	weeks NNS B-noun.time	was VBD 0	associated VBN B-verb.cognition	with IN 0	a DT 0	mean JJ B-adj.all	increase NN B-noun.event	of IN 0	16 CD B-adj.all	% NN 0	in IN 0	methadone NN 0	AUC NNP 0	, , 0	. . 0
DDI-DrugBank.d648.s3	If IN 0	EVISTA NNP B-noun.group	is VBZ 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	warfarin NN B-noun.act	, , 0	prothrombin NN B-noun.person	time NN B-noun.group	should MD 0	be VB 0	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d593.s0	Clinical JJ B-adj.all	studies NNS B-noun.communication	of IN 0	interactions NNS B-noun.act	of IN 0	VIRAZOLE NNP B-noun.group	with IN 0	other JJ 0	drugs NNS B-noun.person	commonly RB B-adv.all	used VBN B-verb.consumption	to TO 0	treat VB B-verb.body	infants NNS B-noun.person	with IN 0	RSV NNP B-noun.group	infections NNS B-noun.communication	, , 0	such JJ 0	as IN 0	digoxin NN B-noun.person	, , 0	bronchodilators NNS B-noun.person	, , 0	other JJ 0	antiviral_agents NNS B-noun.location	, , 0	antibiotics NNS B-noun.person	, , 0	or CC 0	anti NNS B-noun.person	- : 0	metabolites NNS B-noun.time	have VBP 0	not RB 0	been VBN 0	conducted VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d776.s23	The DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	fluconazole NN B-noun.shape	at IN 0	doses NNS B-noun.act	of IN 0	400 CD 0	mg NN B-noun.quantity	or CC 0	greater JJR B-adj.all	with IN 0	terfenadine NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d171.s6	Before IN 0	and CC 0	during IN 0	antiretroviral JJ B-adj.all	treatment NN B-noun.communication	, , 0	antiretroviral JJ B-adj.all	drug NN B-noun.artifact	resistances NNS I-noun.artifact	, , 0	individual JJ B-adj.all	tolerance NN B-noun.act	profiles NNS I-noun.act	and CC 0	the DT 0	needs NNS B-noun.object	of IN 0	the DT 0	individual JJ B-adj.all	patient NN B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	several JJ B-adj.all	interactions NNS B-noun.person	with IN 0	other JJ 0	drugs NNS B-noun.artifact	have VBP 0	to TO 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d179.s8	The DT 0	molecular JJ B-adj.all	basis NN B-noun.cognition	of IN 0	this DT 0	synergism NN B-noun.cognition	is VBZ B-verb.stative	that IN 0	the DT 0	signaling NN B-noun.location	pathways NNS B-noun.artifact	that WDT 0	were VBD B-verb.stative	initially RB B-adv.all	activated VBN B-verb.creation	by IN 0	docetaxel NN B-noun.artifact	exposure NN B-noun.act	were VBD B-verb.stative	efficiently RB B-adv.all	suppressed VBN B-verb.social	by IN 0	the DT 0	subsequent JJ B-adj.all	exposure NN B-noun.communication	to TO 0	sunitinib VB B-verb.communication	. . 0	. . 0
DDI-DrugBank.d737.s10	Dopamine_antagonists NNS B-noun.person	, , 0	Since IN 0	pramipexole NN B-noun.communication	is VBZ B-verb.stative	a DT 0	dopamine_agonist NN B-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	possible JJ B-adj.all	that IN 0	dopamine_antagonists NNS B-noun.person	, , 0	such JJ 0	as IN 0	the DT 0	neuroleptics NNS B-noun.person	( ( 0	phenothiazines NNS B-noun.animal	, , 0	butyrophenones NNS 0	, , 0	thioxanthenes NNS 0	) ) 0	or CC 0	metoclopramide NN B-noun.attribute	, , 0	may MD 0	diminish VB B-verb.change	the DT 0	effectiveness NN B-noun.cognition	of IN 0	MIRAPEX NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d154.s6	Considering VBG B-verb.communication	the DT 0	safety NN B-noun.person	of IN 0	GSLS NNP B-noun.group	, , 0	because IN 0	no DT 0	adverse JJ B-adj.all	effect NN B-noun.phenomenon	was VBD 0	found VBN B-verb.communication	throughout IN 0	the DT 0	experiments NNS B-noun.person	, , 0	GSLS NNP B-noun.group	may MD 0	be VB B-verb.stative	a DT 0	promising JJ B-adj.all	oral JJ B-adj.all	adjuvant NN B-noun.person	to TO 0	improve VB B-verb.social	immunization NN B-noun.act	in IN 0	poultry NN B-noun.animal	. . 0	. . 0
DDI-MedLine.d216.s3	Ticlopidine NNP 0	treatment NN B-noun.artifact	increased VBD B-verb.change	the DT 0	mean JJ B-adj.all	area NN B-noun.cognition	under IN 0	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	- : 0	time NN B-noun.time	curve NN B-noun.communication	extrapolated VBN B-verb.communication	to TO 0	infinity NN B-noun.cognition	( ( 0	AUC(0- VB 0	__ LS 0	) ) 0	) ) 0	of IN 0	oral JJ B-noun.phenomenon	ketamine NN I-noun.phenomenon	by IN 0	2.4-fold JJ B-noun.artifact	, , 0	whereas IN 0	itraconazole NN B-noun.person	treatment NN B-noun.person	did VBD 0	not RB B-adv.all	increase VB B-verb.change	the DT 0	exposure NN B-noun.person	to TO 0	S NNP 0	- : 0	ketamine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d204.s0	Distinct JJ B-adj.all	synergistic JJ B-adj.all	action NN B-noun.state	of IN 0	piperacillin NN B-noun.food	and CC 0	methylglyoxal NN B-noun.attribute	against IN 0	Pseudomonas NNP B-noun.person	aeruginosa NN I-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d640.s5	Oral NNP B-noun.group	Anticoagulants NNPS I-noun.group	, , 0	Interaction NNP B-noun.location	studies NNS I-noun.location	with IN 0	warfarin NN B-noun.person	failed VBD B-verb.social	to TO 0	identify VB B-verb.cognition	any DT 0	clinically RB B-adv.all	important JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	the DT 0	anticoagulant JJ B-adj.all	or CC 0	on IN 0	its PRP$ 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d737.s4	Cimetidine NNP B-noun.person	, , 0	Cimetidine NNP B-noun.person	, , 0	a DT 0	known VBN B-adj.all	inhibitor NN B-noun.person	of IN 0	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	organic JJ B-adj.all	bases NNS B-noun.event	via IN 0	the DT 0	cationic JJ B-adj.pert	transport NN B-noun.cognition	system NN I-noun.cognition	, , 0	caused VBD B-verb.communication	a DT 0	50 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	pramipexole NN B-adj.all	AUC NNP B-noun.group	and CC 0	a DT 0	40 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	half NN B-noun.quantity	- : 0	life NN B-noun.time	( ( 0	N= $ 0	12 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d672.s1	Methylxanthines NNS B-noun.person	, , 0	Sparfloxacin NNP B-noun.person	does VBZ 0	not RB B-adv.all	increase VB B-verb.change	plasma NN 0	theophylline NN 0	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d575.s3	There EX 0	was VBD B-verb.stative	no DT 0	change NN B-noun.act	in IN 0	the DT 0	plasma NN B-noun.plant	kinetics NNS B-noun.cognition	of IN 0	teniposide NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	methotrexate NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d179.s3	NSCLC NNP B-noun.group	cell NN B-noun.artifact	lines NNS B-noun.communication	with IN 0	EGFR NNP B-noun.group	T790 NNP I-noun.group	M NNP I-noun.group	mutation NN B-noun.phenomenon	and CC 0	K NNP 0	- : 0	ras NN 0	mutation NN B-noun.act	were VBD 0	exposed VBN B-verb.perception	to TO 0	either DT 0	sunitinib NN B-noun.state	or CC 0	docetaxel NN B-noun.artifact	or CC 0	both DT 0	based VBN B-verb.cognition	on IN 0	various JJ B-adj.all	sequential JJ B-noun.body	administrations NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d204.s9	Distinct JJ B-adj.all	and CC 0	statistically RB B-adv.all	significant JJ B-adj.all	synergism NN B-noun.artifact	was VBD 0	observed VBN B-verb.perception	between IN 0	methylglyoxal JJ B-adj.all	and CC 0	piperacillin NN B-noun.person	by IN 0	disc NN B-noun.person	diffusion NN B-noun.person	tests NNS B-noun.person	when WRB 0	compared VBN B-verb.cognition	with IN 0	their PRP$ 0	individual JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d675.s4	Less RBR B-adv.all	potent JJ B-adj.all	inhibitors NNS B-noun.person	include VBP B-verb.stative	saquinavir NN I-verb.stative	, , 0	nefazodone NN 0	, , 0	fluconazole NN B-noun.person	, , 0	grapefruit NN B-adj.all	juice NN B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	zileuton NN B-noun.person	, , 0	and CC 0	clotrimazole NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d725.s0	Vasopressors NNS B-noun.person	, , 0	particularly RB B-adj.all	metaraminol NN B-noun.person	, , 0	may MD 0	cause VB B-verb.communication	serious JJ B-adj.all	cardiac NN B-noun.artifact	arrhythmias NN B-noun.artifact	during IN 0	halothane NN 0	anesthesia NN 0	and CC 0	therefore RB 0	should MD 0	be VB 0	used VBN B-verb.consumption	only RB B-adv.all	with IN 0	great JJ B-adj.all	caution NN B-noun.event	or CC 0	not RB B-adv.all	at IN 0	all DT 0	. . 0	. . 0
DDI-DrugBank.d739.s0	Montelukast NNP B-noun.person	at IN 0	a DT 0	Dose NNP B-noun.person	of IN 0	10 CD B-adj.all	mg IN 0	Once NNP B-noun.group	Daily NNP I-noun.group	Dosed NNP I-noun.group	to TO 0	Pharmacokinetic NNP B-noun.person	Steady NNP I-noun.person	State NNP I-noun.person	_ ( 0	; : 0	did VBD 0	not RB B-adv.all	cause VB B-verb.communication	clinically RB B-adv.all	significant JJ B-adj.all	changes NNS B-noun.relation	in IN 0	the DT 0	kinetics NNS B-noun.cognition	of IN 0	a DT 0	single JJ B-adj.all	intravenous JJ B-adj.all	dose NN B-noun.event	of IN 0	theophylline PRP 0	( ( 0	predominantly RB B-adv.all	a DT 0	cytochrome NN B-noun.person	P450 RB I-noun.person	1A2 JJ B-adj.all	substrate NN I-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d709.s5	Although IN 0	such JJ 0	a DT 0	risk NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	verified VBN B-verb.social	for IN 0	roxithromycin NN B-noun.act	, , 0	combination NN B-noun.person	of IN 0	roxithromycin NN B-noun.substance	with IN 0	such JJ B-adj.all	drugs NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d779.s16	Methyldopa NN B-noun.person	does VBZ 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	measurement NN B-noun.attribute	of IN 0	VMA NNP B-noun.group	( ( 0	vanillylmandelic_acid NNP 0	) ) 0	, , 0	a DT 0	test NN B-noun.person	for IN 0	pheochromocytoma NN B-noun.time	, , 0	by IN 0	those DT 0	methods NNS B-noun.attribute	which WDT 0	convert VBP B-verb.change	VMA NNP 0	to TO 0	vanillin VB B-verb.change	. . 0	. . 0
DDI-DrugBank.d777.s3	In IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	acute JJ B-adj.all	MI NNP 0	, , 0	aspirin NN B-noun.person	, , 0	when WRB 0	not RB B-adv.all	otherwise RB 0	contraindicated VBN B-verb.cognition	, , 0	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	Streptokinase NNP B-noun.person	( ( 0	see VB 0	below IN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d610.s1	No DT 0	clinically RB B-adv.all	significant JJ B-adj.all	changes NNS B-noun.relation	to TO 0	lamivudine VB B-verb.social	or CC 0	zidovudine JJ B-adj.all	pharmacokinetics NNS B-noun.person	were VBD 0	observed VBN B-verb.perception	following VBG B-verb.stative	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	abacavir NN B-noun.person	. . 0	. . 0
DDI-MedLine.d195.s0	Influence NN B-noun.cognition	of IN 0	piperine NN B-noun.person	on IN 0	ibuprofen NNS B-noun.person	induced VBN B-verb.creation	antinociception NN B-noun.attribute	and CC 0	its PRP$ 0	pharmacokinetics NNS B-noun.time	. . 0	_ PRP 0	. . 0
DDI-MedLine.d180.s10	We PRP 0	also RB B-adv.all	found VBD B-verb.communication	that IN 0	Bcl-2 NN B-noun.person	was VBD 0	overexpressed VBN B-verb.consumption	in IN 0	DZNep NNP B-noun.other	insensitive JJ B-noun.body	cells NNS I-noun.body	, , 0	and CC 0	cotreatment NN B-noun.person	with IN 0	DZNep NNP B-noun.person	and CC 0	ABT-737 NNP B-noun.other	, , 0	a DT 0	Bcl-2 JJ B-adj.all	family NN B-noun.group	inhibitor NN B-noun.person	, , 0	synergistically RB B-adv.all	inhibited JJ B-adj.all	growth NN B-noun.person	and CC 0	induced VBN B-verb.creation	apoptosis NN B-noun.process	of IN 0	DZNep NNP B-noun.other	insensitive JJ 0	MM NNP 0	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d763.s1	Because IN 0	ondansetron NN 0	is VBZ 0	metabolized VBN B-verb.change	by IN 0	hepatic JJ B-adj.all	cytochrome NN B-noun.person	P-450 NNP I-noun.person	drug NN B-noun.person	- : 0	metabolizing NN B-verb.cognition	enzymes NNS B-noun.person	( ( 0	CYP3A4 NNP B-noun.person	, , 0	CYP2D6 NNP B-noun.person	, , 0	CYP1A2 NNP B-noun.location	) ) 0	, , 0	inducers NNS B-noun.person	or CC 0	inhibitors NNS B-noun.attribute	of IN 0	these DT 0	enzymes NNS B-noun.act	may MD 0	change VB B-verb.change	the DT 0	clearance NN B-noun.person	and CC 0	, , 0	hence RB B-adv.all	, , 0	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	ondansetron NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d733.s2	Misoprostol NNP B-noun.person	has VBZ B-verb.possession	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	kinetics NNS B-noun.cognition	of IN 0	diclofenac NN B-noun.state	or CC 0	ibuprofen NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d780.s5	Hyaluronidase NNP B-noun.person	, , 0	Hyaluronidase NNP B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	diffusion NN B-noun.event	rate NN B-noun.time	of IN 0	procaine_hydrochloride JJ B-noun.other	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	decreased VBN B-adj.all	time NN B-noun.time	of IN 0	onset NN B-noun.event	, , 0	but CC 0	an DT 0	increase NN B-noun.act	in IN 0	systemic JJ B-adj.all	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d693.s2	Daily JJ B-adj.pert	doses NNS B-noun.event	of IN 0	sulfasalazine NN B-noun.communication	2 CD B-adj.all	g NN B-noun.quantity	( ( 0	maximum JJ B-adj.all	3 CD B-adj.all	g NN B-noun.quantity	) ) 0	and CC 0	weekly JJ B-adj.all	doses NNS B-noun.event	of IN 0	methotrexate JJ B-adj.all	7.5 CD 0	mg NN B-noun.quantity	( ( 0	maximum JJ B-adv.all	15 CD B-adj.all	mg NN B-noun.quantity	) ) 0	were VBD 0	administered VBN B-verb.perception	alone RB B-adv.all	or CC 0	in IN 0	combination NN 0	to TO 0	310 CD 0	rheumatoid NN 0	arthritis NN 0	patients NNS B-noun.person	in IN 0	two CD 0	controlled VBD B-verb.social	52-week JJ 0	clinical JJ B-adj.all	studies NNS B-noun.communication	. . 0	. . 0
DDI-MedLine.d182.s2	This DT 0	study NN B-noun.communication	aimed VBN B-verb.communication	to TO 0	evaluate VB B-verb.communication	antimicrobial JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	an DT 0	o SYM 0	- : 0	cymen-5-ol NN B-noun.time	/ '' 0	zinc NN B-noun.cognition	system NN I-noun.cognition	. . 0	. . 0
DDI-DrugBank.d598.s0	Trimethoprim NNP B-noun.person	may MD 0	inhibit VB B-verb.change	the DT 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	phenytoin NN B-noun.food	. . 0	. . 0
DDI-MedLine.d158.s3	All DT 0	mRPCs NNS B-noun.person	of IN 0	20 CD B-adj.all	passages NNS B-noun.communication	or CC 0	less JJR B-noun.quantity	were VBD 0	transplanted VBN B-verb.change	into IN 0	the DT 0	subretinal JJ B-adj.all	space NN B-noun.location	of IN 0	B6 JJ B-adj.all	mice NNS B-noun.animal	together RB B-adv.all	with IN 0	chondroitinase NN B-noun.act	ABC NNP 0	, , 0	and CC 0	into IN 0	Rho(-/- NNP B-noun.location	) ) 0	mice NNS B-noun.animal	combined VBN B-verb.change	with IN 0	chondroitinase NN B-noun.act	ABC NNP 0	, , 0	N-[N-(3,_5-Difluorophenacetyl)-L UH 0	- : 0	alanyl]-S SYM B-noun.group	- : I-noun.group	phenylglycine_t SYM I-noun.group	- : 0	butyl_ester NN 0	( ( 0	DAPT NNP 0	) ) 0	, , 0	and CC 0	insulin_growth_factor NNP B-noun.person	( ( I-noun.person	IGF)-1 JJ I-noun.person	. . 0	. . 0
DDI-MedLine.d213.s1	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	have VBP 0	identified VBN B-verb.cognition	cyclosporine NN B-noun.person	and CC 0	tacrolimus NN B-noun.person	as IN 0	CYP3A JJ B-adj.all	inhibitors NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d189.s3	The DT 0	incubations NNS B-noun.possession	were VBD 0	performed VBN B-verb.social	in IN 0	the DT 0	absence NN B-noun.artifact	and CC 0	presence NN B-noun.person	of IN 0	the DT 0	non NN B-noun.person	- : 0	specific JJ B-adj.all	CYP NNP B-noun.person	inhibitor NN I-noun.person	, , 0	1-aminobenzotriazole JJ 0	( ( 0	ABT NNP 0	) ) 0	and CC 0	isoform NN B-noun.attribute	- : 0	specific JJ B-adj.all	inhibitors NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d672.s0	Digoxin NNP B-noun.person	, , 0	Sparfloxacin NNP B-noun.person	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d737.s2	Selegiline NN B-noun.person	, , 0	In IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	( ( 0	N= $ 0	11 CD 0	) ) 0	, , 0	selegiline NN B-noun.person	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	pramipexole NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d572.s6	Fenofibrate NNP B-noun.person	, , 0	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	, , 0	concomitant JJ B-adj.all	fenofibrate NN B-noun.location	administration NN B-noun.person	increased VBD B-verb.change	total JJ B-adj.all	ezetimibe NN B-noun.person	concentrations NNS B-noun.person	approximately RB B-adv.all	1.5-fold JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d627.s4	While IN 0	no DT 0	formal JJ B-noun.phenomenon	drug NN I-noun.phenomenon	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	been VBN 0	performed VBN B-verb.social	, , 0	the DT 0	following VBG 0	concomitant JJ B-adj.all	drugs NNS B-noun.artifact	were VBD 0	used VBN B-verb.consumption	in IN 0	at IN 0	least JJS 0	10 CD B-adj.all	% NN 0	of IN 0	patients NNS B-noun.person	in IN 0	either CC 0	or CC 0	both DT 0	Sj NNP B-noun.person	__ NNP I-noun.person	grens VBZ B-verb.communication	efficacy NN B-noun.phenomenon	studies NNS B-noun.act	, , 0	acetylsalicylic_acid NNP B-noun.person	, , 0	artificial JJ B-adj.all	tears NNS B-noun.body	, , 0	calcium NN B-noun.person	, , 0	conjugated_estrogens VBZ B-verb.communication	, , 0	hydroxychloroquine_sulfate NNP B-noun.person	, , 0	ibuprofen NN B-noun.person	, , 0	levothyroxine_sodium NN B-noun.state	, , 0	medroxyprogesterone_acetate NNP B-noun.person	, , 0	methotrexate NN B-noun.person	, , 0	multivitamins NNS B-noun.person	, , 0	naproxen NN B-noun.person	, , 0	omeprazole NN B-noun.person	, , 0	paracetamol NN B-noun.person	, , 0	and CC 0	prednisone NN B-noun.person	. . 0	. . 0
DDI-MedLine.d191.s6	Combining VBG 0	with IN 0	cisplatin NN B-noun.food	and CC 0	MWCHCP NNP B-noun.group	caused VBD B-verb.creation	a DT 0	tendency NN B-noun.attribute	of IN 0	increasing VBG B-verb.change	the DT 0	tumor NN B-noun.plant	growth NN 0	inhibition NN 0	rate NN B-noun.time	and CC 0	significant JJ B-adj.all	attenution NN B-noun.attribute	of IN 0	cisplatin NN B-noun.act	- : 0	induced VBN B-verb.creation	diarrhea NN B-noun.person	, , 0	visceral JJ B-adj.all	organ NN B-noun.body	injury NN I-noun.body	, , 0	gastric JJ B-adj.all	mucosal JJ B-noun.body	injury NN I-noun.body	and CC 0	decreased VBD B-verb.change	TNF NNP B-noun.group	- : 0	alpha RB B-adv.all	mRNA JJ B-adj.all	level NN B-noun.state	of IN 0	intestine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d169.s7	Calcium NN B-noun.person	was VBD 0	administered VBN B-verb.possession	as IN 0	calcium_chloride JJ 0	in IN 0	all DT 0	studies NNS B-noun.group	and CC 0	minerals NNS B-noun.food	were VBD 0	ingested VBN B-verb.consumption	on IN 0	an DT 0	empty JJ B-adj.all	stomach NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d597.s2	Aspirin NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.substance	( ( 0	1000 CD 0	mg IN 0	TID NNP 0	) ) 0	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	tended VBD B-verb.social	to TO 0	increase VB B-verb.change	the DT 0	AUC NNP B-noun.group	( ( 0	10 CD B-adj.all	% NN 0	) ) 0	and CC 0	Cmax NNP B-noun.person	( ( 0	24 CD B-adj.all	% NN 0	) ) 0	of IN 0	meloxicam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d659.s0	Although IN 0	a DT 0	causal NN B-adj.all	relationship NN B-noun.state	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.creation	, , 0	there EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	bleeding VBG B-verb.body	and/or CC 0	prolonged VBD B-verb.communication	prothrombin NN B-noun.person	time NN B-noun.person	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	TRENTAL NNP B-noun.group	with IN 0	and CC 0	without IN 0	anticoagulants NNS B-noun.location	or CC 0	platelet_aggregation_inhibitors NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d672.s5	The DT 0	oral JJ B-adj.all	bioavailability NN B-noun.cognition	of IN 0	sparfloxacin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	reduced VBN B-verb.change	when WRB 0	the DT 0	aluminum NN B-noun.person	- : 0	magnesium NN 0	suspension NN 0	is VBZ 0	administered VBN B-verb.possession	4 CD B-adj.all	hours NNS B-noun.artifact	following VBG B-verb.stative	sparfloxacin JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-MedLine.d219.s6	Current JJ B-noun.person	guidelines NNS I-noun.person	recommend VBP 0	starting VBG B-verb.change	antiretroviral JJ B-adj.all	treatment NN B-noun.act	within IN 0	a DT B-adj.all	few JJ I-adj.all	weeks NNS B-noun.time	of IN 0	antituberculosis DT 0	therapy NN B-noun.act	for IN 0	patients NNS B-noun.person	with IN 0	CD4 JJ 0	cell NN B-noun.body	counts NNS I-noun.body	. . 0
DDI-DrugBank.d763.s5	In IN 0	humans NNS B-noun.animal	, , 0	carmustine NN 0	, , 0	etoposide NN 0	, , 0	and CC 0	cisplatin NN B-noun.person	do VBP 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	ondansetron NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d588.s13	Anticoagulants NNS B-noun.person	, , 0	Metolazone NNP B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	other JJ 0	thiazide JJ 0	- : 0	like_diuretics NNS B-noun.person	, , 0	may MD 0	affect VB B-verb.change	the DT 0	hypoprothrombinemic JJ B-adj.all	response NN B-noun.communication	to TO 0	anticoagulants NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d625.s1	Impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	has VBZ 0	been VBN 0	described VBN B-verb.communication	in IN 0	bone NN 0	marrow NN 0	transplant NN B-noun.person	patients NNS B-noun.person	who WP 0	were VBD 0	conditioned VBN B-verb.communication	with IN 0	high JJ B-noun.group	- : 0	dose RB B-verb.creation	intravenous JJ B-adj.all	melphalan NN B-noun.person	and CC 0	who WP 0	subsequently RB B-adv.all	received VBD B-verb.possession	cyclosporin NN B-noun.person	to TO 0	prevent VB B-verb.possession	graft NNS B-noun.person	- : 0	versus NN B-noun.food	- : 0	host NN B-noun.person	disease NN B-noun.person	. . 0
DDI-DrugBank.d721.s0	The DT 0	bioavailability NN B-noun.cognition	of IN 0	SKELID NNP B-noun.group	is VBZ 0	decreased VBN B-verb.change	80 CD B-adj.all	% NN 0	by IN 0	calcium NN B-noun.person	, , 0	when WRB 0	calcium NN B-noun.person	and CC 0	SKELID NNP B-noun.group	are VBP 0	administered VBN B-verb.possession	at IN 0	the DT 0	same JJ B-adj.all	time NN B-noun.time	, , 0	and CC 0	60 CD B-adj.all	% NN 0	by IN 0	some DT 0	aluminum- JJ B-adj.all	or CC 0	magnesium NN B-noun.person	- : 0	containing VBG B-verb.stative	antacids NNS B-noun.substance	, , 0	when WRB 0	administered VBN B-verb.possession	1 CD B-adj.all	hour NN 0	before IN 0	SKELID NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d675.s2	Examples NNS B-noun.person	of IN 0	some DT 0	of IN 0	the DT 0	more RBR B-adv.all	potent JJ B-adj.all	CYP NNP B-noun.person	3A4 CD I-noun.person	inhibitors NNS I-noun.person	include VBP B-verb.stative	macrolide_antibiotics NNS I-verb.stative	( ( 0	e.g. UH 0	, , 0	erythromycin NN B-noun.person	, , 0	troleandomycin NN B-noun.person	, , 0	clarithromycin NN 0	) ) 0	, , 0	HIV_protease CD 0	or CC 0	reverse_transcriptase_inhibitors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	ritonavir NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	nelfinavir NN B-noun.person	, , 0	delavirdine NN 0	) ) 0	or CC 0	azole_antifungals NNS B-noun.substance	( ( 0	e.g. UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	voriconazole NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d584.s6	When WRB 0	oxandrolone NN 0	therapy NN 0	is VBZ 0	initiated VBN B-verb.creation	in IN 0	a DT 0	patient NN B-noun.person	already RB 0	receiving VBG B-verb.communication	treatment NN I-verb.communication	with IN 0	warfarin NN B-noun.act	, , 0	the DT 0	INR NNP B-noun.group	or CC 0	prothrombin NN B-adj.all	time NN B-noun.time	( ( 0	PT NNP 0	) ) 0	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	and CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	warfarin NN 0	adjusted VBN B-verb.change	as RB 0	necessary JJ B-adj.all	until IN 0	a DT 0	stable JJ B-adj.all	target NN B-noun.location	INR NNP I-noun.location	or CC 0	PT NNP 0	has VBZ 0	been VBN 0	achieved VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d744.s1	In IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	, , 0	patients NNS B-noun.person	on IN 0	opioids NNS B-noun.person	often RB B-adv.all	needed VBD B-verb.consumption	higher JJR B-adj.all	serum NN B-noun.person	pegvisomant NN B-noun.person	concentrations NNS B-noun.person	to TO 0	achieve VB B-verb.social	appropriate JJ B-adj.all	IGF NNP B-noun.group	- : 0	I PRP 0	suppression NN 0	compared VBN B-verb.cognition	with IN 0	patients NNS B-noun.person	not RB 0	receiving VBG B-verb.communication	opioids NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d147.s2	The DT 0	effect NN B-noun.cognition	of IN 0	DTIC NNP B-noun.group	and CC 0	imexon NN B-noun.person	, , 0	alone RB 0	and CC 0	in IN 0	combination NN 0	, , 0	was VBD 0	evaluated VBN B-verb.communication	for IN 0	growth NN 0	inhibition NN 0	( ( 0	MTT NNP 0	) ) 0	, , 0	radiolabeled VBN B-verb.consumption	drug NN 0	uptake NN 0	, , 0	cellular JJ B-adj.all	thiol NN B-noun.relation	content NN I-noun.relation	( ( 0	HPLC NNP B-noun.group	) ) 0	, , 0	and CC 0	DNA NNP B-noun.group	strand VBP B-verb.social	breaks NNS B-noun.act	( ( 0	Comet NNP B-noun.person	assay NN I-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d776.s10	Phenytoin NN B-noun.person	, , 0	DIFLUCAN NNP B-noun.group	increases VBZ B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	phenytoin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d750.s0	Concomitant JJ B-adj.all	use NN 0	of IN 0	alcohol NN B-noun.food	with IN 0	phentermine_hydrochloride NN B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	adverse JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	. . 0	. . 0
DDI-MedLine.d161.s6	These DT 0	behavioural JJ B-adj.all	observations NNS B-noun.act	were VBD B-verb.stative	consistent JJ B-adj.all	with IN 0	in IN 0	vivo JJ B-adj.all	positron NN B-noun.phenomenon	emission NN I-noun.phenomenon	tomography NN 0	dopamine NN 0	transporter NN 0	imaging VBG B-verb.cognition	data NNS B-noun.cognition	, , 0	and CC 0	with IN 0	post NN B-noun.act	- : 0	mortem NN B-noun.substance	stereological JJ B-adj.all	counts NNS B-noun.act	of IN 0	midbrain JJ B-adj.all	dopaminergic JJ B-adj.all	neurons NNS B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	striatal JJ B-adj.all	intensity NN B-noun.possession	measurements NNS B-noun.attribute	of IN 0	dopamine NN B-noun.phenomenon	transporter NN B-noun.event	and CC 0	tyrosine JJ B-adj.all	hydroxylase NN B-noun.event	immunoreactivity NN I-noun.event	, , 0	which WDT 0	were VBD B-verb.stative	all DT 0	significantly RB B-adv.all	higher JJR B-adj.all	in IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ 0	- : 0	treated JJ B-verb.communication	animals NNS B-noun.person	than IN 0	in IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD 0	/ : 0	vehicle NN B-noun.communication	- : 0	treated VBD B-verb.communication	monkeys NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d585.s0	The DT 0	following VBG 0	agents NNS B-noun.person	may MD 0	increase VB B-verb.change	certain JJ B-adj.all	actions NNS B-noun.act	or CC 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	anticholinergic_drugs NNS B-noun.object	, , 0	amantadine NN B-noun.person	, , 0	antiarrhythmic_agents_of_class_I NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	quinidine NN B-noun.location	) ) 0	, , 0	antihistamines NNS B-noun.attribute	, , 0	antipsychotic_agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	phenothiazines NNS B-noun.body	) ) 0	, , 0	benzodiazepines NNS B-noun.person	, , 0	MAO_inhibitors NNS B-noun.person	, , 0	narcotic_analgesics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	meperidine NN B-noun.location	) ) 0	, , 0	nitrates NNS B-noun.person	and CC 0	nitrites NNS B-noun.person	, , 0	sympathomimetic_agents NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	having VBG B-verb.change	anticholinergic JJ B-adj.pert	activity NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d736.s8	Potentiation NN B-noun.person	occurs VBZ B-verb.stative	with IN 0	ganglionic NN B-noun.artifact	or CC 0	peripheral_adrenergic_blocking_drugs NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d216.s1	This DT 0	study NN B-noun.communication	examined VBD B-verb.communication	drug NN B-noun.person	- : 0	drug NN B-noun.person	interactions NNS I-noun.person	of IN 0	oral JJ B-adj.all	S NNP 0	- : 0	ketamine NN B-noun.person	with IN 0	the DT 0	cytochrome NN 0	P450 NN 0	( ( 0	CYP NNP 0	) ) 0	2B6 JJ 0	inhibitor NN 0	ticlopidine NN 0	and CC 0	the DT 0	CYP3A NNP B-noun.person	inhibitor NN I-noun.person	itraconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d727.s1	Therefore RB 0	, , 0	use NN 0	of IN 0	zidovudine NN B-noun.person	in IN 0	combination NN 0	with IN 0	ZERIT NNP B-noun.group	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d744.s0	Acromegalic NNP B-noun.person	patients NNS B-noun.person	with IN 0	diabetes NN B-noun.person	mellitus NN 0	being VBG 0	treated VBN B-verb.change	with IN 0	insulin NN B-noun.feeling	and/or CC 0	oral JJ B-adj.all	hypoglycemic JJ B-adj.all	agents NNS B-noun.person	may MD 0	require VB B-verb.communication	dose NN B-noun.event	reductions NNS B-noun.process	of IN 0	these DT 0	therapeutic JJ B-adj.pert	agents NNS B-noun.person	after IN 0	the DT 0	initiation NN B-noun.act	of IN 0	therapy NN 0	with IN 0	SOMAVERT NNP 0	. . 0	. . 0
DDI-DrugBank.d768.s3	A DT 0	study NN B-noun.artifact	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	involving VBG B-verb.social	single JJ B-noun.act	- : 0	dose NN 0	IV NNP 0	palonosetron NN 0	( ( 0	0.75 CD 0	mg NN B-noun.quantity	) ) 0	and CC 0	steady JJ B-adj.all	state NN B-noun.state	oral JJ B-adj.all	metoclopramide NN B-noun.attribute	( ( 0	10 CD 0	mg IN 0	four CD 0	times NNS 0	daily JJ 0	) ) 0	demonstrated VBD B-verb.perception	no DT 0	significant JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d732.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	CHEMET NNP B-noun.group	with IN 0	other JJ 0	chelation NN 0	therapy NN 0	, , 0	such JJ 0	as IN 0	CaNa_2_EDTA NN 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d656.s3	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	be VB 0	monitored VBN B-verb.perception	when WRB 0	initiating VBG B-verb.communication	, , 0	adjusting VBG B-verb.change	and CC 0	discontinuing VBG B-verb.communication	FELDENE NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d216.s4	The DT 0	ratio NN B-noun.time	of IN 0	norketamine JJ B-adj.all	AUC(0- NN B-noun.artifact	__ '' 0	) ) 0	to TO 0	ketamine VB B-verb.social	AUC(0- NNP B-noun.person	__ : 0	) ) 0	was VBD B-verb.stative	significantly RB B-adv.all	decreased VBN B-verb.change	in IN 0	the DT 0	ticlopidine NN B-noun.location	( ( 0	P NNP 0	& CC 0	lt UH 0	, , 0	0.001 CD 0	) ) 0	and CC 0	itraconazole JJ B-adj.all	phases NNS B-noun.time	( ( 0	P UH 0	= SYM 0	0.006 CD 0	) ) 0	as IN 0	compared VBN 0	to TO 0	placebo VB B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d756.s2	Additive JJ B-adj.all	sedative JJ B-adj.all	effects NNS B-noun.phenomenon	and CC 0	confusional JJ B-adj.all	states NNS B-noun.location	may MD 0	emerge VB B-verb.communication	if IN 0	levomepromazine NN B-noun.person	is VBZ 0	given VBN B-verb.possession	with IN 0	benzodiazepines NNS B-noun.artifact	or CC 0	barbiturates NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d196.s0	Single JJ B-noun.act	- : 0	dose NN B-noun.quantity	bioequivalence NN B-noun.act	of IN 0	105-mg JJ B-adj.all	fenofibric_acid JJ I-adj.all	tablets NNS B-noun.person	versus CC 0	145-mg JJ B-adj.all	fenofibrate NN I-adj.all	tablets NNS B-noun.artifact	under IN 0	fasting VBG B-verb.creation	and CC 0	fed VBN B-verb.consumption	conditions NNS I-verb.consumption	, , 0	a DT 0	report NN B-noun.person	of IN 0	two CD 0	phase NN 0	I PRP 0	, , 0	open JJ B-noun.person	- : 0	label NN B-noun.substance	, , 0	single JJ B-adj.all	- : 0	dose NN B-noun.person	, , 0	randomized VBD B-verb.cognition	, , 0	crossover VBP B-verb.motion	clinical JJ B-adj.all	trials NNS B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d628.s6	DIPRIVAN NNP B-noun.group	Injectable NNP I-noun.group	Emulsion NNP I-noun.group	does VBZ 0	not RB B-adv.all	cause VB B-verb.creation	a DT 0	clinically RB B-adv.all	significant JJ B-adj.all	change NN B-noun.relation	in IN 0	onset NN 0	, , 0	intensity NN B-noun.attribute	, , 0	or CC 0	duration NN B-noun.act	of IN 0	action NN B-noun.process	of IN 0	the DT 0	commonly RB B-adv.all	used VBN B-verb.consumption	neuromuscular_blocking_agents NNS B-noun.person	( ( 0	eg UH 0	, , 0	succinylcholine NN B-noun.person	and CC 0	nondepolarizing_muscle_relaxants NNS B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d664.s1	Therefore RB 0	, , 0	warfarin NN 0	dose NN 0	changes NNS B-noun.artifact	and CC 0	monitoring VBG B-verb.perception	for IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	warfarin NN B-noun.act	on IN 0	blood NN B-noun.act	clotting NN I-noun.act	are VBP B-verb.stative	necessary JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d179.s10	Sunitinib NNP B-noun.person	as IN 0	a DT 0	single JJ B-adj.all	agent NN B-noun.person	exhibits VBZ B-verb.stative	anti NNS I-verb.stative	- : 0	proliferative JJ B-adj.all	effects NNS B-noun.phenomenon	in IN 0	vitro NN B-noun.food	in IN 0	NSCLC NNP 0	cell NN B-noun.body	lines NNS B-noun.communication	with IN 0	EGFR NNP B-noun.group	T790 NNP I-noun.group	M NNP I-noun.group	and CC 0	K NNP 0	- : 0	ras VBD B-verb.stative	mutations NNS B-noun.person	but CC 0	the DT 0	sequential JJ B-adj.all	administration NN B-noun.time	of IN 0	docetaxel NN 0	followed VBN B-verb.stative	by IN 0	sunitinib NN B-noun.person	is VBZ B-verb.stative	superior JJ B-adj.all	to TO 0	sunitinib VB 0	followed VBN B-verb.stative	by IN 0	docetaxel NN B-noun.artifact	and CC 0	concurrent JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d736.s7	Thiazides NNS 0	may MD 0	add VB B-verb.communication	to TO 0	or CC 0	potentiate VB B-verb.communication	the DT 0	action NN B-noun.process	of IN 0	other JJ B-adj.all	antihypertensive_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d712.s1	Administration NN B-noun.person	of IN 0	paclitaxel NN B-noun.artifact	in IN 0	combination NN 0	with IN 0	HERCEPTIN NNP B-noun.group	resulted VBD B-verb.competition	in IN 0	a DT 0	two CD 0	- : 0	fold JJ B-adj.all	decrease NN B-noun.act	in IN 0	HERCEPTIN NNP 0	clearance NN B-noun.attribute	in IN 0	a DT 0	non NN B-noun.person	- : 0	human JJ B-adj.all	primate NN B-noun.person	study NN B-noun.artifact	and CC 0	in IN 0	a DT 0	1.5-fold JJ B-adj.all	increase NN B-noun.event	in IN 0	HERCEPTIN NNP 0	serum NN B-noun.body	levels NNS B-noun.attribute	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d768.s4	In IN 0	controlled VBN B-verb.social	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	ALOXI NNP B-noun.group	injection NN I-noun.group	has VBZ 0	been VBN 0	safely RB B-adv.all	administered VBN B-verb.possession	with IN 0	corticosteroids NNS B-noun.food	, , 0	analgesics NNS B-noun.person	, , 0	antiemetics NNS B-noun.attribute	/ CC 0	antinauseants NNS B-noun.quantity	, , 0	antispasmodics NNS B-noun.person	and CC 0	anticholinergic_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d647.s2	a DT 0	reduction NN B-noun.act	of IN 0	the DT 0	doxorubicin NN B-noun.artifact	dosage NN B-noun.artifact	should MD 0	be VB 0	considered VBN B-verb.cognition	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	ZANOSAR NNP B-noun.group	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d705.s0	Telbivudine NN B-noun.person	is VBZ 0	excreted VBN B-verb.change	mainly RB B-adv.all	by IN 0	passive JJ B-adj.all	diffusion NN B-noun.state	so IN 0	the DT 0	potential NN B-noun.person	for IN 0	interactions NNS B-noun.act	between IN 0	telbivudine NN B-noun.location	and CC 0	other JJ 0	drugs NNS B-noun.person	eliminated VBN B-verb.emotion	by IN 0	renal JJ B-adj.all	excretion NN B-noun.act	is VBZ B-verb.stative	low JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d773.s2	Anticoagulants NNS B-noun.person	( ( 0	such JJ 0	as IN 0	heparin NN B-noun.person	and CC 0	vitamin_K_antagonists NNS B-noun.location	) ) 0	and CC 0	drugs NNS B-noun.artifact	that WDT 0	alter VBP B-verb.change	platelet NN B-verb.creation	function NN B-noun.attribute	( ( 0	such JJ 0	as IN 0	acetylsalicylic_acid JJ 0	, , 0	dipyridamole NN B-noun.person	, , 0	and CC 0	GP NNP B-noun.person	IIb NNP I-noun.person	/ NNP I-noun.person	IIIa NNP I-noun.person	inhibitors NNS I-noun.person	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	bleeding VBG B-verb.communication	if IN 0	administered VBN B-verb.possession	prior RB 0	to TO 0	, , 0	during IN 0	, , 0	or CC 0	after IN 0	TNKase NNP B-noun.person	therapy NN 0	. . 0	. . 0
DDI-MedLine.d219.s4	The DT 0	treatment NN B-noun.communication	of IN 0	coinfected JJ B-adj.all	patients NNS B-noun.person	requires VBZ B-verb.communication	antituberculosis NN B-noun.attribute	and CC 0	antiretroviral_drugs NNS B-noun.object	to TO 0	be VB 0	administered VBN B-verb.possession	concomittantly RB B-adv.all	, , 0	. . 0
DDI-MedLine.d181.s8	Drug NN 0	interaction NN 0	of IN 0	thyroxine NN B-noun.body	with IN 0	simeticone NN 0	has VBZ 0	not RB 0	been VBN 0	reported VBN B-verb.communication	previously RB B-adv.all	and CC 0	is VBZ B-verb.stative	not RB B-adv.all	listed VBN B-verb.social	in IN 0	the DT 0	British NNP B-noun.other	National NNP I-noun.other	Formulary NNP I-noun.other	for IN I-noun.other	Children NNP I-noun.other	. . 0	. . 0
DDI-DrugBank.d752.s10	The DT 0	sedative JJ B-adj.all	effect NN B-noun.cognition	of IN 0	VERSED_Syrup NNP B-noun.person	is VBZ 0	accentuated VBN B-verb.change	by IN 0	any DT 0	concomitantly RB B-adv.all	administered VBN B-verb.possession	medication NN B-noun.artifact	which WDT 0	depresses VBZ B-verb.stative	the DT 0	central JJ B-noun.body	nervous JJ I-noun.body	system NN B-noun.cognition	, , 0	particularly RB B-adj.all	narcotics NNS B-noun.person	( ( 0	eg UH 0	, , 0	morphine NN B-noun.person	, , 0	meperidine NN B-noun.person	and CC 0	fentanyl NN B-noun.location	) ) 0	, , 0	propofol NN B-noun.person	, , 0	ketamine NN B-noun.person	, , 0	nitrous_oxide JJ 0	, , 0	secobarbital JJ B-adj.all	and CC 0	droperidol NN B-noun.person	. . 0	. . 0
DDI-MedLine.d194.s0	The DT 0	role NN B-noun.attribute	of IN 0	p27(Kip1 NNP B-noun.location	) ) 0	in IN 0	dasatinib NN B-noun.person	- : 0	enhanced JJ B-adj.all	paclitaxel NN B-noun.artifact	cytotoxicity NN I-noun.artifact	in IN 0	human JJ B-adj.all	ovarian JJ B-adj.all	cancer NN B-noun.state	cells NNS B-noun.body	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d717.s0	Mitotane NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	accelerate VB B-verb.communication	the DT 0	metabolism NN B-noun.attribute	of IN 0	warfarin NN B-noun.act	by IN 0	the DT 0	mechanism NN B-noun.attribute	of IN 0	hepatic JJ B-adj.all	microsomal JJ B-adj.all	enzyme NN B-noun.person	induction NN B-noun.person	, , 0	leading VBG B-verb.motion	to TO 0	an DT 0	increase NN B-noun.act	in IN 0	dosage NN 0	requirements NNS B-noun.person	for IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-MedLine.d182.s17	nucleatum NN B-noun.artifact	, , 0	with IN 0	MIC NNP 0	of IN 0	0.42 CD 0	mM/0.69 NNS B-noun.quantity	mM CC 0	for IN 0	o SYM 0	- : 0	cymen-5-ol NN B-noun.time	/ '' 0	zinc_gluconate NNP B-noun.other	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-MedLine.d218.s10	Warfarin NN B-noun.person	users NNS B-noun.person	who WP 0	initiated VBD B-verb.communication	citalopram NN B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	amitriptyline NN B-noun.person	, , 0	or CC 0	mirtazapine NN B-noun.person	had VBD 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	hospitalization NN B-noun.act	for IN 0	gastrointestinal JJ B-adj.all	bleeding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d711.s3	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	tetracycline NN B-noun.attribute	and CC 0	methoxyflurane NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	result VB B-verb.stative	in IN 0	fatal JJ B-adj.all	renal JJ B-noun.body	toxicity NN I-noun.body	. . 0	. . 0
DDI-MedLine.d220.s2	Luteolin NNP B-noun.person	and CC 0	apigenin RB B-adj.all	experienced JJ B-adj.all	extensive JJ 0	first RB B-adv.all	- : 0	pass NN B-noun.person	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d192.s8	Our PRP$ 0	results NNS B-noun.communication	characterize VBP B-verb.change	and CC 0	identify VB B-verb.cognition	a DT 0	novel JJ B-adj.all	opiate NN B-noun.person	addiction NN B-noun.person	switching VBG B-verb.motion	mechanism NN 0	directly RB B-adv.all	in IN 0	the DT 0	BLA NNP B-noun.group	that WDT 0	can MD 0	control VB B-verb.social	the DT 0	processing NN B-noun.act	of IN 0	opiate JJ B-adj.all	reward NN B-noun.possession	information NN B-noun.cognition	as IN 0	a DT 0	direct JJ 0	function NN 0	of IN 0	opiate JJ B-adj.all	exposure NN B-noun.state	state NN B-noun.state	via IN 0	D1 : 0	or CC 0	D2 : 0	receptor NN B-noun.person	signaling VBG B-verb.communication	substrates NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d575.s5	An DT 0	increase NN B-noun.event	in IN 0	intracellular JJ B-adj.all	levels NNS B-noun.state	of IN 0	methotrexate NN B-noun.person	was VBD 0	observed VBN B-verb.perception	in IN 0	vitro NN B-noun.food	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	teniposide NN 0	. . 0	. . 0
DDI-DrugBank.d597.s22	Patients NNS B-noun.person	on IN 0	lithium NN B-noun.substance	treatment NN B-noun.plant	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	when WRB 0	MOBIC NNP 0	is VBZ 0	introduced VBN B-verb.contact	or CC 0	withdrawn VBN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d607.s1	Drugs NNS B-noun.artifact	which WDT 0	may MD 0	potentiate VB B-verb.communication	the DT 0	myeloproliferative JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	Leukine NNP B-noun.person	, , 0	such JJ 0	as IN 0	lithium NN B-noun.person	and CC 0	corticosteroids NNS B-noun.person	, , 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d752.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	Inhibitors NNP B-noun.person	of IN 0	CYP3A4 NNP B-noun.group	Isozymes NNPS I-noun.group	, , 0	Caution NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	when WRB 0	midazolam NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	known VBN B-verb.cognition	to TO 0	inhibit VB B-verb.change	the DT 0	cytochrome NN 0	P450 RB 0	3A4 JJ 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	( ( 0	ie UH 0	, , 0	some DT 0	drugs NNS B-noun.artifact	in IN 0	the DT 0	drug NN B-noun.group	classes NNS B-noun.attribute	of IN 0	azole_antimycotics NNS B-noun.person	, , 0	protease_inhibitors NNS B-noun.person	, , 0	calcium_channel_antagonists NNS B-noun.person	, , 0	and CC 0	macrolide_antibiotics NNS B-noun.person	) ) 0	. . 0	. . 0
DDI-MedLine.d190.s6	Hyaluronan_lyase NN B-noun.state	had VBD B-verb.stative	a DT 0	limited JJ B-adj.all	effect NN B-noun.cognition	and CC 0	collagenase NN B-noun.person	was VBD B-verb.stative	ineffective JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d641.s3	Although IN 0	ibuprofen JJ 0	( ( 0	400 CD 0	mg NN B-noun.quantity	qid NN 0	) ) 0	can MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	ALIMTA NNP B-noun.group	in IN 0	patients NNS B-noun.person	with IN 0	normal JJ B-adj.all	renal JJ B-noun.phenomenon	function NN I-noun.phenomenon	( ( 0	creatinine JJ B-adj.all	clearance NN B-noun.attribute	___ CD 0	80 CD B-adj.all	mL CD B-noun.quantity	/ JJ 0	min NN 0	) ) 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	administering VBG B-verb.communication	ibuprofen NNS B-noun.person	concurrently RB B-adv.all	with IN 0	ALIMTA NNP B-noun.group	to TO 0	patients NNS B-noun.person	with IN 0	mild JJ 0	to TO 0	moderate VB B-verb.change	renal JJ B-adj.all	insufficiency NN B-noun.attribute	( ( 0	creatinine JJ B-adj.all	clearance NN B-noun.person	from IN 0	45 CD 0	to TO 0	79 CD B-adj.all	mL CD B-noun.quantity	/ JJ 0	min NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d169.s8	Calcium NN B-noun.person	doses VBZ B-verb.stative	__ $ 0	1000 CD 0	mg NN B-noun.quantity	diminished VBD B-verb.change	nonheme_iron JJ B-adj.all	absorption NN B-noun.artifact	by IN 0	an DT 0	average NN B-noun.act	of IN 0	49.6 CD 0	% NN 0	. . 0	. . 0
DDI-MedLine.d220.s3	The DT 0	elimination NN B-noun.act	percent NN B-noun.person	of IN 0	luteolin NN B-noun.substance	and CC 0	apigenin NN B-noun.person	was VBD 0	found VBN B-verb.cognition	to TO 0	be VB B-verb.stative	91.9 CD 0	% NN 0	and CC 0	86.7 CD 0	% NN 0	after IN 0	120 CD 0	min NN 0	of IN 0	incubation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d666.s2	Pindolol NNP B-noun.person	has VBZ 0	been VBN 0	used VBN B-verb.consumption	with IN 0	a DT 0	variety NN B-noun.cognition	of IN 0	antihypertensive_agents NNS B-noun.location	, , 0	including VBG B-verb.stative	hydrochlorothiazide NN 0	, , 0	hydralazine NN B-noun.person	, , 0	and CC 0	guanethidine NN B-noun.act	without IN 0	unexpected JJ B-adj.all	adverse JJ B-noun.body	interactions NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d715.s0	Caution NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	in IN 0	administering VBG B-verb.change	DEMSER NNP B-noun.group	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	phenothiazines NNS B-noun.communication	or CC 0	haloperidol NN B-noun.act	because IN 0	the DT 0	extrapyramidal JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	these DT 0	drugs NNS B-noun.person	can MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	inhibition NN B-noun.time	of IN 0	catecholamine NN B-noun.act	synthesis NN I-noun.act	. . 0	. . 0
DDI-MedLine.d197.s6	PXR SYM 0	- : 0	ligands NNS B-noun.person	include VBP B-verb.change	a DT 0	wide JJ B-adj.all	variety NN B-noun.attribute	of IN 0	pharmaceutical JJ B-adj.all	agents NNS B-noun.person	, , 0	such JJ 0	as IN 0	antiepileptic_drugs NNS B-noun.object	, , 0	taxol NN B-noun.person	, , 0	rifampicin NN B-noun.person	, , 0	and CC 0	human_immunodeficiency_virus_protease_inhibitors NNS B-noun.person	such JJ 0	as IN 0	ritonavir NN B-noun.person	and CC 0	saquinavir NN B-noun.person	. . 0	. . 0
DDI-MedLine.d195.s7	From IN 0	this DT 0	study NN B-noun.communication	it PRP 0	can MD 0	be VB 0	concluded VBN B-verb.cognition	that IN 0	piperine NN B-noun.person	can MD 0	be VB 0	used VBN B-verb.consumption	as IN 0	a DT 0	bioenhancer NN B-noun.person	along IN 0	with IN 0	ibuprofen NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d175.s3	We PRP 0	sought VBD B-verb.social	to TO 0	determine VB B-verb.communication	( ( 0	1 CD 0	) ) 0	the DT 0	frequency NN B-noun.person	of IN 0	colchicine NN B-noun.phenomenon	toxicity NN B-noun.phenomenon	among IN 0	hospitalized JJ B-adj.all	patients NNS B-noun.person	taking VBG B-verb.social	colchicine NN B-noun.person	who WP 0	died VBD B-verb.social	during IN 0	an DT 0	admission NN B-noun.person	, , 0	( ( 0	2 CD 0	) ) 0	the DT 0	likelihood NN 0	that IN 0	colchicine NN B-noun.person	contributed VBD B-verb.communication	to TO 0	death NN 0	, , 0	( ( 0	3 CD 0	) ) 0	whether IN 0	patients NNS B-noun.person	were VBD 0	taking VBG B-verb.social	interacting JJ B-adj.all	medications NNS B-noun.communication	that WDT 0	could MD 0	have VB 0	contributed VBN B-verb.communication	to TO 0	toxicity NN B-noun.attribute	, , 0	and CC 0	( ( 0	4 CD 0	) ) 0	whether IN 0	colchicine NN 0	dosing NN B-verb.creation	among IN 0	these DT 0	patients NNS B-noun.person	adhered VBD B-verb.communication	to TO 0	established VBN B-verb.creation	guidelines NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d640.s9	Other JJ 0	Agents NNPS B-noun.person	, , 0	No DT 0	clinically RB B-adv.all	important JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	occurred VBD B-verb.cognition	when WRB 0	UNIVASC NNP B-noun.group	___ NNP I-noun.group	was VBD 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	hydrochlorothiazide NN 0	, , 0	digoxin NN B-noun.person	, , 0	or CC 0	cimetidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d588.s8	Curariform_Drugs NNS B-noun.artifact	, , 0	Diuretic JJ B-noun.person	- : 0	induced VBN B-verb.creation	hypokalemia NN 0	may MD 0	enhance VB B-verb.change	neuromuscular JJ 0	blocking VBG B-verb.communication	effects NNS B-noun.phenomenon	of IN 0	curariform_drugs NNS B-noun.cognition	( ( 0	such JJ 0	as IN 0	tubocurarine NN 0	) ) 0	the DT 0	most RBS 0	serious JJ B-adj.all	effect NN B-noun.cognition	would MD 0	be VB B-verb.stative	respiratory JJ B-adj.all	depression NN B-noun.act	which WDT 0	could MD 0	proceed VB B-verb.perception	to TO 0	apnea NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d633.s4	In IN 0	this DT 0	crossover NN B-noun.animal	steady JJ I-noun.animal	state NN B-adj.all	study NN B-noun.artifact	, , 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	propafenone NN B-noun.person	were VBD B-verb.stative	unaffected JJ B-adj.all	in IN 0	either DT 0	phenotype NN B-noun.person	by IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	mexiletine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d227.s2	The DT 0	purpose NN B-noun.attribute	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	evaluate VB B-verb.communication	whether IN 0	the DT 0	psychostimulant JJ B-adj.all	drug NN B-noun.person	ephedrine NN B-noun.person	has VBZ B-verb.possession	any DT 0	effect NN B-noun.cognition	on IN 0	dexmedetomidine NN B-noun.person	- : 0	induced VBN B-verb.creation	antinociception NN B-noun.attribute	and CC 0	locomotor NN B-noun.person	inhibitor NN B-noun.person	activity NN B-noun.process	in IN 0	mice NNS B-noun.animal	in IN 0	acute JJ B-adj.all	application NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d709.s3	Although IN 0	such JJ 0	a DT 0	reaction NN B-noun.process	has VBZ 0	not RB 0	been VBN 0	demonstrated VBN B-verb.cognition	with IN 0	roxithromycin NN B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	roxithromycin NN B-noun.substance	with IN 0	terfenadine NN B-noun.artifact	or CC 0	astemizole NN B-noun.communication	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d696.s1	Concurrent JJ B-adj.all	use NN 0	with IN 0	vasoconstrictor_agents NNS B-noun.artifact	including VBG B-verb.stative	ergot_alkaloids NNS I-verb.stative	, , 0	sumatriptan NN 0	, , 0	and CC 0	nicotine NN B-noun.person	( ( 0	e.g. JJ B-adv.all	smoking NN B-verb.consumption	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	enhanced JJ B-adj.all	vasoconstriction NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d591.s0	Ropivacaine NN 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	other JJ B-adj.all	local JJ B-adj.all	anesthetics NNS B-noun.group	or CC 0	agents NNS B-noun.person	structurally RB B-adv.all	related VBN B-verb.cognition	to TO 0	amide VB B-verb.social	- : 0	type_local_anesthetics NNS B-noun.person	, , 0	since IN 0	the DT 0	toxic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	these DT 0	drugs NNS B-noun.artifact	are VBP B-verb.stative	additive JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d637.s0	Use NN 0	with IN 0	Other JJ 0	Central_Nervous_System_Depressants NNS B-noun.location	, , 0	The DT 0	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	morphine NN B-noun.person	are VBP 0	potentiated VBN B-verb.communication	by IN 0	the DT 0	presence NN B-noun.person	of IN 0	other JJ B-adj.all	CNS_depressants NNS B-noun.object	such JJ 0	as IN 0	alcohol NN B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	antihistaminics NNS B-noun.person	, , 0	or CC 0	psychotropic_drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d639.s2	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	SUTENT NNP B-noun.group	with IN 0	inducers NNS B-noun.person	of IN 0	the DT 0	CYP3A4 NNP B-noun.person	family NN B-noun.group	( ( 0	e.g. UH 0	, , 0	dexamethasone NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	rifampin NN B-noun.person	, , 0	rifabutin NN B-noun.person	, , 0	rifapentin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	St. NNP B-noun.group	Johns NNP I-noun.group	Wort NNP I-noun.group	) ) 0	may MD 0	decrease VB B-verb.change	sunitinib JJ B-adj.all	concentrations NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d196.s20	The DT 0	90 CD B-adj.all	% NN 0	CIs CC 0	about IN 0	the DT 0	ratio NN B-noun.time	of IN 0	the DT 0	fenofibric_acid JJ B-adj.all	geometric JJ B-adj.all	mean NN B-noun.attribute	to TO 0	the DT 0	fenofibrate JJ B-adj.all	geometric JJ B-adj.all	mean NN B-noun.attribute	were VBD B-verb.stative	within IN 0	the DT 0	80 CD B-adj.all	% NN 0	and CC 0	125 CD 0	% NN 0	limits NNS B-noun.attribute	for IN 0	the DT 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.event	C(max VBP 0	) ) 0	, , 0	AUC(0-t NNP B-noun.location	) ) 0	, , 0	and CC 0	AUC(0- VB B-verb.communication	__ LS 0	) ) 0	of IN 0	the DT 0	ln SYM 0	- : 0	transformed VBN B-verb.cognition	data NNS B-noun.cognition	in IN 0	both DT 0	study NN B-noun.communication	1 CD 0	( ( 0	fasted VBN B-verb.creation	) ) 0	and CC 0	study NN B-noun.communication	2 CD B-adj.all	. . 0	. . 0
DDI-DrugBank.d576.s5	Salicylates NNS B-noun.location	may MD 0	enhance VB B-verb.change	the DT 0	hypoglycemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	oral JJ B-adj.all	antidiabetic_drugs NNS B-noun.object	of IN 0	the DT 0	sulfonylurea NN B-noun.artifact	class NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d782.s0	Vindesine NNP B-noun.person	can MD 0	interact VB B-verb.change	with IN 0	the DT 0	drugs NNS B-noun.artifact	of IN 0	the DT 0	following JJ B-adj.all	categories NNS B-noun.person	, , 0	_ PRP 0	; : 0	Blood NNP B-noun.person	dyscrasia NN I-noun.person	, , 0	can MD 0	cause VB B-verb.creation	unpredictable JJ B-adj.all	myelotoxicity NN B-noun.attribute	; : 0	Bone NNP 0	marrow NN 0	depressants NNS B-noun.person	, , 0	can MD 0	cause VB B-verb.creation	a DT 0	predictable JJ B-adj.all	dose NN B-noun.person	- : 0	related JJ B-adj.all	myelotoxicity NN B-noun.attribute	; : 0	Radiation NNP B-noun.person	therapy NN 0	, , 0	may MD 0	cause VB B-verb.communication	marrow JJ B-adj.all	depression NN B-noun.feeling	; : 0	Neurotoxic JJ B-noun.person	medications NNS I-noun.person	, , 0	can MD 0	cause VB B-verb.creation	neurologic JJ B-adj.all	toxicity NN B-noun.attribute	; : 0	Phenytoin NNP B-noun.person	, , 0	can MD 0	increase VB B-verb.change	seizure NN B-noun.phenomenon	activity NN B-noun.process	; : 0	Live_virus_vaccines NNS B-noun.animal	, , 0	may MD 0	potentiate VB B-verb.communication	the DT 0	replication NN B-noun.act	of IN 0	the DT 0	vaccine NN B-noun.artifact	virus NN B-noun.artifact	, , 0	may MD 0	increase VB B-verb.change	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	the DT 0	vaccination NN B-noun.artifact	, , 0	and CC 0	decrease VB B-verb.cognition	patient NN B-noun.person	's POS 0	response NN B-noun.communication	to TO 0	the DT 0	vaccine NN B-noun.attribute	; : 0	Mitomycin NNP B-noun.person	- : 0	C NN 0	, , 0	may MD 0	cause VB B-verb.emotion	shortness NN 0	of IN 0	breath NN B-noun.person	and CC 0	bronchospasm NN B-noun.feeling	; : 0	Killed_virus_vaccines NNS B-noun.artifact	, , 0	may MD 0	decrease VB B-verb.cognition	patient NN B-noun.person	's POS 0	response NN B-noun.communication	to TO 0	the DT 0	vaccine NN B-noun.location	. . 0
DDI-DrugBank.d733.s0	Misoprostol NNP B-noun.person	has VBZ 0	not RB 0	been VBN 0	shown VBN B-verb.perception	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	beneficial JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	aspirin NN B-noun.person	on IN 0	signs NNS B-noun.communication	and CC 0	symptoms NNS B-noun.communication	of IN 0	rheumatoid JJ B-noun.body	arthritis NN I-noun.body	. . 0	. . 0
DDI-DrugBank.d604.s2	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	In IN 0	10 CD B-adj.all	healthy JJ B-adj.all	women NNS B-noun.person	, , 0	the DT 0	pharmacokinetic JJ B-adj.all	profiles NNS B-noun.shape	of IN 0	norethindrone NN B-noun.person	and CC 0	ethinyl_estradiol NN 0	following VBG B-verb.stative	administration NN B-noun.act	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.communication	containing VBG B-verb.stative	1.0 CD 0	mg NN B-noun.quantity	of IN 0	norethindrone_acetate JJ B-adj.all	and CC 0	75 CD 0	___ CD 0	g NN B-noun.quantity	of IN 0	ethinyl_estradiol NN B-noun.food	were VBD 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d711.s4	Concurrent JJ B-adj.all	use NN 0	of IN 0	tetracyclines NNS B-noun.shape	with IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.possession	may MD 0	render VB B-verb.possession	oral JJ B-adj.all	contraceptives NNS B-noun.event	less RBR B-adv.all	effective JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d147.s1	We PRP 0	evaluated VBD B-verb.communication	mechanisms NNS B-noun.person	of IN 0	interaction NN B-noun.act	between IN 0	the DT 0	alkyating VBG B-adj.all	agent NN B-noun.person	dacarbazine NN B-noun.person	( ( 0	DTIC NNP 0	) ) 0	and CC 0	the DT 0	pro JJ B-noun.person	- : 0	oxidant NN B-noun.person	, , 0	imexon NN B-noun.person	, , 0	in IN 0	the DT 0	human JJ B-adj.all	A375 NN B-noun.group	melanoma NN B-noun.communication	cell NN 0	line NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d698.s2	requirements NNS B-noun.object	for IN 0	riboflavin NN 0	may MD 0	be VB 0	increased VBN B-verb.change	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	probenecid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d636.s2	Those DT 0	anticonvulsants NNS B-noun.location	include VBP B-verb.stative	divalproex_sodium NN I-verb.stative	, , 0	valproic_acid NNP B-noun.person	, , 0	and CC 0	phenobarbital NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d624.s3	TOBI NNP B-noun.group	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	ethacrynic_acid JJ 0	, , 0	furosemide RB 0	, , 0	urea NN B-noun.person	, , 0	or CC 0	mannitol NN B-noun.group	. . 0	. . 0
DDI-MedLine.d200.s0	[ DT 0	Efficacy NNP B-noun.person	of IN 0	fixed VBN B-verb.consumption	combination NN 0	amlodipine NN 0	/ : 0	valsartan NN B-noun.attribute	in IN 0	hospitalized VBN B-verb.social	patients NNS B-noun.person	with IN 0	hypertensive JJ B-adj.all	disease NN B-noun.person	] : 0	. . 0
DDI-DrugBank.d640.s2	Potassium NNP B-noun.person	Supplements NNPS I-noun.person	and CC 0	Potassium NNP B-noun.person	- : 0	Sparing_Diuretics NNS B-noun.person	, , 0	UNIVASC NNP B-noun.group	___ NNP I-noun.group	can MD 0	increase VB B-verb.change	serum NN 0	potassium NN 0	because IN 0	it PRP 0	decreases VBZ B-verb.change	aldosterone JJ B-adj.all	secretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d622.s3	morphine NN B-noun.person	, , 0	theophylline PRP 0	, , 0	aminophylline NN B-noun.person	, , 0	succinylcholine NN B-noun.person	, , 0	reserpine NN B-noun.person	, , 0	and CC 0	phenothiazine NN B-noun.person	- : 0	type_tranquilizers NNS B-noun.person	should MD 0	be VB 0	avoided VBN B-verb.social	in IN 0	patients NNS B-noun.person	with IN 0	organophosphate NN B-noun.cognition	poisoning NN I-noun.cognition	. . 0	. . 0
DDI-DrugBank.d739.s13	Phenobarbital JJ B-adj.all	, , 0	which WDT 0	induces VBZ B-verb.stative	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	, , 0	decreased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	montelukast NN B-noun.person	approximately RB B-adv.all	40 CD B-adj.all	% NN 0	following VBG B-verb.stative	a DT 0	single JJ B-adj.all	10-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	montelukast NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d584.s5	A DT 0	5.5-fold JJ B-noun.artifact	decrease NN I-noun.artifact	in IN 0	the DT 0	mean JJ B-adj.all	warfarin NN B-noun.location	dose NN B-noun.person	from IN 0	6.13 CD 0	mg NN B-noun.quantity	/ : 0	day NN 0	to TO 0	1.13 CD 0	mg NN B-noun.quantity	/ : 0	day NN B-noun.person	( ( 0	approximately RB B-adv.all	80 CD B-adj.all	- : 0	85 CD 0	% NN 0	reduction NN B-noun.act	of IN 0	warfarin NN B-noun.act	dose NN B-noun.event	) ) 0	, , 0	was VBD B-verb.stative	necessary JJ B-adj.all	to TO 0	maintain VB B-verb.consumption	a DT 0	target NN B-noun.person	INR NNP I-noun.person	of IN 0	1.5 CD 0	. . 0	. . 0
DDI-MedLine.d194.s15	The DT 0	siRNA CD 0	knockdown VBN B-verb.cognition	of IN 0	p27(Kip1 NNP B-noun.location	) ) 0	decreased VBD B-verb.change	dasatinib- NNP B-noun.person	and CC 0	paclitaxel NN B-noun.person	- : 0	induced VBN B-verb.creation	apoptosis NN B-noun.feeling	compared VBN B-verb.change	with IN 0	a DT 0	negative JJ B-adj.all	control NN B-noun.person	siRNA NNP I-noun.person	( ( 0	sub SYM 0	- : 0	G1 SYM 0	fraction NN B-noun.artifact	, , 0	control FW 0	siRNA FW B-noun.other	vs. FW I-noun.other	p27(Kip1 NNP I-noun.other	) ) 0	siRNA NN B-noun.location	, , 0	42.5 CD 0	% NN 0	vs. CC 0	20.1 CD 0	% NN 0	, , 0	difference NN B-noun.cognition	= SYM 0	22.4 CD 0	% NN 0	, , 0	95 CD 0	% NN 0	CI NN 0	= SYM 0	20.1 CD 0	% NN 0	to TO 0	24.7 CD 0	% NN 0	, , 0	P NNP 0	= : 0	.017 LS 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d762.s2	Therefore RB 0	, , 0	the DT 0	coadministration NN B-noun.person	of IN 0	probenecid NN B-noun.person	with IN 0	meropenem NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d722.s1	As IN 0	there EX 0	is VBZ B-verb.stative	in IN 0	vitro JJ B-adj.all	evidence NN B-noun.attribute	that WDT 0	aminosalicylate_derivatives VBZ B-verb.stative	( ( 0	e.g. UH 0	, , 0	olsalazine JJ 0	, , 0	mesalazine NN B-noun.person	, , 0	or CC 0	sulphasalazine NN B-noun.location	) ) 0	inhibit VBP B-verb.stative	the DT 0	TPMT NNP B-noun.group	enzyme NN B-noun.person	, , 0	they PRP 0	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.change	concurrent JJ B-adj.all	thioguanine NN 0	therapy NN 0	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d718.s0	Interactions NNS B-noun.person	_ POS 0	Interaction NNP B-noun.act	may MD 0	occur VB B-verb.stative	with IN 0	Antacids NNP B-noun.person	, , 0	Calcium NNP B-noun.person	supplements NNS B-noun.artifact	, , 0	Cholestyramine NNP B-noun.person	, , 0	Choline NNP B-noun.person	and CC 0	magnesium_salicylates NNS B-noun.person	, , 0	Colestipol NNP B-noun.person	, , 0	Iron NNP B-noun.person	- : 0	containing VBG B-verb.communication	drugs NNS B-noun.person	, , 0	Laxatives NNPS B-noun.person	, , 0	Magnesium_salicylate JJ B-noun.person	, , 0	these DT 0	drugs NNS B-noun.artifact	may MD 0	decrease VB B-verb.cognition	the DT 0	potency NN B-noun.person	of IN 0	tetracyclines NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d746.s0	ARAMINE NN B-noun.group	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	digitalized JJ B-adj.all	patients NNS B-noun.person	, , 0	since IN 0	the DT 0	combination NN B-noun.event	of IN 0	digitalis NN B-noun.food	and CC 0	sympathomimetic_amines NNS B-noun.object	may MD 0	cause VB B-verb.communication	ectopic JJ B-adj.pert	arrhythmias NNS B-noun.communication	. . 0	. . 0
DDI-MedLine.d227.s6	saline NN B-noun.act	+ : 0	saline NN B-noun.person	, , 0	ephedrine NN B-noun.person	( ( 0	10 CD B-adj.all	__ CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	+ : 0	saline NN B-noun.person	, , 0	saline NN B-noun.act	+ : 0	dexmedetomidine NN B-noun.person	( ( 0	15 CD B-adj.all	____ JJ B-adj.all	g IN 0	/ : 0	kg LS 0	) ) 0	and CC 0	ephedrine NN B-noun.person	( ( 0	10 CD B-adj.all	__ CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	+ : 0	dexmedetomidine NN B-noun.person	( ( 0	15 CD B-adj.all	____ JJ B-adj.all	g IN 0	/ : 0	kg LS 0	) ) 0	, , 0	intraperitoneally RB B-adv.all	, , 0	30 CD B-adj.all	min NN B-noun.quantity	before IN 0	hot JJ B-adj.all	plate NN B-noun.substance	or CC 0	holed VBD B-verb.contact	open JJ B-adj.all	field NN B-noun.object	tests NNS I-noun.object	. . 0	. . 0
DDI-DrugBank.d597.s30	Caution NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	administering VBG B-verb.creation	MOBIC NNP I-verb.creation	with IN 0	warfarin NN 0	since IN 0	patients NNS B-noun.person	on IN 0	warfarin NN B-noun.act	may MD 0	experience VB B-verb.change	changes NNS B-noun.food	in IN 0	INR NNP 0	and CC 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	bleeding VBG B-verb.body	complications NNS B-noun.artifact	when WRB 0	a DT 0	new JJ B-adj.all	medication NN B-noun.person	is VBZ 0	introduced VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d588.s4	Digitalis_Glycosides NNS B-noun.artifact	, , 0	Diuretic JJ B-noun.person	- : 0	induced VBN B-verb.creation	hypokalemia NN 0	can MD 0	increase VB B-verb.change	the DT 0	sensitivity NN B-noun.time	of IN 0	the DT 0	myocardium NN B-noun.artifact	to TO 0	digitalis VB B-verb.change	. . 0	. . 0
DDI-DrugBank.d781.s10	Use NNP B-noun.person	of IN 0	a DT 0	diuretic JJ B-noun.person	may MD 0	further RBR 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d733.s1	Misoprostol NNP B-noun.person	does VBZ 0	not RB B-adv.all	exert VB B-verb.body	clinically RB B-adv.all	significant JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	the DT 0	absorption NN B-noun.artifact	, , 0	blood NN B-noun.body	levels NNS I-noun.body	, , 0	and CC 0	anti NNS B-noun.person	- : 0	platelet NN B-verb.creation	effects NNS B-noun.phenomenon	of IN 0	therapeutic JJ B-adj.all	doses NNS B-noun.event	of IN 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d718.s1	Oral JJ B-adj.all	contraceptives NNS B-noun.event	containing VBG B-verb.stative	estrogen NN B-noun.substance	, , 0	tetracyclines NNS B-noun.artifact	may MD 0	decrease VB B-verb.cognition	the DT 0	contraceptive JJ B-adj.all	effect NN B-noun.cognition	and CC 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	unwanted JJ B-adj.all	pregnancy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d628.s0	The DT 0	induction NN 0	dose NN 0	requirements NNS B-noun.object	of IN 0	DIPRIVAN NNP B-noun.group	Injectable NNP I-noun.group	Emulsion NNP I-noun.group	may MD 0	be VB 0	reduced VBN B-verb.change	in IN 0	patients NNS B-noun.person	with IN 0	intramuscular JJ B-adj.all	or CC 0	intravenous JJ B-adj.all	premedication NN B-noun.person	, , 0	particularly RB B-adv.all	with IN 0	narcotics NNS B-noun.person	( ( 0	eg UH 0	, , 0	morphine NN B-noun.person	, , 0	meperidine NN B-noun.person	, , 0	and CC 0	fentanyl NN B-noun.person	, , 0	etc FW 0	. . 0	) ) 0	. . 0
DDI-DrugBank.d628.s4	The DT 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	potent JJ B-adj.all	inhalational JJ B-adj.all	agents NNS B-noun.person	( ( 0	eg UH 0	, , 0	isoflurane NN B-noun.person	, , 0	enflurane NN B-noun.person	, , 0	and CC 0	halothane NN 0	) ) 0	during IN 0	maintenance NN B-noun.person	with IN 0	DIPRIVAN NNP B-noun.group	Injectable NNP I-noun.group	Emulsion NNP I-noun.group	has VBZ 0	not RB 0	been VBN 0	extensively RB B-adv.all	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d182.s3	o SYM 0	- : 0	Cymen-5-ol NN B-noun.person	and CC 0	zinc_gluconate JJ B-adj.all	minimum NN B-noun.quantity	inhibitory JJ B-adj.all	concentration NN B-noun.cognition	( ( 0	MIC NNP 0	) ) 0	and CC 0	minimum JJ B-adj.all	bactericidal NN B-noun.phenomenon	concentration NN I-noun.phenomenon	( ( 0	MBC NNP 0	) ) 0	were VBD 0	determined VBN B-verb.communication	against IN 0	Streptococcus NNP B-noun.person	mutans NNS I-noun.person	, , 0	Actinomyces NNPS B-noun.person	viscosus NN I-noun.substance	, , 0	Porphyromonas NNP B-noun.other	gingivalis NN I-noun.other	, , 0	Fusobacterium NNP B-noun.location	nucleatum NN B-noun.artifact	and CC 0	Candida NNP B-noun.person	albicans NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d608.s5	TOLECTIN NNP 0	and CC 0	other JJ 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_drugs NNS B-noun.cognition	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	reduce VB B-verb.change	the DT 0	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	methotrexate NN B-noun.food	in IN 0	an DT 0	animal NN B-adj.all	model NN B-noun.person	, , 0	possibly RB 0	enhancing VBG B-verb.change	the DT 0	toxicity NN B-noun.attribute	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-MedLine.d174.s2	In IN 0	the DT 0	light NN B-noun.location	of IN 0	contradictory JJ B-adj.all	data NNS B-noun.cognition	on IN 0	efficacy NN B-noun.person	and CC 0	safety NN B-noun.person	of IN 0	NSAID NNP B-noun.group	in IN 0	cardiovascular JJ B-adj.all	patients NNS B-noun.artifact	selection NN B-noun.act	of IN 0	most JJS 0	appropriate JJ B-adj.all	NSAID NNP B-noun.group	( ( 0	basing VBG B-verb.cognition	on IN 0	profile NN B-noun.quantity	of IN 0	efficacy NN B-noun.phenomenon	and CC 0	safety NN B-noun.artifact	) ) 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	continuous JJ B-adj.all	therapy NN B-noun.act	with IN 0	low JJ B-adj.all	dose NN B-noun.phenomenon	aspirin NN B-noun.attribute	appears VBZ B-verb.cognition	to TO 0	be VB B-verb.stative	a DT 0	problem NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d756.s1	Combination NN B-noun.person	with IN 0	tramadol NN B-noun.person	( ( 0	Ultram NNP B-noun.person	) ) 0	is VBZ 0	associated VBN B-verb.cognition	with IN 0	increased VBN B-verb.change	risk NN 0	of IN 0	seizures NNS B-noun.body	. . 0	. . 0
DDI-MedLine.d200.s10	We PRP 0	have VBP 0	demonstrated VBN B-verb.perception	appropriateness NN B-noun.person	of IN 0	inhospital JJ B-adj.all	administration NN B-noun.time	of IN 0	fixed VBN B-verb.consumption	amlodipine NN I-verb.consumption	/ : 0	valsartan JJ B-adj.all	combination NN B-noun.person	as IN 0	an DT 0	approach NN B-noun.person	allowing VBG B-verb.communication	to TO 0	achieve VB B-verb.social	target NN B-noun.group	BP NNP 0	in IN 0	shorter JJR B-adj.all	time NN B-noun.time	, , 0	with IN 0	the DT 0	use NN 0	of IN 0	fewer JJR B-adj.all	antihypertensive_drugs NNS B-noun.object	, , 0	and CC 0	diminishing VBG B-verb.change	concealed JJ B-adj.all	inefficacy NN B-noun.person	of IN 0	treatment NN B-noun.plant	. . 0	. . 0
DDI-MedLine.d218.s5	In IN 0	total NN 0	, , 0	430,455 CD 0	warfarin NN B-noun.location	users NNS B-noun.person	contributed VBD B-verb.social	407,370 CD 0	person NN B-noun.person	- : 0	years NNS B-noun.time	of IN 0	warfarin NN B-noun.location	use NN 0	. . 0	. . 0
DDI-DrugBank.d577.s3	Sulfamethoxazole NNP B-noun.person	may MD 0	inhibit VB B-verb.change	the DT 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	phenytoin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d633.s15	Mexitil NNP B-noun.person	___ NNP I-noun.person	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.attribute	but CC 0	magnesium NN B-noun.person	- : 0	aluminum_hydroxide RB 0	, , 0	when WRB 0	used VBN B-verb.consumption	to TO 0	treat VB B-verb.body	gastrointestinal JJ B-adj.all	symptoms NNS B-noun.body	due JJ 0	to TO 0	Mexitil NNP B-noun.person	__ NNP I-noun.person	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	lower JJR B-adj.all	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.state	. . 0	. . 0
DDI-MedLine.d206.s3	All PDT 0	the DT 0	tests NNS B-noun.person	were VBD 0	carried VBN B-verb.change	out RP I-verb.change	in IN 0	the DT 0	following VBG 0	seven CD 0	groups NNS B-noun.group	( ( 0	n UH 0	= $ 0	6 CD B-adj.all	in IN 0	each DT 0	group NN 0	) ) 0	, , 0	drugs NNS B-noun.artifact	being VBG 0	given VBN B-verb.possession	orally RB B-adv.all	( ( 0	doses NNS B-noun.person	for IN 0	mice NNS B-noun.animal	) ) 0	, , 0	Group NNP B-noun.group	1 CD 0	( ( 0	vehicle NN B-noun.communication	) ) 0	, , 0	group NN 0	2 CD 0	( ( 0	curcumin VB B-verb.consumption	50 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	group NN B-noun.communication	3 CD 0	( ( 0	curcumin VB 0	100 CD 0	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	group NN 0	4 CD 0	( ( 0	fluoxetine JJ 0	20 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	, , 0	group NN B-noun.communication	5 CD 0	( ( 0	imipramine JJ B-adv.all	15 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	group NN 0	6 CD 0	( ( 0	curcumin VB 0	100 CD 0	mg PRP 0	/ ( 0	kg IN 0	plus CC 0	fluoxetine VBP B-verb.change	20 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	and CC 0	group NN B-noun.communication	7 CD 0	( ( 0	curcumin VB 0	100 CD 0	mg PRP 0	/ ( 0	kg IN 0	plus CC 0	imipramine JJ B-noun.communication	15 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d617.s2	hydralazine NN 0	, , 0	prazosin NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d779.s9	Coadministration NN B-noun.person	of IN 0	methyldopa NN B-noun.food	with IN B-adj.all	ferrous_sulfate JJ I-adj.all	or CC 0	ferrous_gluconate NNP B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d194.s16	Studies NNS B-noun.person	with IN 0	forced JJ B-adj.all	expression NN B-noun.communication	and CC 0	siRNA CD 0	knockdown VBN B-verb.cognition	of IN 0	Bcl-2 NN B-noun.food	and CC 0	Cdk1 NNS B-noun.person	suggest VBP B-verb.communication	that IN 0	dasatinib NN B-noun.person	- : 0	mediated JJ B-adj.all	induction NN B-noun.act	of IN 0	p27(Kip1 NNP B-noun.location	) ) 0	enhanced VBN B-verb.change	paclitaxel NN B-noun.artifact	- : 0	induced VBN B-verb.communication	apoptosis NN I-verb.communication	by IN 0	negatively RB B-adj.all	regulating VBG B-verb.stative	Bcl-2 NN 0	and CC 0	Cdk1 JJ B-adj.all	expression NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d737.s5	Probenecid NNP B-noun.person	, , 0	Probenecid NNP B-noun.person	, , 0	a DT 0	known VBN B-adj.all	inhibitor NN B-noun.person	of IN 0	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	organic JJ B-adj.all	acids NNS B-noun.substance	via IN 0	the DT 0	aruonic JJ B-adj.pert	transporter NN B-noun.person	, , 0	did VBD 0	not RB B-adv.all	noticeably RB B-adv.all	influence VB B-verb.body	pramipexole NN B-noun.person	pharmacokinetics NNS B-noun.person	( ( 0	N= $ 0	12 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d780.s4	CNS_depressant JJ B-adj.all	medications NNS B-noun.artifact	, , 0	Concurrent JJ 0	use NN 0	of IN 0	procaine_hydrochloride JJ B-noun.other	and CC 0	CNS_depressant_medications NNS B-noun.artifact	may MD 0	result VB B-verb.stative	in IN 0	additive JJ B-adj.all	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d720.s1	Because IN 0	there EX 0	is VBZ B-verb.stative	a DT 0	theoretical JJ B-adj.all	basis NN B-noun.cognition	that IN 0	these DT 0	effects NNS B-noun.phenomenon	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	, , 0	use NN 0	of IN 0	ergotamine NN B-noun.person	- : 0	containing VBG B-verb.communication	or CC 0	ergot NN B-noun.person	- : 0	type_medications NNS B-noun.person	( ( 0	like IN 0	dihydroergotamine NN B-noun.person	or CC 0	methysergide NN B-noun.attribute	) ) 0	and CC 0	sumatriptan NN 0	within IN 0	24 CD B-adj.all	hours NNS B-noun.time	of IN 0	each DT 0	other JJ 0	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d217.s11	These DT 0	results NNS B-noun.communication	, , 0	if IN 0	confirmed VBN B-verb.change	in IN 0	- : 0	vivo NN B-noun.person	, , 0	indicate VBP B-verb.cognition	that IN 0	celecoxib NN B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	suitable JJ B-adj.all	chemosensitizer NN B-noun.communication	for IN 0	breast NN 0	cancer NN B-noun.state	or CC 0	with IN 0	doxorubicin NN B-noun.food	for IN 0	other JJ 0	cancers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d204.s7	Results NNS B-noun.person	revealed VBD B-verb.communication	that IN 0	the DT 0	strains NNS B-noun.artifact	were VBD B-verb.stative	resistant JJ B-adj.all	to TO 0	many JJ 0	drugs NNS B-noun.person	at IN 0	high JJ B-adj.all	levels NNS B-noun.attribute	, , 0	only RB B-adv.all	piperacillin NN 0	, , 0	carbenicillin NN B-noun.communication	, , 0	amikacin NN B-noun.person	and CC 0	ciprofloxacin NN B-noun.person	showed VBD B-verb.communication	resistances NNS B-noun.person	at IN 0	comparatively RB B-adv.all	lower JJR B-adj.all	levels NNS B-noun.state	. . 0	. . 0
DDI-MedLine.d161.s4	Weekly RB B-adj.all	intramuscular JJ I-adj.all	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine JJ B-adj.all	injections NNS B-noun.artifact	( ( 0	0.2 CD 0	- : 0	0.5 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	body NN 0	weight NN B-noun.attribute	) ) 0	, , 0	in IN 0	combination NN 0	with IN 0	daily JJ B-adj.pert	administration NN B-noun.time	of IN 0	3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine CD 0	or CC 0	vehicle NN B-noun.communication	, , 0	were VBD 0	performed VBN B-verb.change	until IN 0	the DT 0	development NN B-noun.process	of IN 0	parkinsonian JJ B-adj.all	motor NN B-noun.artifact	symptoms NNS I-noun.artifact	in IN 0	either DT 0	of IN 0	the DT 0	two CD 0	experimental JJ B-adj.all	groups NNS B-noun.group	( ( 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ 0	versus IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD 0	/ : 0	vehicle NN B-noun.communication	) ) 0	. . 0	. . 0
DDI-DrugBank.d752.s6	Inducers NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.group	Isozymes NNPS I-noun.group	, , 0	Cytochrome NNP B-noun.person	P450 NNP I-noun.person	inducers NNS I-noun.person	, , 0	such JJ 0	as IN 0	rifampin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	and CC 0	phenytoin NN B-noun.person	, , 0	induce VBP B-verb.cognition	metabolism NN B-noun.attribute	and CC 0	caused VBD B-verb.creation	a DT 0	markedly RB B-adv.all	decreased VBD B-verb.change	C NNP 0	max NN 0	and CC 0	AUC NNP B-noun.group	of IN 0	oral JJ B-adj.all	midazolam NN B-noun.person	in IN 0	adult NN B-noun.act	studies NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d781.s4	The DT 0	bioavailability NN B-noun.cognition	of IN 0	perindoprilat NN B-noun.person	was VBD 0	reduced VBN B-verb.change	by IN 0	diuretics NNS B-noun.person	, , 0	however RB 0	, , 0	and CC 0	this DT 0	was VBD 0	associated VBN B-verb.cognition	with IN 0	a DT 0	decrease NN B-noun.event	in IN 0	plasma NN 0	ACE NNP 0	inhibition NN 0	. . 0	. . 0
DDI-DrugBank.d632.s6	Mixing VBG B-verb.change	SYMLIN NNP B-noun.group	and CC 0	Insulin NNP B-noun.person	The DT 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.event	of IN 0	SYMLIN NNP B-noun.group	were VBD 0	altered VBN B-verb.change	when WRB 0	mixed VBN B-verb.change	with IN 0	regular JJ B-adj.all	, , 0	NPH NNP 0	, , 0	and CC 0	70/30 CD 0	premixed VBD B-verb.creation	formulations NNS B-noun.communication	of IN 0	recombinant JJ B-adj.all	human_insulin NNP B-noun.person	immediately RB I-noun.person	prior RB 0	to TO 0	injection NN B-noun.act	. . 0	. . 0
DDI-MedLine.d213.s5	This DT 0	implies VBZ B-verb.communication	that IN 0	in IN 0	vivo JJ B-adj.all	hepatic JJ B-adj.all	and CC 0	first JJ B-verb.competition	- : 0	pass VB B-verb.communication	CYP3A NNP B-noun.person	activities NNS I-noun.person	are VBP 0	significantly RB B-adv.all	lower JJR B-adj.all	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	cyclosporine NN B-noun.person	than IN 0	in IN 0	those DT 0	receiving VBG B-verb.communication	tacrolimus NN I-verb.communication	, , 0	indicating VBG B-verb.communication	that IN 0	, , 0	at IN 0	the DT 0	doses NNS B-noun.person	generally RB B-adv.all	used VBN B-verb.consumption	in IN 0	clinical JJ B-adj.all	practice NN B-noun.communication	, , 0	cyclosporine NN B-noun.person	is VBZ B-verb.stative	the DT 0	stronger JJR B-adj.all	of IN 0	the DT 0	two CD 0	with IN 0	respect NN B-noun.act	to TO 0	CYP3A NNP B-noun.location	inhibition NN I-noun.location	. . 0	. . 0
DDI-DrugBank.d713.s3	Coadministration NN B-noun.person	of IN 0	Sanctura NNP B-noun.person	with IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	eliminated VBN B-verb.cognition	by IN 0	active JJ B-adj.all	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	may MD 0	increase VB B-verb.change	the DT 0	serum NN B-noun.body	concentration NN B-noun.event	of IN 0	Sanctura NNP B-noun.person	and/or NNP I-noun.person	the DT 0	coadministered VBN B-noun.artifact	drug NN I-noun.artifact	due JJ 0	to TO 0	competition NN B-noun.act	for IN 0	this DT 0	elimination NN B-noun.act	pathway NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d161.s8	In IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD 0	/ : 0	vehicle NN B-noun.communication	- : 0	treated JJ B-verb.communication	animals NNS B-noun.person	, , 0	almost RB B-adv.all	40 CD B-adj.all	% NN 0	loss NN B-noun.attribute	of IN 0	tyrosine JJ B-adj.all	hydroxylase NN B-noun.person	- : 0	positive JJ B-adj.all	norepinephrine NN B-noun.person	neurons NNS B-noun.person	was VBD 0	found VBN B-verb.possession	in IN 0	locus NN 0	coeruleus NN 0	/ : 0	A5/A7 JJ B-adj.all	noradrenaline NN B-noun.body	cell NN B-noun.body	groups NNS B-noun.group	, , 0	whereas IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	neuronal JJ B-adj.all	loss NN B-noun.possession	was VBD B-verb.stative	lower JJR B-adj.all	than IN 0	15 CD B-adj.all	% NN 0	of IN 0	control NN B-noun.act	values NNS B-noun.attribute	in IN 0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ 0	- : 0	treated VBD B-verb.communication	monkeys NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d645.s5	Terbinafine NN B-noun.person	increases VBZ B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	cyclosporine NN B-noun.phenomenon	by IN 0	15 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d171.s5	In IN 0	most JJS B-adj.all	cases NNS B-noun.event	, , 0	the DT 0	application NN B-noun.act	of IN 0	two CD 0	nucleoside_or_nucleotide_reverse_transcriptase_inhibitors NNS B-noun.other	( ( 0	NRTI NNP B-noun.group	) ) 0	together RB 0	with IN 0	a DT 0	non NN B-noun.person	- : 0	nucleoside_reverse_transcriptase_inhibitor NN B-noun.other	( ( 0	NNRTI NNP B-noun.group	) ) 0	, , 0	a DT 0	protease_inhibitor NN B-noun.person	( ( 0	PI NNP 0	) ) 0	or CC 0	an DT 0	integrase_inhibitor NN B-noun.person	( ( 0	II NNP 0	) ) 0	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d646.s0	Drug NN B-noun.person	- : 0	Drug NN B-noun.person	Interactions NNS I-noun.person	Although IN 0	in IN 0	vitro NN B-noun.animal	studies NNS B-noun.group	demonstrated VBD B-verb.perception	the DT 0	potential NN B-noun.person	of IN 0	rifaximin NN 0	to TO 0	interact VB B-verb.contact	with IN 0	cytochrome JJ B-noun.person	P450 JJ I-noun.person	3A4 NN I-noun.person	( ( I-noun.person	CYP3A4 NNP I-noun.person	) ) 0	, , 0	a DT 0	clinical JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	demonstrated VBD B-verb.perception	that DT 0	rifaximin NN B-noun.person	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	midazolam NN B-noun.phenomenon	either RB 0	presystemically RB B-adv.all	or CC 0	systemically RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d747.s0	Tetracycline NNP B-noun.person	, , 0	a DT 0	bacteriostatic JJ B-adj.all	antibiotic JJ B-adj.all	, , 0	may MD 0	antagonize VB B-verb.cognition	the DT 0	bactericidal JJ B-adj.all	effect NN B-noun.cognition	of IN 0	penicillin NN B-noun.food	and CC 0	concurrent JJ B-adj.all	use NN 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d183.s5	The DT 0	biochemical JJ B-adj.all	and CC 0	cellular JJ B-noun.body	alterations NNS I-noun.body	that WDT 0	occur VBP B-verb.stative	after IN 0	1-methyl-4-phenyl-1,2,3,6-_tetrahydropyridine JJ 0	( ( 0	MPTP NNP B-noun.group	) ) 0	treatment NN B-noun.communication	are VBP B-verb.stative	remarkably RB B-adv.all	similar JJ B-adj.all	to TO 0	that DT 0	observed VBN B-verb.perception	in IN 0	idiopathic JJ B-adj.all	PD NNP 0	. . 0	. . 0
DDI-DrugBank.d736.s6	Lithium NNP 0	renal JJ B-adj.all	clearance NN B-noun.person	is VBZ 0	reduced VBN B-verb.change	by IN 0	thiazides NNS B-noun.person	, , 0	increasing VBG B-verb.change	the DT 0	risk NN 0	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d700.s9	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	Given VBN B-verb.possession	the DT 0	different JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	Myfortic NNP B-noun.person	and CC 0	oral JJ B-noun.body	contraceptives NNS I-noun.body	, , 0	no DT 0	drug NN 0	interaction NN 0	between IN 0	these DT 0	two CD 0	classes NNS B-noun.attribute	of IN 0	drug NN B-noun.person	is VBZ 0	expected VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d588.s12	Methenamine NN B-noun.person	, , 0	Efficacy NNP B-noun.person	may MD 0	be VB 0	decreased VBN B-verb.change	due JJ 0	to TO 0	urinary VB 0	alkalizing VBG B-verb.change	effect NN B-noun.cognition	of IN 0	metolazone NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d781.s3	The DT 0	rate NN B-noun.time	and CC 0	extent NN B-noun.act	of IN 0	perindopril NN B-noun.time	absorption NN I-noun.time	and CC 0	elimination NN B-noun.act	are VBP B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	diuretics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d212.s6	The DT 0	permeation NN B-noun.person	of IN 0	colchicine NN B-noun.person	in IN 0	the DT 0	nanoemulsion NN B-noun.group	across IN 0	the DT 0	intestinal JJ B-adj.all	membrane NN B-noun.person	was VBD B-verb.stative	significantly RB B-adv.all	different JJ B-adv.all	from IN 0	that DT 0	of IN 0	the DT 0	control NN B-noun.location	group NN 0	( ( 0	0.2 CD 0	mM CD B-noun.quantity	colchicine NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d775.s2	Evidence NN B-noun.time	of IN 0	spontaneous JJ B-adj.all	recovery NN B-noun.act	from IN 0	succinylcholine NN B-noun.location	should MD 0	be VB 0	observed VBN B-verb.perception	before IN 0	the DT 0	administration NN B-noun.time	of IN 0	MIVACRON NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d651.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	Women NNP B-noun.person	on IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.feeling	have VBP 0	shown VBN B-verb.perception	a DT 0	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	plasma NN B-noun.substance	vitamin_A JJ I-noun.substance	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d743.s11	A DT B-adj.all	few JJ I-adj.all	spontaneous JJ B-adj.all	accounts NNS B-noun.communication	of IN 0	QT NNP 0	interval JJ B-adj.all	prolongation NN B-noun.person	with IN 0	ventricular JJ B-adj.all	arrhythmia NN B-noun.person	including VBG B-verb.social	torsades NNS B-noun.person	de IN 0	pointes NNS B-noun.time	, , 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	erythromycin NN B-noun.communication	or CC 0	troleandomycin NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d665.s0	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	bacteriostatic_antibiotics NNS B-noun.other	( ( 0	e.g. UH 0	, , 0	erythromycin NN B-noun.person	, , 0	tetracycline NN 0	) ) 0	may MD 0	diminish VB B-verb.change	the DT 0	bactericidal JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	penicillins NNS B-noun.possession	by IN 0	slowing VBG B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	bacterial JJ B-adj.all	growth NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d682.s0	Sulfoxone NN 0	may MD 0	increase VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	barbiturates NNS B-noun.location	, , 0	tolbutamide NN 0	, , 0	and CC 0	uricosurics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d200.s1	Efficacy NN B-noun.person	and CC 0	tolerability NN B-noun.attribute	of IN 0	fixed VBN B-verb.consumption	amlodipine NN I-verb.consumption	/ : 0	valsartan JJ B-adj.all	combination NN B-noun.person	was VBD 0	studied VBN B-verb.cognition	in IN 0	86 CD 0	patients NNS B-noun.person	with IN 0	hypertensive JJ B-adj.all	disease NN B-noun.person	hospitalized VBN B-verb.social	in IN 0	departments NNS B-noun.quantity	of IN 0	general JJ B-adj.all	internal JJ B-noun.possession	medicine NN I-noun.possession	or CC 0	cardiology NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d673.s0	No DT 0	significant JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	were VBD 0	reported VBN B-verb.communication	in IN 0	studies NNS B-noun.artifact	in IN 0	which WDT 0	olmesartan_medoxomil NNP B-noun.person	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	digoxin NN B-noun.person	or CC 0	warfarin NN B-noun.act	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d640.s1	The DT 0	possibility NN B-noun.state	of IN 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	UNIVASC NNP B-noun.group	___ NNP I-noun.group	can MD 0	be VB 0	minimized VBN B-verb.change	by IN 0	discontinuing VBG B-verb.change	diuretic JJ B-adj.all	therapy NN B-noun.act	for IN 0	several JJ B-adj.all	days NNS B-noun.phenomenon	or CC 0	cautiously RB B-adv.all	increasing VBG B-verb.change	salt NN 0	intake NN 0	before IN 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	UNIVASC NNP B-noun.group	__ : 0	. . 0	If IN 0	this DT 0	is VBZ B-verb.stative	not RB B-adv.all	possible JJ B-adj.all	, , 0	the DT 0	starting VBG B-verb.change	dose NN 0	of IN 0	moexpril NN B-noun.animal	should MD 0	be VB 0	reduced VBN B-verb.change	.. . 0	. . 0
DDI-DrugBank.d700.s10	However RB 0	, , 0	in IN 0	a DT 0	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	, , 0	mean JJ B-adj.all	levonorgesterol NN B-noun.person	AUC NNP I-noun.person	was VBD 0	decreased VBN B-verb.change	by IN 0	15 CD B-adj.all	% NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	mycophenolate_mofetil NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d752.s12	No DT 0	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.person	with IN 0	common JJ B-noun.person	premedications NNS I-noun.person	( ( 0	such JJ 0	as IN 0	atropine NN 0	, , 0	scopolamine NN B-noun.person	, , 0	glycopyrrolate NN B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	hydroxyzine NN B-noun.person	, , 0	and CC 0	other JJ B-adj.all	muscle_relaxants NNS B-noun.location	) ) 0	or CC 0	local JJ B-adj.all	anesthetics NNS B-noun.group	have VBP 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d588.s0	Diuretics NNS B-noun.person	, , 0	Furosemide NNP B-noun.location	and CC 0	probably RB B-adv.all	other JJ B-adj.all	loop_diuretics NNS B-noun.group	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	metolazone NN B-noun.person	can MD 0	cause VB B-verb.creation	unusually RB B-adj.all	large JJ B-adj.all	or CC 0	prolonged VBN B-verb.creation	losses NNS B-noun.process	of IN 0	fluid NN B-noun.substance	and CC 0	electrolytes NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d608.s0	The DT 0	in FW 0	vitro FW 0	binding NN 0	of IN 0	warfarin NN 0	to TO 0	human JJ B-adj.all	plasma NN B-noun.person	proteins NNS B-noun.person	is VBZ B-verb.stative	unaffected JJ B-adj.all	by IN 0	tolmetin NN B-noun.person	, , 0	and CC 0	tolmetin NN B-noun.communication	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	of IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d151.s5	Attention NN 0	is VBZ 0	paid VBN B-verb.possession	to TO 0	calcium_channel_blockers NNS B-noun.person	, , 0	diuretics NNS B-noun.person	and CC 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d156.s7	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	moxidectin NN B-noun.person	with IN 0	inhibitors NNS B-noun.person	of IN 0	ABC NNP 0	transporter NN 0	function NN B-noun.attribute	did VBD 0	not RB B-adv.all	enhance VB B-verb.change	sensitivity NN B-noun.feeling	to TO 0	moxidectin VB B-verb.contact	in IN 0	males NNS B-noun.animal	, , 0	. . 0
DDI-DrugBank.d584.s0	Anticoagulants NNPS B-noun.group	Anabolic_steroids NNPS I-noun.group	may MD 0	increase VB B-verb.change	sensitivity NN B-noun.feeling	to TO 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d617.s8	Chemical NNP B-noun.group	Interactions NNPS I-noun.group	There EX 0	is VBZ B-verb.stative	an DT 0	immediate JJ B-adj.all	chemical NN B-noun.body	interaction NN B-noun.act	which WDT 0	is VBZ 0	evidenced VBN B-verb.communication	by IN 0	the DT 0	formation NN B-noun.act	of IN 0	a DT 0	precipitate NN B-noun.time	when WRB 0	furosemide NN 0	is VBZ 0	injected VBN B-verb.change	into IN 0	an DT 0	intravenous JJ B-adj.all	line NN B-noun.communication	of IN 0	an DT 0	infusion NN B-noun.cognition	of IN 0	PRIMACOR NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d181.s6	Questioning VBG 0	revealed VBD B-verb.perception	the DT 0	child NN B-noun.person	was VBD 0	taking VBG B-verb.social	Infacol NNP B-noun.person	drops VBZ B-verb.motion	before IN 0	feeds NNS B-noun.plant	while IN 0	on IN 0	levothyroxine NN B-noun.state	. . 0	. . 0
DDI-MedLine.d190.s7	Electroretinograms NNS B-noun.person	survived VBD B-verb.stative	with IN 0	higher JJR B-adj.all	concentrations NNS B-noun.attribute	of IN 0	heparinase_III NNP B-noun.person	and CC 0	chondroitin_ABC_lyase NN B-noun.act	than IN 0	were VBD 0	required VBN B-verb.stative	for IN 0	optimal JJ B-adj.all	retinal JJ B-adj.all	transduction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d700.s12	Live_Vaccines NNS B-noun.artifact	, , 0	During IN 0	treatment NN B-noun.plant	with IN 0	Myfortic NNP B-noun.person	, , 0	the DT 0	use NN 0	of IN 0	live_attenuated_vaccines NNS B-noun.group	should MD 0	be VB 0	avoided VBN B-verb.social	and CC 0	patients NNS B-noun.person	should MD 0	be VB 0	advised VBN B-verb.communication	that IN 0	vaccinations NNS B-noun.animal	may MD 0	be VB B-verb.stative	less RBR B-adv.all	effective JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d187.s5	Different JJ B-adj.all	chemical NN B-noun.body	structures NNS I-noun.body	of IN 0	precursors NNS B-noun.person	, , 0	smoking VBG B-verb.consumption	dynamics NNS I-verb.consumption	, , 0	pyrolysis NN B-noun.cognition	of IN 0	phytocannabinoids NNS B-noun.person	and CC 0	frequency NN B-noun.person	of IN 0	drug NN 0	use NN 0	affect VB B-verb.change	the DT 0	amount NN B-noun.possession	of IN 0	THC NNP 0	absorbed VBD B-verb.contact	. . 0	. . 0
DDI-DrugBank.d709.s1	Concomitant JJ B-adj.all	administrations NNS B-noun.person	not RB B-adv.all	recommended VBN B-verb.communication	, , 0	_ PRP 0	; : 0	Terfenadine NNP B-noun.person	and CC 0	astemizole NN B-noun.location	, , 0	Certain JJ B-noun.person	macrolides NNS I-noun.person	interact VBP B-verb.contact	with IN 0	terfenadine NN B-noun.artifact	and CC 0	astemizole NN B-noun.plant	leading VBG B-verb.stative	to TO 0	increased VBN B-verb.change	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	the DT 0	latter JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d190.s8	AAV2-mediated JJ B-adj.all	retinal JJ B-adj.all	transduction NN B-noun.act	is VBZ 0	improved VBN B-verb.change	by IN 0	co SYM 0	- : 0	injection NN B-noun.act	of IN 0	heparinase_III NNP B-noun.person	or CC 0	chondroitin_ABC_lyase NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d742.s7	Alcohol NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	alcohol NN B-noun.animal	( ( 0	equivalent JJ B-adv.all	to TO 0	60 CD B-adj.all	g NN B-noun.quantity	) ) 0	had VBD B-verb.stative	a DT 0	minimal JJ B-adj.all	effect NN B-noun.cognition	on IN 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	mirtazapine NN B-noun.person	( ( 0	15 CD B-adj.all	mg NN B-noun.quantity	) ) 0	in IN 0	6 CD B-adj.all	healthy JJ B-adj.all	male NN B-noun.person	subjects NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d742.s8	However RB 0	, , 0	the DT 0	impairment NN B-noun.attribute	of IN 0	cognitive NN B-noun.food	and CC 0	motor NN 0	skills NNS 0	produced VBN B-verb.creation	by IN 0	REMERON NNP B-noun.person	___ NNP I-noun.person	were VBD 0	shown VBN B-verb.perception	to TO 0	be VB B-verb.stative	additive JJ B-adj.all	with IN 0	those DT 0	produced VBN B-verb.creation	by IN 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s18	Nevertheless RB B-adv.all	, , 0	during IN 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	furosemide NN B-noun.artifact	and CC 0	MOBIC NNP B-noun.group	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adj.all	for IN 0	signs NNS B-noun.communication	of IN 0	declining VBG B-verb.communication	renal JJ B-adj.ppl	function NN B-noun.act	, , 0	as RB 0	well RB 0	as IN 0	to TO 0	assure VB B-verb.change	diuretic JJ B-adj.all	efficacy NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d603.s5	ProAmatine NNP B-noun.person	. . 0	Alpha NNP B-noun.person	- : 0	adrenergic_blocking_agents NNS B-noun.person	, , 0	such JJ 0	as IN 0	prazosin NN B-noun.person	, , 0	terazosin NN B-noun.person	, , 0	and CC 0	doxazosin NN B-noun.person	, , 0	can MD 0	antagonize VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	ProAmatine NNP B-noun.person	. . 0	Potential NNP B-noun.person	for IN 0	Drug NNP B-noun.person	Interactions NNP I-noun.person	, , 0	It PRP 0	appears VBZ B-verb.perception	possible JJ B-adj.all	, , 0	although IN 0	there EX 0	is VBZ B-verb.stative	no DT 0	supporting VBG B-verb.social	experimental JJ B-adj.all	evidence NN B-noun.attribute	, , 0	that IN 0	the DT 0	high JJ B-adj.all	renal JJ B-adj.all	clearance NN B-noun.act	of IN 0	desglymidodrine NN B-noun.location	( ( 0	a DT 0	base NN B-noun.event	) ) 0	is VBZ B-verb.stative	due JJ 0	to TO 0	active JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	by IN 0	the DT 0	base NN B-noun.person	- : 0	secreting VBG B-verb.communication	system NN B-noun.cognition	also RB B-adv.all	responsible JJ B-adj.all	for IN 0	the DT 0	secretion NN B-noun.act	of IN 0	such JJ B-adj.all	drugs NNS B-noun.artifact	as IN 0	metformin NN B-noun.food	, , 0	cimetidine NN B-noun.person	, , 0	ranitidine NN B-noun.person	, , 0	procainamide NN B-noun.person	, , 0	triamterene NN B-noun.person	, , 0	flecainide NN 0	, , 0	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d163.s1	This DT 0	study NN B-noun.communication	aimed VBN B-verb.communication	to TO 0	evaluate VB B-verb.communication	the DT 0	in FW 0	vitro FW 0	activity NN B-noun.process	of IN 0	minocycline NN 0	combined VBN B-verb.change	with IN 0	fosfomycin NN 0	against IN 0	isolates NNS B-noun.time	of IN 0	methicillin NN B-noun.food	- : 0	resistant JJ B-verb.communication	Staphylococcus NNP B-noun.person	aureus NN I-noun.person	( ( 0	MRSA NNP B-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d749.s2	Two CD 0	early JJ B-adj.all	clinical JJ B-adj.all	studies NNS B-noun.communication	conducted VBN B-verb.creation	in IN 0	patients NNS B-noun.person	who WP 0	received VBD B-verb.possession	Macugen NNP B-noun.person	alone RB 0	and CC 0	in IN 0	combination NN 0	with IN 0	PDT NNP 0	revealed VBD B-verb.perception	no DT 0	apparent JJ B-adj.all	difference NN B-noun.cognition	in IN 0	the DT 0	plasma NN B-noun.plant	pharmacokinetics NNS B-noun.person	of IN 0	pegaptanib NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d751.s1	The DT 0	use NN 0	of IN 0	AGGRASTAT NNP B-noun.group	, , 0	in IN 0	combination NN 0	with IN 0	heparin NN B-noun.person	and CC 0	aspirin NN B-noun.person	, , 0	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	an DT 0	increase NN B-noun.act	in IN 0	bleeding VBG 0	compared VBN B-verb.communication	to TO 0	heparin VB B-verb.consumption	and CC 0	aspirin VB B-verb.social	alone RB I-verb.social	( ( 0	see VB 0	. . 0
DDI-DrugBank.d780.s6	Neuromuscular_blocking_agents NNS B-noun.person	( ( 0	such JJ 0	as IN 0	suxamethonium_chloride JJ 0	) ) 0	, , 0	Concurrent JJ 0	use NN 0	of IN 0	procaine_hydrochloride JJ B-noun.other	and CC 0	neuromuscular_blocking_agents NNS B-noun.person	may MD 0	result VB B-verb.stative	in IN 0	prolongation NN B-noun.act	or CC 0	enhancement NN B-noun.act	of IN 0	the DT 0	neuromuscular JJ B-adj.all	blockade NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d601.s0	Barbiturates NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	effectiveness NN B-noun.cognition	of IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	certain JJ B-adj.all	antibiotics NNS B-noun.person	, , 0	quinidine NN B-noun.location	, , 0	theophylline PRP 0	, , 0	corticosteroids NNS B-noun.person	, , 0	anticoagulants NNS B-noun.person	, , 0	and CC 0	beta_blockers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d227.s7	In IN 0	the DT 0	hot JJ 0	plate NN 0	test NN 0	in IN 0	mice NNS B-noun.animal	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	15 CD B-adj.all	____ NNP B-noun.person	g FW 0	/ FW 0	kg FW 0	dexmedetomidine NN 0	with IN 0	10 CD B-adj.all	__ CD 0	mg FW 0	/ FW 0	kg FW 0	ephedrine NN 0	intraperitoneally RB 0	not RB 0	only RB B-adv.all	enhanced VBN B-verb.change	, , 0	but CC 0	also RB B-adv.all	prolonged VBD B-verb.communication	the DT 0	duration NN 0	of IN 0	antinociception NN B-noun.communication	induced VBN B-verb.creation	by IN 0	dexmedetomidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d734.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	propranolol NN B-noun.person	with IN 0	phenothiazines NNS B-noun.food	results NNS I-noun.food	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	levels NNS B-noun.state	of IN 0	both DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d196.s5	In IN 0	study NN B-noun.communication	1 CD 0	( ( 0	fasted VBN B-verb.creation	) ) 0	, , 0	during IN 0	each DT 0	study NN B-noun.artifact	period NN B-noun.person	, , 0	volunteers NNS B-noun.person	received VBD B-verb.possession	a DT 0	single JJ B-adj.all	105-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	fenofibric_acid JJ B-noun.possession	or CC 0	single JJ B-adj.all	145-mg JJ 0	dose NN B-noun.quantity	of IN 0	fenofibrate NN B-noun.animal	( ( 0	depending VBG B-verb.contact	on IN 0	their PRP$ 0	randomization NN B-noun.act	scheme NN B-noun.event	) ) 0	after IN 0	an DT 0	overnight JJ B-adj.all	fast RB B-adv.all	( ( 0	a DT 0	minimum NN 0	fast RB 0	of IN 0	10 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-MedLine.d227.s0	Ephedrine NNP B-noun.person	enhances VBZ B-verb.communication	the DT 0	antinociceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	dexmedetomidine NN B-noun.person	in IN 0	mice NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d693.s0	Reduced NNP B-verb.change	absorption NN B-noun.process	of IN 0	folic_acid JJ B-noun.shape	and CC 0	digoxin NN B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	those DT 0	agents NNS B-noun.person	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	with IN 0	sulfasalazine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d640.s6	Lithium NNP B-noun.person	, , 0	Increased VBD B-verb.change	serum NN B-noun.body	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	symptoms NNS B-noun.communication	of IN 0	lithium NN B-noun.substance	toxicity NN B-noun.phenomenon	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ACE_inhibitors NNS B-noun.person	during IN 0	therapy NN 0	with IN 0	lithium NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d641.s5	In IN 0	the DT 0	absence NN B-noun.act	of IN 0	data NNS B-noun.cognition	regarding VBG B-verb.stative	potential JJ B-adj.all	interaction NN B-noun.act	between IN 0	ALIMTA NNP B-noun.group	and CC 0	NSAIDs NNP B-noun.person	with IN 0	longer JJR B-adj.all	half NN B-noun.person	- : 0	lives NNS B-noun.person	, , 0	all DT 0	patients NNS B-noun.person	taking VBG B-verb.social	these DT 0	NSAIDs NNP B-noun.other	should MD 0	interrupt VB 0	dosing VBG B-verb.social	for IN 0	at IN 0	least JJS 0	5 CD B-adj.all	days NNS B-noun.act	before RB 0	, , 0	the DT 0	day NN 0	of IN 0	, , 0	and CC 0	2 CD B-adj.all	days NNS B-noun.artifact	following VBG 0	ALIMTA NNP B-noun.other	administration NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d697.s0	Interactions NNS B-noun.person	for IN 0	Vitamin_B1 NNP B-noun.person	( ( 0	Thiamine NNP 0	) ) 0	, , 0	_ PRP$ 0	Loop_Diuretics NNS B-noun.group	, , 0	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	Stavudine NNP B-noun.location	, , 0	Tricyclic_Antidepressants NNS B-noun.person	. . 0
DDI-MedLine.d222.s0	Treatment NN B-noun.person	of IN 0	nicotine JJ B-adj.all	dependence NN B-noun.person	with IN 0	Chantix NNP B-noun.person	( ( 0	varenicline NN B-noun.attribute	) ) 0	. . 0	_ PRP 0	. . 0
DDI-MedLine.d143.s4	Pantoprazole NNP B-noun.person	has VBZ B-verb.possession	a DT 0	much JJ 0	weaker JJR B-adj.all	effect NN B-noun.cognition	on IN 0	clopidogrel NN B-noun.artifact	's POS 0	pharmacokinetics NNS B-noun.person	and CC 0	on IN 0	platelet NN 0	reactivity NN 0	during IN 0	concomitant JJ B-adj.all	use NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d657.s1	Although IN 0	no DT 0	drug NN 0	/ : 0	drug NN B-noun.person	interactions NNS I-noun.person	were VBD 0	discovered VBN B-verb.creation	during IN 0	the DT 0	clinical JJ B-adj.all	trials NNS B-noun.cognition	of IN 0	MARINOL NNP B-noun.group	Capsules NNPS I-noun.group	, , 0	cannabinoids NNS B-noun.communication	may MD 0	interact VB B-verb.change	with IN 0	other JJ 0	medications NNS B-noun.artifact	through IN 0	both DT 0	metabolic JJ B-adj.all	and CC 0	pharmacodynamic JJ B-adj.all	mechanisms NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d200.s8	But CC 0	the DT 0	use NN 0	of IN 0	fixed VBN B-verb.consumption	combination NN 0	amlodipine NN 0	/ : 0	valsartan NN B-noun.attribute	compared VBN B-verb.change	with IN 0	traditional JJ B-adj.all	therapy NN B-noun.act	was VBD 0	associated VBN B-verb.cognition	with IN 0	lower JJR B-adj.all	clinical JJ B-adj.all	and CC 0	self NN B-noun.person	measured VBN B-verb.change	BP NNP 0	, , 0	quicker JJR B-adj.all	achievement NN B-noun.act	of IN 0	target NN B-noun.cognition	BP NNP 0	( ( 0	5.8+/-2.3 JJ 0	and CC 0	9.2+/-1.8 JJ B-adj.all	days NNS B-noun.person	, , 0	respectively RB B-adv.all	, , 0	0.05 CD 0	) ) 0	, , 0	lesser JJR B-adj.all	number NN B-noun.quantity	of IN 0	antihypertensive_drugs NNS B-noun.object	( ( 0	2.5+/-0.6 JJ 0	and CC 0	3.0+/-0.9 JJ B-adj.all	days NNS B-noun.person	, , 0	respectively RB B-adv.all	) ) 0	, , 0	lower JJR B-adj.all	rate NN B-noun.time	of IN 0	concealed JJ B-adj.all	inefficacy NN B-noun.person	of IN 0	treatment NN B-noun.communication	( ( 0	12 CD 0	and CC 0	31 CD 0	% NN 0	, , 0	respectively RB B-adv.all	, , 0	0.05 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d596.s0	Drug NN B-noun.person	- : 0	Drug NN B-noun.group	Interactions NNP I-noun.group	Effect NNP I-noun.group	of IN I-noun.group	Exelon NNP I-noun.group	___ NNP I-noun.group	( ( 0	rivastigmine_tartrate JJ 0	) ) 0	on IN 0	the DT 0	Metabolism NNP B-noun.other	of IN I-noun.other	Other NNP I-noun.other	Drugs NNP I-noun.other	, , 0	Rivastigmine NNP B-noun.person	is VBZ B-verb.stative	primarily RB B-adv.all	metabolized VBN B-verb.cognition	through IN 0	hydrolysis NN 0	by IN 0	esterases NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d670.s7	Paliperidone NNP B-noun.person	may MD 0	antagonize VB B-verb.cognition	the DT 0	effect NN B-noun.cognition	of IN 0	levodopa NN B-noun.state	and CC 0	other JJ B-adj.all	dopamine_agonists NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d220.s0	Evaluation NNP B-noun.person	of IN 0	hepatic JJ B-adj.all	clearance NN B-noun.person	and CC 0	drug NN B-noun.person	- : 0	drug NN B-noun.person	interactions NNS I-noun.person	of IN 0	luteolin NN B-noun.substance	and CC 0	apigenin RB 0	by IN 0	using VBG B-verb.consumption	primary JJ B-adj.all	cultured JJ B-adj.all	rat NN B-noun.person	hepatocytes NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-MedLine.d182.s0	Antimicrobial JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	o SYM 0	- : 0	cymen-5-ol NN B-noun.person	and CC 0	zinc NN B-noun.person	, , 0	alone RB 0	& CC 0	. . 0
DDI-DrugBank.d590.s1	Coadministration NN B-noun.person	with IN 0	aspirin NN B-noun.food	results NNS I-noun.food	in IN 0	a DT 0	slight JJ B-adj.all	decrease NN B-noun.event	in IN 0	the DT 0	rate NN B-noun.time	of IN 0	salicylate JJ B-adj.all	absorption NN B-noun.artifact	that WDT 0	is VBZ B-verb.stative	clinically RB B-adv.all	unimportant JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d633.s8	A DT 0	variety NN B-noun.attribute	of IN 0	antiarrhythmics NNS B-noun.object	such JJ 0	as IN 0	quinidine JJ B-adj.all	or CC 0	propranolol NN B-noun.possession	were VBD B-verb.stative	also RB B-adv.all	added VBD B-verb.communication	, , 0	sometimes RB B-adv.all	with IN 0	improved JJ B-adj.all	control NN B-noun.act	of IN 0	ventricular JJ B-adj.all	ectopy NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d700.s3	Acyclovir NNP B-noun.person	/ NNP I-noun.person	Ganciclovir NNP I-noun.person	, , 0	may MD 0	be VB 0	taken VBN B-verb.cognition	with IN 0	Myfortic NNP B-noun.person	, , 0	. . 0
DDI-MedLine.d143.s3	Concomitant JJ B-adj.all	use NN 0	of IN 0	omeprazole NN B-noun.shape	and CC 0	clopidogrel NN B-noun.artifact	was VBD 0	found VBN B-verb.cognition	to TO 0	decrease VB B-verb.communication	the DT 0	exposure NN B-noun.cognition	( ( 0	AUC NNP 0	) ) 0	to TO 0	clopidogrel VB B-verb.motion	's POS 0	active JJ B-adj.all	metabolite NN B-noun.food	by IN 0	50 CD B-adj.all	% NN 0	and CC 0	to TO 0	sharply RB B-adv.all	increase VB B-verb.change	platelet NN B-noun.phenomenon	reactivity NN B-noun.process	, , 0	as IN 0	a DT 0	result NN B-noun.act	of IN 0	inhibition NN B-noun.attribute	by IN 0	omeprazole NN B-noun.person	of IN 0	CYP2C19 NNP B-noun.person	, , 0	a DT 0	cytochrome NN 0	P450 NN 0	( ( 0	CYP NNP 0	) ) 0	enzyme NN B-noun.quantity	. . 0	. . 0
DDI-MedLine.d222.s2	In IN 0	a DT 0	randomized VBN 0	controlled VBN B-verb.social	clinical JJ B-adj.all	trial NN B-noun.cognition	, , 0	the DT 0	abstinence NN B-noun.event	rate NN B-noun.time	at IN 0	1 CD B-adj.all	year NN B-noun.time	for IN 0	patients NNS B-noun.person	using VBG B-verb.consumption	varencline NN B-noun.artifact	was VBD B-verb.stative	superior JJ B-adj.all	to TO 0	that DT 0	of IN 0	patients NNS B-noun.person	in IN 0	the DT 0	group NN B-noun.food	using VBG B-verb.consumption	bupropion_SR NNP B-noun.person	( ( 0	Zyban NNP B-noun.location	) ) 0	and CC 0	in IN 0	the DT 0	placebo NN B-noun.location	group NN 0	( ( 0	11 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d632.s0	Due JJ 0	to TO 0	its PRP$ 0	effects NNS B-noun.phenomenon	on IN 0	gastric JJ B-adj.all	emptying NN B-verb.change	, , 0	SYMLIN NNP 0	therapy NN 0	should MD 0	not RB 0	be VB 0	considered VBN B-verb.cognition	for IN 0	patients NNS B-noun.person	taking VBG B-verb.social	drugs NNS I-verb.social	that WDT 0	alter VBP B-verb.change	gastrointestinal JJ B-adj.all	motility NN B-noun.motive	( ( 0	e.g. UH 0	, , 0	anticholinergic_agents NNS B-noun.object	such JJ 0	as IN 0	atropine NN 0	) ) 0	and CC 0	agents NNS B-noun.person	that WDT 0	slow VBP B-verb.change	the DT 0	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	nutrients NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	alpha_glucosidase_inhibitors NNS B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d672.s8	Probenecid NNP B-noun.person	, , 0	Probenecid NNP B-noun.person	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	sparfloxacin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d221.s1	A DT 0	fatal JJ B-adj.all	poisoning NN B-noun.artifact	case NN I-noun.artifact	involving VBG B-verb.stative	etizolam NN 0	, , 0	phenobarbital JJ B-adj.all	, , 0	promethazine NN B-noun.person	and CC 0	chlorpromazine NN B-noun.person	is VBZ 0	presented VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d617.s0	No DT 0	untoward JJ B-adj.all	clinical JJ B-adj.all	manifestations NNS B-noun.communication	have VBP 0	been VBN 0	observed VBN B-verb.perception	in IN 0	limited JJ B-adj.all	experience NN B-noun.person	with IN 0	patients NNS B-noun.person	in IN 0	whom WP 0	PRIMACOR NNP B-noun.person	was VBD 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	digitalis_glycosides VBZ B-verb.motion	, , 0	. . 0
DDI-DrugBank.d596.s9	Use NN 0	with IN 0	Cholinomimetics NNPS B-noun.person	and CC 0	Other JJ 0	Cholinesterase_Inhibitors NNS B-noun.person	, , 0	A DT 0	synergistic JJ B-adj.all	effect NN B-noun.phenomenon	may MD 0	be VB 0	expected VBN B-verb.cognition	when WRB 0	cholinesterase_inhibitors NNS B-noun.person	are VBP 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	succinylcholine NN B-noun.person	, , 0	similar JJ B-adj.all	neuromuscular_blocking_agents NNS B-noun.artifact	or CC 0	cholinergic_agonists NNS B-noun.group	such JJ 0	as IN 0	bethanechol NN 0	. . 0	. . 0
DDI-DrugBank.d610.s0	Pharmacokinetic JJ B-adj.all	properties NNS B-noun.attribute	of IN 0	abacavir NN B-noun.person	were VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	by IN 0	the DT 0	addition NN B-noun.act	of IN 0	either DT 0	lamivudine NN B-noun.location	or CC 0	zidovudine NN B-noun.substance	or CC 0	the DT 0	combination NN B-noun.event	of IN 0	lamivudine NN B-noun.location	and CC 0	zidovudine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d779.s2	Patients NNS B-noun.person	may MD 0	require VB B-verb.stative	reduced JJ B-adj.all	doses NNS B-noun.quantity	of IN 0	anesthetics NNS B-noun.person	when WRB 0	on IN 0	methyldopa NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d688.s1	A DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	demonstrated VBD B-verb.perception	that DT 0	coadministration NN B-noun.person	of IN 0	megestrol_acetate JJ B-adj.all	and CC 0	indinavir NN B-noun.person	results NNS I-noun.person	in IN 0	a DT 0	significant JJ B-adj.all	decrease NN B-noun.state	in IN 0	the DT 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.person	( ( 0	~36 CD 0	% NN 0	for IN 0	Cmax NNP B-noun.person	and CC 0	~28 CD 0	% NN 0	for IN 0	AUC NNP 0	) ) 0	of IN 0	indinavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s2	Digoxin NNP B-noun.person	, , 0	In IN 0	12 CD B-adj.all	normal JJ B-adj.pert	- : 0	weight NN B-noun.artifact	subjects NNS B-noun.artifact	receiving VBG B-verb.change	XENICAL NNP B-noun.group	120 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	for IN 0	6 CD B-adj.all	days NNS B-noun.time	, , 0	XENICAL NNP B-noun.group	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d763.s3	Phenytoin NN B-noun.person	, , 0	Carbamazepine NNP B-noun.person	, , 0	and CC 0	Rifampicin NNP B-noun.person	, , 0	In IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	potent JJ B-adj.all	inducers NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	( ( 0	i.e. FW B-adv.all	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	and CC 0	rifampicin NN B-noun.body	) ) 0	, , 0	the DT 0	clearance NN B-noun.act	of IN 0	ondansetron NN B-noun.person	was VBD B-verb.stative	significantly RB B-adv.all	increased VBN B-verb.change	and CC 0	ondansetron NN 0	blood NN B-noun.location	concentrations NNS B-noun.person	were VBD 0	decreased VBN B-verb.change	. . 0	. . 0
DDI-MedLine.d163.s4	The DT 0	susceptibility NN B-noun.phenomenon	results NNS B-noun.location	for IN 0	minocycline NN B-noun.act	and CC 0	fosfomycin JJ 0	were VBD 0	interpreted VBN B-verb.cognition	according VBG 0	to TO 0	the DT 0	most RBS 0	relevant JJ B-adj.all	criteria NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d608.s2	Therefore RB 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	administering VBG B-verb.perception	TOLECTIN NNP 0	to TO 0	patients NNS B-noun.person	on IN 0	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d212.s9	The DT 0	procedure NN B-noun.person	indicated VBD B-verb.communication	that IN 0	the DT 0	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	colchicine NN B-noun.person	was VBD 0	enhanced VBN B-verb.change	significantly RB B-adv.all	by IN 0	eugenol NN B-noun.person	in IN 0	the DT 0	tested VBN B-verb.social	nanoemulsion NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d617.s4	chlorthalidone NN B-noun.artifact	, , 0	furosemide RB 0	, , 0	hydrochlorothiazide NN 0	, , 0	spironolactone NN 0	, , 0	. . 0
DDI-DrugBank.d728.s1	No DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	85 CD 0	mg NN B-noun.quantity	/ '' 0	m2 IN 0	ELOXATIN NNP B-noun.group	and CC 0	infusional JJ B-adj.all	5-FU NN B-noun.group	has VBZ 0	been VBN 0	observed VBN B-verb.perception	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	every DT 0	2 CD B-adj.all	weeks NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d675.s7	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	Methergine NNP B-noun.person	___ NNP I-noun.person	( ( I-noun.person	methylergonovine_maleate JJ I-noun.person	) ) 0	is VBZ 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	other JJ 0	vasoconstrictors NNS B-noun.person	or CC 0	ergot_alkaloids NNS B-noun.substance	. . 0	. . 0
DDI-DrugBank.d642.s0	Prothrombin NNP B-noun.person	time NN B-noun.time	or CC 0	other JJ 0	suitable JJ B-adj.all	anticoagulation NN 0	test NN 0	should MD 0	be VB 0	monitored VBN B-verb.communication	if IN 0	tigecycline NN 0	is VBZ 0	administered VBN B-verb.possession	with IN 0	warfarin NN B-noun.act	. . 0	__ PRP 0	. . 0
DDI-DrugBank.d743.s12	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	terfenadine NN 0	with IN 0	clarithromycin NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	or CC 0	troleandomycin NN B-noun.substance	is VBZ 0	contraindicated VBN B-verb.communication	, , 0	Pending VBG B-verb.competition	full JJ B-adj.all	characterization NN 0	of IN 0	potential JJ B-adj.all	interactions NNS B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	terfenadine NN 0	with IN 0	other JJ B-adj.all	macrolide_antibiotics NNS B-noun.person	, , 0	including VBG B-verb.change	azithromycin NN B-noun.food	, , 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d766.s1	Agents NNS B-noun.person	that WDT 0	might MD 0	be VB 0	coadministered VBN B-verb.contact	with IN 0	trimetrexate NN B-noun.person	in IN 0	AIDS NNP B-noun.group	patients NNS B-noun.person	for IN 0	other JJ 0	indications NNS B-noun.motive	that WDT 0	could MD 0	elicit VB B-verb.emotion	this DT 0	activity NN B-noun.state	include VBP B-verb.stative	erythromycin NN I-verb.stative	, , 0	rifampin NN B-noun.person	, , 0	rifabutin NN B-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	and CC 0	fluconazole NN B-noun.plant	. . 0	. . 0
DDI-MedLine.d231.s6	The DT 0	response NN B-noun.communication	of IN 0	moxifloxacin NN B-noun.person	and CC 0	lomefloxacin NN B-noun.body	after IN 0	interaction NN B-noun.act	with IN 0	co SYM 0	- : 0	administered VBN B-verb.communication	drugs NNS B-noun.person	at IN 0	different JJ B-adj.all	conditions NNS B-noun.artifact	and CC 0	temperature NN B-noun.attribute	were VBD 0	noted VBN B-verb.perception	using VBG B-verb.consumption	a DT 0	Shimadzu NNP B-noun.person	HPLC NNP I-noun.person	system NN B-noun.body	with IN 0	PDA NNP B-noun.person	detector NN I-noun.person	. . 0	. . 0
DDI-MedLine.d206.s6	The DT 0	effect NN B-noun.cognition	of IN 0	curcumin NN B-noun.communication	( ( 0	100 CD 0	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	was VBD B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	of IN 0	fluoxetine NN B-noun.substance	and CC 0	imipramine NN B-noun.act	( ( 0	p IN 0	> $ 0	0.05 CD 0	) ) 0	but CC 0	its PRP$ 0	addition NN 0	to TO 0	fluoxetine VB B-verb.change	and CC 0	imipramine NN B-noun.person	did VBD 0	not RB B-adv.all	improve VB B-verb.creation	their PRP$ 0	antidepressant JJ B-adj.all	activity NN B-noun.state	( ( 0	p IN 0	> $ 0	0.05 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d597.s6	MOBIC NNP B-noun.group	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	substitute NN B-noun.person	for IN 0	aspirin NN B-noun.person	for IN 0	cardiovascular JJ B-adj.all	prophylaxis NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d768.s5	Palonosetron NNP B-noun.person	did VBD 0	not RB B-adv.all	inhibit VB B-verb.change	the DT 0	antitumor NN B-noun.phenomenon	activity NN B-noun.process	of IN 0	the DT 0	five CD B-adj.all	chemotherapeutic_agents NNS B-noun.communication	tested VBN B-verb.social	( ( 0	cisplatin NN B-noun.person	, , 0	cyclophosphamide NN 0	, , 0	cytarabine NN B-noun.person	, , 0	doxorubicin NN B-noun.person	and CC 0	mitomycin_C NNP B-noun.location	) ) 0	in IN 0	murine NN B-noun.act	tumor NN B-noun.artifact	models NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d588.s3	Alcohol NNP B-noun.person	, , 0	Barbiturates NNP B-noun.person	, , 0	and CC 0	Narcotics NNP B-noun.person	, , 0	The DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	these DT 0	drugs NNS B-noun.artifact	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	the DT 0	volume NN B-noun.artifact	contraction NN B-noun.act	that WDT 0	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	metolazone NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-MedLine.d169.s2	However RB 0	, , 0	the DT 0	evidence NN B-noun.attribute	for IN 0	a DT 0	calcium NN B-noun.person	effect NN B-noun.cognition	on IN 0	iron NN B-noun.person	absorption NN B-noun.artifact	mainly RB B-adv.all	comes VBZ B-verb.stative	from IN 0	studies NNS B-noun.communication	that WDT 0	did VBD 0	not RB B-adv.all	isolate VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	calcium NN B-noun.person	from IN 0	that DT 0	of IN 0	other JJ 0	dietary JJ B-adj.all	components NNS B-noun.person	, , 0	because IN 0	it PRP 0	was VBD 0	detected VBN B-verb.perception	in IN 0	single JJ B-adj.all	- : 0	meal NN B-noun.food	studies NNS B-noun.group	. . 0	. . 0
DDI-MedLine.d149.s4	The DT 0	effects NNS B-noun.phenomenon	of IN 0	extracts NNS B-noun.act	of IN 0	ginseng NN B-noun.person	and CC 0	ginko NN B-noun.person	( ( 0	EGGB NNP B-noun.group	) ) 0	on IN 0	cellular JJ B-adj.all	proliferative JJ B-adj.all	activity NN B-noun.process	, , 0	apoptotic JJ B-adj.all	rate NN B-noun.time	, , 0	ultrastructure NN B-noun.person	and CC 0	caspase-3 JJ B-adj.all	expression NN B-noun.communication	were VBD 0	detected VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d776.s24	The DT 0	coadministration NN B-noun.person	of IN 0	fluconazole NN B-noun.shape	at IN 0	doses NNS B-noun.location	lower JJR B-adj.all	than IN 0	400 CD 0	mg RB 0	/ JJ 0	day NN 0	with IN 0	terfenadine NN B-noun.artifact	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-MedLine.d216.s0	Exposure NN B-noun.person	to TO 0	oral JJ B-adj.all	S NNP 0	- : 0	ketamine NN B-noun.person	is VBZ B-verb.stative	unaffected JJ B-adj.all	by IN 0	itraconazole NN B-noun.person	but CC 0	greatly RB B-adv.all	increased VBN B-verb.change	by IN 0	ticlopidine NN B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d776.s32	Patients NNS B-noun.person	receiving VBG B-verb.communication	rifabutin NN B-noun.person	and CC 0	fluconazole NN B-noun.person	concomitantly RB B-adv.all	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-MedLine.d211.s2	The DT 0	preclinical JJ B-adj.all	combination NN B-noun.event	of IN 0	lenalidomide NN B-noun.food	with IN 0	the DT 0	mTOR NN B-noun.location	inhibitor NN I-noun.location	CCI-779 NN B-noun.group	has VBZ 0	displayed VBN B-verb.consumption	synergy NN I-verb.consumption	in IN 0	vitro NN B-noun.animal	and CC 0	represents VBZ B-verb.communication	a DT 0	novel NN 0	combination NN 0	in IN 0	MM NNP 0	. . 0	. . 0
DDI-DrugBank.d777.s5	The DT 0	addition NN 0	of IN 0	aspirin NN B-noun.person	to TO 0	Streptokinase NNP B-noun.person	causes VBZ B-verb.creation	a DT 0	minimal JJ B-adj.all	increase NN B-noun.event	in IN 0	the DT 0	risk NN 0	of IN 0	minor JJ B-adj.all	bleeding NN B-noun.act	( ( 0	3.9 CD 0	% NN 0	vs. CC 0	3.1 CD 0	% NN 0	) ) 0	, , 0	but CC 0	does VBZ 0	not RB B-adv.all	appear VB B-verb.change	to TO 0	increase VB B-verb.change	the DT 0	incidence NN B-noun.event	of IN 0	major JJ B-adj.all	bleeding NN B-noun.act	( ( 0	see VB 0	. . 0
DDI-MedLine.d179.s7	When WRB 0	cells NNS B-noun.body	were VBD 0	exposed VBN B-verb.perception	to TO 0	docetaxel VB 0	followed VBN B-verb.stative	by IN 0	sunitinib NN B-noun.person	, , 0	synergism NN B-noun.artifact	was VBD 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d604.s4	Important JJ B-adj.all	Non NNP B-noun.person	- : 0	Thalidomide IN 0	Drug NNP B-noun.person	Interactions NNP I-noun.person	Drugs NNP I-noun.person	That NNP I-noun.person	Interfere NNP I-noun.person	with IN 0	Hormonal_Contraceptives NNS B-noun.artifact	, , 0	Concomitant JJ 0	use NN 0	of IN 0	HIV NNP B-noun.group	- : 0	protease_inhibitors NNS B-noun.person	, , 0	griseofulvin NN 0	, , 0	modafinil NN B-noun.person	, , 0	penicillins NNS B-noun.person	, , 0	rifampin NN B-noun.person	, , 0	rifabutin NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	or CC 0	certain JJ B-adj.all	herbal JJ B-adj.all	supplements NNS B-noun.artifact	such JJ 0	as IN 0	St. NNP 0	. . 0
DDI-DrugBank.d716.s5	Before IN 0	taking VBG 0	this DT 0	medication NN B-noun.communication	, , 0	tell VB B-verb.communication	your PRP$ 0	doctor NN B-noun.person	if IN 0	you PRP 0	are VBP 0	taking VBG B-verb.social	a DT 0	tricyclic_antidepressant JJ B-adj.all	such JJ I-adj.all	as IN 0	amitriptyline NN 0	( ( 0	Elavil NNP B-noun.person	) ) 0	, , 0	amoxapine NN 0	( ( 0	Asendin NNP 0	) ) 0	, , 0	doxepin NN 0	( ( 0	Sinequan NNP 0	) ) 0	, , 0	nortriptyline NN B-noun.person	( ( 0	Pamelor NNP 0	) ) 0	, , 0	imipramine NN B-noun.person	( ( 0	Tofranil NNP B-noun.location	) ) 0	, , 0	clomipramine NN B-noun.person	( ( 0	Anafranil NNP 0	) ) 0	, , 0	protriptyline NN B-noun.person	( ( 0	Vivactil NNP 0	) ) 0	, , 0	or CC 0	desipramine NN B-noun.communication	( ( 0	Norpramin NNP 0	) ) 0	. . 0	. . 0
DDI-MedLine.d193.s1	The DT 0	FDA NNP B-noun.group	has VBZ 0	approved VBN B-verb.communication	ticagrelor NN 0	( ( 0	Brilinta NNP B-noun.person	- : 0	AstraZeneca NNP B-noun.location	) ) 0	, , 0	an DT 0	oral JJ B-adj.all	antiplatelet_drug NN B-noun.attribute	, , 0	for IN 0	use NN 0	with IN 0	low JJ B-adj.all	- : 0	dose NN 0	aspirin NN 0	to TO 0	reduce VB B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	thrombotic JJ B-adj.all	cardiovascular JJ B-adj.all	events NNS B-noun.state	in IN 0	patients NNS B-noun.person	with IN 0	acute JJ B-adj.all	coronary JJ B-adj.all	syndrome NN B-noun.person	( ( 0	ACS NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-MedLine.d154.s0	Enhancement NNP B-noun.person	of IN 0	humoral JJ B-adj.all	immune JJ B-adj.all	responses NNS B-noun.act	to TO 0	inactivated JJ B-adj.all	Newcastle NNP B-noun.person	disease NN I-noun.person	and CC 0	avian_influenza_vaccines NNS B-noun.food	by IN 0	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	ginseng_stem NN B-noun.person	- : 0	and CC 0	- : 0	leaf_saponins NNS B-noun.person	in IN 0	chickens NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d624.s2	Some DT 0	diuretics NNS B-noun.person	can MD 0	enhance VB B-verb.social	aminoglycoside IN 0	toxicity NN B-noun.attribute	by IN 0	altering VBG B-verb.change	antibiotic JJ B-adj.all	concentrations NNS B-noun.food	in IN 0	serum NN B-noun.body	and CC 0	tissue NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d700.s5	Both DT 0	acyclovir VBP B-verb.stative	/ : 0	ganciclovir NN B-noun.person	and CC 0	MPAG NNP B-noun.person	concentrations NNS I-noun.person	are VBP 0	increased VBN B-verb.change	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	renal JJ B-adj.all	impairment NN B-noun.state	, , 0	their PRP$ 0	coexistence NN B-noun.act	may MD 0	compete VB B-verb.cognition	for IN 0	tubular JJ B-adj.all	secretion NN B-noun.act	and CC 0	further JJ B-adj.all	increase NN B-noun.act	in IN 0	the DT 0	concentrations NNS B-noun.cognition	of IN 0	the DT 0	two CD 0	. . 0	. . 0
DDI-DrugBank.d738.s1	Patients NNS B-noun.person	with IN 0	Congenital NNP B-noun.other	or CC 0	Acquired NNP B-noun.group	QT NNP I-noun.group	Prolongation NNP I-noun.group	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	solifenacin NN B-noun.person	on IN 0	the DT 0	QT NNP 0	interval NN 0	in IN 0	76 CD 0	healthy JJ B-adj.all	women NNS B-noun.person	, , 0	the DT 0	QT NNP 0	prolonging VBG B-verb.change	effect NN B-noun.substance	appeared VBD B-verb.change	less RBR B-adv.all	with IN 0	solifenacin NN B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	than IN 0	with IN 0	30 CD B-adj.all	mg NN B-noun.quantity	( ( 0	three CD 0	times NNS B-noun.event	the DT 0	maximum NN B-noun.person	recommended VBN B-verb.communication	dose NN B-noun.quantity	) ) 0	, , 0	and CC 0	the DT 0	effect NN B-noun.cognition	of IN 0	solifenacin JJ B-adj.all	30 CD B-adj.all	mg NN B-noun.quantity	did VBD 0	not RB B-adv.all	appear VB B-verb.change	as IN 0	large JJ B-adj.all	as IN 0	that DT 0	of IN 0	the DT 0	positive JJ B-adj.all	control NN B-noun.act	moxifloxacin NN B-noun.person	at IN 0	its PRP$ 0	therapeutic JJ B-adj.all	dose NN B-noun.event	. . 0	. . 0
DDI-MedLine.d209.s5	Paroxetine NNP B-noun.person	and CC 0	fluoxetine NN 0	reduce VB B-verb.change	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	endoxifen VBN B-verb.social	by IN 0	about IN 0	50 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d690.s0	The DT 0	CNS NNP B-noun.group	- : 0	depressant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	propoxyphene NN B-noun.person	is VBZ B-verb.stative	additive JJ B-adj.all	with IN 0	that DT 0	of IN 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	, , 0	including VBG B-verb.social	alcohol NN I-verb.social	. . 0	. . 0
DDI-DrugBank.d596.s3	No DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	was VBD 0	observed VBN B-verb.perception	between IN 0	rivastigmine NN B-noun.location	and CC 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	diazepam NN B-noun.person	, , 0	or CC 0	fluoxetine NN B-noun.substance	in IN 0	studies NNS B-noun.artifact	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d220.s4	The DT 0	predicted VBN B-verb.communication	% NN 0	liver NN B-noun.substance	blood NN B-noun.attribute	flow NN B-noun.process	was VBD B-verb.stative	82.3 CD 0	% NN 0	and CC 0	85.4 CD 0	% NN 0	for IN 0	luteolin NN B-noun.person	and CC 0	apigenin RB 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d590.s2	Coadministration NN B-noun.person	with IN 0	a DT 0	high JJ B-adj.all	dose NN B-noun.quantity	of IN 0	antacid NN B-noun.attribute	( ( 0	170 CD 0	mEq NN 0	) ) 0	results NNS B-noun.communication	in IN 0	a DT 0	28 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	ranitidine NN B-noun.state	and CC 0	may MD 0	decrease VB B-verb.cognition	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	bismuth NN B-noun.food	from IN 0	TRITEC NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d572.s24	Multiple JJ B-adj.all	dose NN B-noun.act	studies NNS B-noun.act	of IN 0	ezetimibe NN B-noun.person	given VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	( ( 0	statins NNS B-noun.animal	) ) 0	in IN 0	rats NNS B-noun.animal	and CC 0	rabbits NNS B-noun.artifact	during IN 0	organogenesis NN B-noun.cognition	result NN B-noun.act	in IN 0	higher JJR B-adj.all	ezetimibe NN B-noun.person	and CC 0	statin NN B-noun.artifact	exposures NNS I-noun.artifact	. . 0	. . 0
DDI-MedLine.d184.s5	In IN 0	female JJ B-adj.all	rats NNS B-noun.location	, , 0	neonatal JJ B-adj.all	quinpirole JJ B-adj.all	treatment NN B-noun.plant	enhanced VBN B-verb.change	amphetamine JJ B-adj.all	locomotor NN 0	sensitization NN 0	compared VBN B-verb.cognition	with IN 0	quinpirole JJ B-adj.all	- : 0	free JJ B-adj.all	controls NNS B-noun.artifact	sensitized VBN B-verb.change	to TO 0	amphetamine VB B-verb.social	. . 0	. . 0
DDI-DrugBank.d597.s12	Digoxin NNP B-noun.person	, , 0	Meloxicam NNP B-noun.person	15 CD B-adj.all	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	for IN 0	7 CD B-adj.all	days NNS B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	plasma NN B-noun.substance	concentration NN 0	profile NN 0	of IN 0	digoxin NN B-noun.food	after IN 0	b SYM 0	- : 0	acetyldigoxin NN B-noun.person	administration NN B-noun.person	for IN 0	7 CD B-adj.all	days NNS B-noun.person	at IN 0	clinical JJ B-adj.all	doses NNS B-noun.event	. . 0	. . 0
DDI-DrugBank.d599.s7	These DT 0	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	GH NNP 0	administration NN 0	may MD 0	alter VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	compounds NNS B-noun.person	known VBN B-verb.cognition	to TO 0	be VB 0	metabolized VBN B-verb.cognition	by IN 0	CP450 JJ B-noun.person	liver NN I-noun.person	enzymes NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	corticosteroids NNS B-noun.person	, , 0	sex_steroids NNS B-noun.body	, , 0	anticonvulsants NNS B-noun.person	, , 0	cyclosporin NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d680.s1	Based VBN B-verb.cognition	on IN 0	studies NNS B-noun.artifact	evaluating VBG B-verb.perception	possible JJ B-adj.all	interactions NNS B-noun.person	of IN 0	pantoprazole NN B-noun.person	with IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	no DT 0	dosage NN B-noun.relation	adjustment NN I-noun.relation	is VBZ 0	needed VBN B-verb.consumption	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	the DT 0	following NN 0	, , 0	theophylline PRP 0	, , 0	cisapride NN 0	, , 0	antipyrine NN B-noun.location	, , 0	caffeine NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	diazepam NN B-noun.person	( ( 0	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.food	, , 0	desmethyldiazepam NN B-noun.location	) ) 0	, , 0	diclofenac NN B-noun.person	, , 0	naproxen NN B-noun.person	, , 0	piroxicam NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	ethanol NN 0	, , 0	glyburide NN 0	, , 0	an DT 0	oral JJ B-adj.all	contraceptive NN B-noun.cognition	( ( 0	levonorgestrel NN B-noun.attribute	/ : 0	ethinyl_estradiol NN 0	) ) 0	, , 0	metoprolol NN B-noun.person	, , 0	nifedipine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	midazolam NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	metronidazole NN B-noun.attribute	, , 0	or CC 0	amoxicillin NN B-noun.possession	. . 0	. . 0
DDI-DrugBank.d669.s0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	vancomycin NN B-noun.food	and CC 0	anesthetic_agents NNS B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	erythema NN B-noun.person	and CC 0	histamine NN B-noun.person	- : 0	like IN 0	flushing VBG B-verb.motion	and CC 0	anaphylactoid JJ B-noun.body	reactions NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d194.s10	Treatment NN B-noun.person	of IN 0	HEY NNP 0	xenograft NNS 0	- : 0	bearing NN B-verb.creation	mice NNS I-verb.creation	with IN 0	dasatinib NN B-noun.person	plus CC 0	paclitaxel VB B-verb.change	inhibited JJ B-adj.all	tumor NN B-noun.person	growth NN B-noun.person	more JJR B-noun.quantity	than IN 0	treatment NN B-noun.communication	with IN 0	either DT 0	agent NN B-noun.person	alone RB 0	( ( 0	average JJ B-adj.all	tumor NN B-noun.person	volume NN B-noun.artifact	per IN 0	mouse NN B-noun.animal	, , 0	dasatinib NN B-noun.person	+ : 0	paclitaxel NN B-noun.artifact	vs IN 0	paclitaxel NN B-noun.artifact	, , 0	0.28 CD B-noun.other	vs. JJ I-noun.other	0.81 CD I-noun.other	cm3 CD I-noun.other	, , 0	difference NN B-noun.cognition	= SYM 0	0.53 CD 0	cm3 CD B-noun.quantity	, , 0	95 CD 0	% NN 0	confidence NN B-noun.act	interval NN I-noun.act	[ '' 0	CI NNP 0	] : 0	= SYM 0	0.44 CD 0	to TO 0	0.62 CD 0	cm3 CD 0	, , 0	P NNP 0	= : 0	.014 LS 0	) ) 0	, , 0	. . 0
DDI-DrugBank.d771.s3	e.g. NN B-noun.artifact	, , 0	other JJ B-adj.all	belladonna_alkaloids NNPS B-noun.person	, , 0	antihistamines NNS B-noun.attribute	( ( 0	including VBG B-verb.change	meclizine NN B-noun.attribute	) ) 0	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	and CC 0	muscle_relaxants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d753.s4	In IN 0	addition NN 0	, , 0	CNS NNP 0	toxicity NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	( ( 0	confusion NN B-noun.cognition	, , 0	disorientation NN B-noun.person	, , 0	respiratory JJ B-adj.all	depression NN B-noun.person	, , 0	apnea NN B-noun.person	, , 0	seizures NNS B-noun.body	) ) 0	following VBG 0	coadministration NN B-noun.person	of IN 0	cimetidine NN B-noun.person	with IN 0	opioid_analgesics NNS B-noun.person	, , 0	. . 0
DDI-MedLine.d163.s7	The DT 0	combination NN B-noun.event	of IN 0	minocycline NN B-noun.act	and CC 0	fosfomycin NN B-noun.person	can MD 0	be VB B-verb.stative	synergistic JJ B-adj.all	against IN 0	MRSA NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d615.s0	Triprolidine NNP B-noun.person	may MD 0	enhance VB B-verb.change	the DT 0	sedative JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	central_nervous_system_depressants NNS B-noun.location	including VBG B-verb.emotion	alcohol NN I-verb.emotion	, , 0	barbiturates NNS B-noun.person	, , 0	hypnotics NNS B-noun.person	, , 0	narcotic_analgesics NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	and CC 0	tranquillisers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d182.s23	A DT 0	system NN B-noun.substance	combining VBG B-verb.stative	o SYM 0	- : 0	cymen-5-ol NN B-noun.person	and CC 0	zinc NN B-noun.person	shows VBZ B-verb.perception	properties NNS B-noun.attribute	desirable JJ B-adj.all	for IN 0	incorporation NN B-noun.act	in IN 0	toothpastes NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d715.s1	Concurrent JJ B-adj.all	use NN 0	of IN 0	DEMSER NNP B-noun.group	with IN 0	alcohol NN B-noun.feeling	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	can MD 0	increase VB B-verb.change	their PRP$ 0	sedative JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d780.s0	Anticholinesterases NNS B-noun.person	, , 0	Concurrent JJ 0	use NN 0	of IN 0	procaine_hydrochloride JJ B-noun.other	and CC 0	anticholinesterase_agents NNS B-noun.location	may MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	systemic JJ B-adj.all	toxicity NN B-noun.state	since IN 0	anticholinesterases NNS B-noun.act	inhibit VBP B-verb.stative	the DT 0	breakdown NN B-noun.person	of IN 0	procaine_hydrochloride NN B-noun.other	. . 0	. . 0
DDI-MedLine.d212.s4	The DT 0	colchicine NN B-noun.person	nanoemulsion NN B-noun.person	was VBD 0	prepared VBN B-verb.creation	with IN 0	isopropyl_myristate JJ B-noun.other	, , 0	eugenol NN B-noun.person	, , 0	Tween80 CD 0	, , 0	ethanol NN B-noun.person	and CC 0	water NN B-noun.object	, , 0	and CC 0	eugenol NN B-noun.person	was VBD 0	used VBN B-verb.consumption	as IN 0	an DT 0	oil NN B-noun.group	phase NN B-noun.time	in IN 0	the DT 0	formulation NN B-noun.act	, , 0	. . 0
DDI-MedLine.d194.s5	The DT 0	roles NNS B-noun.act	of IN 0	p27(Kip1 NNP B-noun.location	) ) 0	, , 0	Bcl-2 NN 0	, , 0	and CC 0	Cdk1 NNS B-noun.person	in IN 0	apoptosis NN 0	induced VBN B-verb.creation	by IN 0	dasatinib NN B-noun.person	and CC 0	paclitaxel NN B-noun.artifact	were VBD 0	assessed VBN B-verb.cognition	using VBG B-verb.consumption	a DT 0	terminal JJ B-noun.possession	deoxynucleotidyl NN I-noun.possession	transferase NN B-noun.act	- : 0	mediated VBD B-verb.stative	dUTP JJ B-adj.all	nick NN B-noun.person	- : 0	end NN 0	labeling NN B-verb.stative	( ( 0	TUNEL NNP B-noun.group	) ) 0	assay NN B-noun.location	, , 0	siRNA CD 0	knockdown VBN B-verb.cognition	of IN 0	gene NN B-noun.artifact	expression NN I-noun.artifact	, , 0	transfection NN B-noun.act	with IN 0	Bcl-2 NN B-noun.food	and CC 0	Cdk1 JJ B-adj.all	expression NN B-noun.communication	vectors NNS B-noun.communication	, , 0	and CC 0	flow NN B-noun.plant	cytometry NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d635.s0	Other JJ 0	short JJ B-noun.body	- : 0	acting_beta_adrenergic_aerosol_bronchodilators NNS B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	MAXAIR_AUTOHALER NN B-noun.artifact	because IN 0	they PRP 0	may MD 0	have VB B-verb.change	additive JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d164.s2	We PRP 0	evaluated VBD B-verb.communication	how WRB 0	lapatinib JJ B-adj.all	interacts NNS B-noun.person	with IN 0	Herceptin NNP B-noun.person	in IN 0	HER2-positive JJ 0	breast NN 0	cancer NN B-noun.person	, , 0	with IN 0	a DT 0	particular JJ B-adj.all	focus NN B-noun.person	on IN 0	Herceptin NNP B-noun.person	- : 0	mediated VBD B-verb.stative	antibody NN 0	- : 0	dependent JJ B-adj.all	cellular JJ B-noun.body	cytotoxicity NN I-noun.body	( ( 0	ADCC NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d779.s5	When WRB 0	methyldopa NN B-noun.person	and CC 0	lithium NN B-noun.person	are VBP 0	given VBN B-verb.possession	concomitantly RB B-adv.all	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.contact	for IN 0	symptoms NNS B-noun.relation	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d224.s4	Group NNP 0	2 CD 0	consisted VBD B-verb.stative	of IN I-verb.stative	10 CD B-adj.all	% NN 0	carbamide_peroxide NN B-noun.group	- : 0	based VBN B-verb.cognition	bleaching JJ 0	gel NN 0	and CC 0	0.01 CD 0	% NN 0	manganese_gluconate NN B-noun.group	. . 0	. . 0
DDI-DrugBank.d584.s9	Oral NNP B-noun.group	hypoglycemic_agents NNP I-noun.group	Oxandrolone NNP I-noun.group	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d737.s3	Amantadine NNP B-noun.person	, , 0	Population NNP B-noun.other	pharmacokinetic JJ B-adj.all	analysis NN B-noun.communication	suggests VBZ B-verb.communication	that IN 0	amantadine NN B-noun.person	is VBZ B-verb.stative	unlikely JJ B-adj.all	to TO 0	alter VB B-verb.change	the DT 0	oral JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	pramipexole NN B-noun.communication	( ( 0	N= $ 0	54 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d742.s10	However RB 0	, , 0	the DT 0	impairment NN B-noun.attribute	of IN 0	motor NN 0	skills NNS 0	produced VBN B-verb.creation	by IN 0	REMERON NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	be VB B-verb.stative	additive JJ B-adj.all	with IN 0	those DT 0	caused VBN B-verb.creation	by IN 0	diazepam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d668.s0	Although IN 0	specific JJ B-adj.all	drug NN B-noun.attribute	or CC 0	food NN B-noun.act	interactions NNS I-noun.act	with IN 0	mifepristone NN 0	have VBP 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	, , 0	on IN 0	the DT 0	basis NN B-noun.cognition	of IN 0	this DT 0	drug NN B-noun.group	__ : 0	s PRP 0	metabolism NN B-noun.attribute	by IN 0	CYP NNP B-noun.person	3A4 NNP I-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	possible JJ B-adj.all	that IN 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	and CC 0	grapefruit NN B-adj.all	juice NN B-noun.group	may MD 0	inhibit VB B-verb.stative	its PRP$ 0	metabolism NN B-noun.attribute	( ( 0	increasing VBG B-verb.change	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	mifepristone NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d213.s3	Systemic NNP B-noun.person	and CC 0	apparent JJ B-adj.all	oral JJ B-adj.all	midazolam NN B-noun.phenomenon	clearance NN B-noun.act	were VBD B-verb.stative	24 CD B-adj.all	% NN 0	( ( 0	269 CD 0	___ CD 0	73 CD B-noun.other	vs. FW I-noun.other	354 CD I-noun.other	___ CD I-noun.other	102 CD I-noun.other	_ : 0	ml PRP 0	/ `` 0	min NN 0	, , 0	P NNP 0	= SYM 0	0.022 CD 0	) ) 0	and CC 0	31 CD 0	% NN 0	( ( 0	479 CD 0	___ CD 0	190 CD B-noun.other	vs. IN I-noun.other	688 CD I-noun.other	___ CD I-noun.other	265 CD I-noun.other	_ : 0	ml PRP 0	/ `` 0	min NN 0	, , 0	P NNP 0	= SYM 0	0.013 CD 0	) ) 0	, , 0	respectively RB B-adv.all	, , 0	lower JJR B-adj.all	in IN 0	cyclosporine NN 0	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	( ( 0	n UH 0	= $ 0	20 CD B-adj.all	) ) 0	than IN 0	in IN 0	matched VBN B-verb.contact	tacrolimus NN B-noun.person	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	( ( 0	n UH 0	= $ 0	20 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-MedLine.d217.s0	Interaction NN B-noun.act	of IN 0	celecoxib NN B-noun.body	with IN 0	different JJ B-adj.all	anti NNS B-noun.person	- : 0	cancer_drugs NNS B-noun.communication	is VBZ B-verb.stative	antagonistic JJ B-adj.all	in IN 0	breast NN 0	but CC 0	not RB B-adv.all	in IN 0	other JJ 0	cancer NN B-noun.body	cells NNS B-noun.body	. . 0	_ PRP 0	. . 0
DDI-MedLine.d218.s0	Antidepressant JJ B-adj.all	- : 0	warfarin NN 0	interaction NN B-noun.act	and CC 0	associated VBN B-verb.cognition	gastrointestinal JJ B-adj.all	bleeding NN B-verb.social	risk NN I-verb.social	in IN 0	a DT 0	case NN B-noun.person	- : 0	control NN B-noun.act	study NN B-noun.artifact	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d611.s1	Beta_adrenergic_agonists NNS B-noun.person	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	being VBG 0	treated VBN B-verb.change	with IN 0	monoamine_oxidase_inhibitors NNS B-noun.person	or CC 0	tricyclic_antidepressants NNS B-noun.plant	, , 0	since IN 0	the DT 0	action NN B-noun.process	of IN 0	beta_adrenergic_agonists NNS B-noun.person	on IN 0	the DT 0	vascular JJ B-adj.all	system NN B-noun.substance	may MD 0	be VB 0	potentiated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d776.s41	While IN 0	there EX 0	is VBZ B-verb.stative	evidence NN B-noun.attribute	that IN 0	fluconazole NN B-noun.person	can MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	ethinyl_estradiol NN B-noun.food	and CC 0	levonorgestrel NN B-noun.attribute	, , 0	there EX 0	is VBZ B-verb.stative	no DT 0	evidence NN B-noun.attribute	that IN 0	fluconazole NN B-noun.person	is VBZ B-verb.stative	a DT 0	net JJ B-adj.all	inducer NN B-noun.state	of IN 0	ethinyl_estradiol NN B-noun.act	or CC 0	levonorgestrel NN B-noun.artifact	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d742.s11	Accordingly RB B-adv.all	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	advised VBN B-verb.communication	to TO 0	avoid VB B-verb.social	diazepam NN B-noun.person	and CC 0	other JJ 0	similar JJ B-adj.all	drugs NNS B-noun.artifact	while IN 0	taking VBG B-verb.social	REMERON_SolTab JJ I-verb.social	. . 0	. . 0
DDI-MedLine.d184.s8	Rats NNS B-noun.person	treated VBN B-verb.social	with IN 0	neonatal JJ B-adj.all	quinpirole NN B-noun.communication	enhanced VBD B-verb.possession	time NN 0	spent VBN B-verb.stative	in IN 0	the DT 0	amphetamine JJ B-noun.person	- : 0	paired VBN B-verb.contact	context NN B-noun.feeling	compared VBN B-verb.change	with IN 0	quinpirole JJ B-adj.all	- : 0	free JJ B-adj.all	controls NNS B-noun.artifact	conditioned VBN B-verb.stative	with IN 0	amphetamine NN B-noun.person	, , 0	but CC 0	only RB B-adv.all	female JJ B-adj.all	controls NNS B-noun.cognition	conditioned VBN B-verb.social	with IN 0	amphetamine NN B-noun.person	spent VBD B-verb.stative	more JJR B-adj.all	time NN B-noun.time	in IN 0	the DT 0	drug NN B-noun.group	- : 0	paired VBN B-verb.contact	context NN B-noun.feeling	compared VBN B-verb.change	with IN 0	saline NN B-noun.act	- : 0	treated VBN B-verb.body	controls NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d625.s0	DRUG NN B-noun.group	INTERACTIONS NNS B-noun.group	_ CC 0	There EX 0	are VBP B-verb.stative	no DT 0	known VBN B-verb.cognition	drug NN B-noun.quantity	/ : 0	drug NN B-noun.act	interactions NNS I-noun.act	with IN 0	oral JJ B-adj.all	ALKERAN NNP B-noun.group	_ POS 0	Vaccinations NNS B-noun.person	with IN 0	live_organism_vaccines NNS B-noun.artifact	are VBP B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	in IN 0	immunocompromised JJ B-adj.all	individuals NNS B-noun.person	_ : 0	Nalidixic_acid JJ B-adj.all	together RB I-adj.all	with IN 0	high JJ B-noun.group	- : 0	dose RB B-verb.creation	intravenous JJ B-adj.all	melphalan NN B-noun.person	has VBZ 0	caused VBN B-verb.communication	deaths NNS B-noun.person	in IN 0	children NNS 0	due JJ 0	to TO 0	haemorrhagic JJ B-adj.all	enterocolitis NN B-noun.event	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d752.s9	The DT 0	difficulty NN B-noun.attribute	in IN 0	achieving VBG B-verb.social	adequate JJ B-adj.all	sedation NN B-noun.act	may MD 0	have VB 0	been VBN B-verb.stative	the DT 0	result NN B-noun.act	of IN 0	decreased VBN B-verb.change	absorption NN B-noun.process	of IN 0	the DT 0	sedatives NNS B-noun.body	due JJ 0	to TO 0	both DT 0	the DT 0	gastrointestinal JJ B-adj.pert	effects NNS B-noun.phenomenon	and CC 0	stimulant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	methylphenidate NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d700.s2	Cyclosporine NNP B-noun.person	, , 0	When WRB 0	studied VBN B-verb.cognition	in IN 0	stable JJ B-adj.all	renal JJ B-adj.all	transplant NN B-noun.person	patients NNS B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	USP NNP B-noun.group	( ( 0	MODIFIED VBN B-verb.change	) ) 0	pharmacokinetics NNS B-noun.person	were VBD B-verb.stative	unaffected JJ B-adj.all	by IN 0	steady JJ B-adj.all	state NN B-noun.state	dosing NN B-noun.quantity	of IN 0	Myfortic NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d606.s0	MAO_inhibitors NNS B-noun.person	and CC 0	beta_adrenergic_blockers NNS B-noun.person	increase VBP B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	pseudoephedrine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d726.s3	Drugs NNS B-noun.artifact	that WDT 0	impair VBP B-verb.change	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	fat SYM 0	- : 0	soluble_vitamins NNS B-noun.person	, , 0	such JJ 0	as IN 0	cholestyramine NN B-noun.person	, , 0	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	Zemplar NNP B-noun.other	Capsules NNPS I-noun.other	. . 0	. . 0
DDI-DrugBank.d678.s4	Metopirone NN B-noun.person	inhibits VBZ B-verb.change	the DT 0	glucuronidation NN B-noun.act	of IN 0	acetaminophen NN B-noun.person	and CC 0	could MD 0	possibly RB 0	potentiate VB B-verb.communication	acetaminophen JJ B-noun.person	toxicity NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d673.s1	The DT 0	bioavailability NN B-noun.cognition	of IN 0	olmesartan NN B-noun.communication	was VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	altered VBN B-verb.change	by IN 0	the DT 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	antacids NNS B-noun.attribute	[ : 0	Al(OH)3/Mg(OH)2 RB 0	] RB 0	. . 0	. . 0
DDI-DrugBank.d628.s7	No DT 0	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.person	with IN 0	commonly RB B-adv.all	used VBN B-verb.consumption	premedications NNS B-noun.possession	or CC 0	drugs NNS B-noun.artifact	used VBN B-verb.consumption	during IN 0	anesthesia NN B-noun.state	or CC 0	sedation NN B-noun.act	( ( 0	including VBG B-verb.change	a DT 0	range NN B-noun.person	of IN 0	muscle_relaxants NNS B-noun.location	, , 0	inhalational JJ B-adj.all	agents NNS B-noun.person	, , 0	analgesic_agents NNS B-noun.person	, , 0	and CC 0	local JJ B-adj.all	anesthetic_agents NNS B-noun.group	) ) 0	have VBP 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-MedLine.d196.s4	Two CD 0	separate JJ B-adj.all	studies NNS B-noun.plant	were VBD 0	conducted VBN B-verb.communication	to TO 0	evaluate VB B-verb.communication	the DT 0	bioequivalence NN B-noun.cognition	of IN 0	fenofibric_acid JJ B-adj.all	relative JJ B-noun.motive	to TO 0	fenofibrate VB B-verb.cognition	under IN 0	fasted VBN B-verb.creation	and CC 0	fed VBN B-verb.consumption	( ( 0	standard JJ B-adj.all	breakfast NN B-noun.event	) ) 0	conditions NNS B-noun.quantity	, , 0	characterize VBP B-verb.change	the DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.person	, , 0	and CC 0	assess VB B-verb.cognition	the DT 0	safety NN B-noun.artifact	and CC 0	tolerability NN B-noun.attribute	of IN 0	fenofibric_acid NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d779.s7	Several JJ B-adj.all	studies NNS B-noun.act	demonstrate VBP B-verb.stative	a DT 0	decrease NN B-noun.event	in IN 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	methyldopa NN B-noun.attribute	when WRB 0	it PRP 0	is VBZ 0	ingested VBN B-verb.consumption	with IN 0	ferrous_sulfate JJ B-adj.all	or CC 0	ferrous_gluconate NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d578.s8	This DT 0	could MD 0	lead VB B-verb.cognition	to TO 0	decreased VBN B-verb.change	salicylate NN B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	or CC 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	salicylate JJ B-adj.all	toxicity NN B-noun.attribute	when WRB 0	methylprednisolone NN B-noun.person	is VBZ 0	withdrawn VBN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d777.s0	The DT 0	interaction NN B-noun.act	of IN 0	Streptase NNP B-noun.person	, , 0	Streptokinase NNP B-noun.person	, , 0	with IN 0	other JJ 0	drugs NNS B-noun.person	has VBZ 0	not RB B-adv.all	been VBN B-verb.stative	well RB 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d672.s3	Warfarin NNP B-noun.person	, , 0	Sparfloxacin NNP B-noun.person	does VBZ 0	not RB B-adv.all	increase VB B-verb.change	the DT 0	anti NNS B-noun.person	- : 0	coagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d742.s5	While IN 0	in IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	have VBP 0	shown VBN B-verb.cognition	that IN 0	mirtazapine NN B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	any DT 0	of IN 0	these DT 0	enzymes NNS B-noun.act	, , 0	an DT 0	indication NN B-noun.communication	that WDT 0	mirtazapine VBP 0	is VBZ B-verb.stative	not RB B-adv.all	likely JJ B-adj.all	to TO 0	have VB B-verb.social	a DT 0	clinically RB B-adv.all	significant JJ B-adj.all	inhibitory JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	substrates NNS B-noun.person	for IN 0	these DT 0	cytochrome VBP B-verb.stative	P450 JJ 0	enzymes NNS B-noun.artifact	, , 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	REMERON_SolTab NN B-noun.food	with IN 0	most JJS 0	other JJ 0	drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	these DT 0	enzymes NNS B-noun.Tops	has VBZ 0	not RB 0	been VBN 0	formally RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d580.s1	However RB 0	, , 0	ketoconazole NN B-noun.person	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 JJ I-noun.person	3A4 NN I-noun.person	, , 0	may MD 0	increase VB B-verb.change	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	mometasone_furoate NN B-noun.location	during IN 0	concomitant JJ B-adj.all	dosing NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d752.s3	Although IN 0	not RB B-adv.all	studied VBN B-verb.cognition	, , 0	the DT 0	potent JJ B-adj.all	cytochrome NN B-noun.person	P450 RB I-noun.person	3A4 JJ I-noun.person	inhibitors NNS I-noun.person	ritonavir VBP B-verb.contact	and CC 0	nelfinavir NN B-noun.person	may MD 0	cause VB B-verb.communication	intense JJ B-adj.all	and CC 0	prolonged VBN B-verb.communication	sedation NN B-noun.person	and CC 0	respiratory JJ B-adj.all	depression NN B-noun.event	due JJ 0	to TO 0	a DT 0	decrease NN B-noun.event	in IN 0	plasma NN 0	clearance NN 0	of IN 0	midazolam NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d578.s10	The DT 0	effect NN B-noun.cognition	of IN 0	methylprednisolone NN B-noun.attribute	on IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	is VBZ B-verb.stative	variable JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d735.s2	There EX 0	was VBD B-verb.stative	no DT 0	effect NN B-noun.cognition	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.communication	or CC 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	MYCAMINE NNP B-noun.group	on IN 0	mycophenolate_mofetil NNP B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	tacrolimus NN B-noun.person	, , 0	prednisolone NN B-noun.person	, , 0	and CC 0	fluconazole JJ B-adj.all	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d169.s10	In IN 0	conclusion NN 0	, , 0	we PRP 0	demonstrated VBD B-verb.perception	an DT 0	isolated JJ B-adj.all	effect NN B-noun.cognition	of IN 0	calcium NN B-noun.substance	( ( 0	as IN 0	chloride NN 0	) ) 0	on IN 0	absorption NN B-noun.act	of IN 0	5 CD B-adj.all	mg NN B-noun.quantity	of IN 0	iron NN B-noun.person	provided VBD B-verb.communication	as RB 0	nonheme JJ 0	( ( 0	as IN 0	sulfate NN 0	) ) 0	and CC 0	heme NN B-noun.person	( ( 0	as IN 0	CRBC NNP B-noun.group	) ) 0	iron NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d775.s4	There EX 0	are VBP B-verb.stative	no DT 0	clinical JJ B-adj.all	data NNS B-noun.cognition	on IN 0	the DT 0	use NN 0	of IN 0	MIVACRON NNP B-noun.person	with IN 0	other JJ B-adj.all	nondepolarizing_neuromuscular_blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d585.s3	Anticholinergic_agents NNS B-noun.animal	may MD 0	affect VB B-verb.change	gastrointestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	various JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	slowly RB B-adj.all	dissolving JJ 0	dosage NN 0	forms NNS 0	of IN 0	digoxin NN B-noun.person	, , 0	. . 0
DDI-MedLine.d182.s18	Zinc NNP B-noun.person	inhibited VBD B-verb.possession	glycolysis NN B-noun.person	and CC 0	protease NN B-noun.person	to TO 0	a DT 0	greater JJR B-adj.all	degree NN B-noun.person	than IN 0	o SYM 0	- : 0	cymen-5-ol NN B-noun.time	, , 0	. . 0
DDI-DrugBank.d614.s7	Preclinical JJ B-adj.all	data NNS B-noun.cognition	also RB B-adv.all	suggest VBP B-verb.communication	that IN 0	tissue NN B-noun.substance	ischemia NN I-noun.substance	, , 0	allopurinol NN B-noun.person	, , 0	calcium_channel_blockers NNS B-noun.person	and CC 0	some DT 0	prostaglandin NN B-noun.person	synthesis NN I-noun.person	inhibitors NNS B-noun.person	could MD 0	interfere VB B-verb.contact	with IN 0	PHOTOFRIN NNP B-noun.group	___ NNP I-noun.group	PDT NNP I-noun.group	. . 0	. . 0
DDI-DrugBank.d653.s4	Corticosteroids NNS B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	chronic JJ B-adj.pert	high JJ B-adj.all	dose NN 0	aspirin NN 0	. . 0	. . 0
DDI-MedLine.d153.s2	Following VBG 0	liquid JJ B-adj.all	- : 0	liquid JJ B-adj.all	extraction NN 0	with IN 0	ethyl_acetate JJ 0	, , 0	the DT 0	separation NN B-noun.body	was VBD 0	performed VBN B-verb.social	on IN 0	a DT 0	reverse JJ B-adj.all	phase NN B-noun.time	C18 NN 0	column NN B-noun.communication	with IN 0	a DT 0	mobile JJ B-noun.artifact	phase NN I-noun.artifact	consisted VBD B-verb.stative	of IN I-verb.stative	methanol NN B-noun.act	- : 0	ammonium_acetate JJ B-noun.other	( ( 0	pH $ 0	4.0 CD 0	, , 0	10 CD B-adj.all	mM CD B-noun.quantity	) ) 0	( ( 0	70,30 CD 0	, , 0	v UH 0	/ : 0	v LS 0	) ) 0	. . 0	. . 0
DDI-MedLine.d198.s3	We PRP 0	observed VBD B-verb.perception	that IN 0	GLIC NNP B-noun.other	recapitulates VBZ B-verb.communication	bimodal JJ B-noun.phenomenon	modulation NN I-noun.phenomenon	by IN 0	n SYM 0	- : 0	alcohols NNS B-noun.artifact	, , 0	similar JJ B-adj.all	to TO 0	some DT 0	eukaryotic JJ B-adj.all	pLGICs NNS B-noun.person	, , 0	methanol NN B-noun.person	and CC 0	ethanol NN 0	weakly RB B-adv.all	potentiated JJ B-adj.all	proton NN B-noun.person	- : 0	activated VBN B-verb.creation	currents NNS B-noun.person	in IN 0	GLIC NNP B-noun.other	, , 0	whereas IN 0	n SYM 0	- : 0	alcohols NNS B-noun.artifact	larger JJR B-adj.all	than IN 0	ethanol NN B-noun.person	inhibited VBD B-verb.change	them PRP 0	. . 0	. . 0
DDI-DrugBank.d579.s1	The DT 0	action NN B-noun.state	of IN 0	Mecamylamine NNP B-noun.person	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	anesthesia NN B-noun.person	, , 0	other JJ B-adj.all	antihypertensive_drugs NNS B-noun.object	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-MedLine.d185.s2	This DT 0	study NN B-noun.communication	evaluated VBD B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	a DT 0	potent JJ B-noun.person	CYP3A NNP I-noun.person	inhibitor NN I-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	and CC 0	safety NN B-noun.person	of IN 0	panobinostat NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d699.s0	Mequitazine NN B-noun.person	can MD 0	interact VB B-verb.change	with IN 0	CNS_depressant JJ B-adj.all	, , 0	antichlolinergic JJ B-adj.all	, , 0	TCA NNP B-noun.group	, , 0	MAOIs NNP B-noun.person	, , 0	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d662.s0	Mitoxantrone NNP B-noun.person	and CC 0	its PRP$ 0	metabolites NNS B-noun.time	are VBP 0	excreted VBN B-verb.stative	in IN 0	bile NN B-noun.possession	and CC 0	urine NN B-noun.location	, , 0	but CC 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	whether IN 0	the DT 0	metabolic JJ B-adj.all	or CC 0	excretory JJ B-adj.all	pathways NNS B-noun.artifact	are VBP B-verb.stative	saturable JJ B-adj.all	, , 0	may MD 0	be VB 0	inhibited VBN B-verb.change	or CC 0	induced VBN B-verb.creation	, , 0	or CC 0	if IN 0	mitoxantrone NN 0	and CC 0	its PRP$ 0	metabolites NNS B-noun.time	undergo VBP B-verb.stative	enterohepatic JJ B-adj.all	circulation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d727.s2	In IN 0	vitro NN B-noun.animal	data NNS I-noun.animal	indicate VBP B-verb.communication	that IN 0	the DT 0	phosphorylation NN B-noun.time	of IN 0	stavudine NN B-noun.state	is VBZ B-verb.stative	also RB B-adv.all	inhibited VBN B-verb.possession	at IN 0	relevant JJ B-adj.all	concentrations NNS B-noun.person	by IN 0	doxorubicin NN B-noun.person	and CC 0	ribavirin NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d760.s0	Concomitant NNP B-noun.person	Therapy NNP I-noun.person	_ POS 0	Special JJ B-adj.all	care NN B-noun.group	should MD 0	be VB 0	exercised VBN B-verb.body	in IN 0	treating VBG B-verb.communication	patients NNS B-noun.person	who WP 0	are VBP 0	receiving VBG B-verb.change	concomitant JJ B-adj.all	therapy NN B-noun.cognition	( ( 0	either RB 0	topically RB B-adv.all	or CC 0	systemically RB B-noun.body	) ) 0	with IN 0	known VBN B-verb.cognition	photosensitizing VBG B-verb.communication	agents NNS B-noun.person	such JJ 0	as IN 0	anthralin NN B-noun.person	, , 0	coal_tar NN B-noun.person	or CC 0	coal_tar_derivatives NNS B-noun.artifact	, , 0	griseofulvin NN 0	, , 0	phenothiazines NNS B-noun.body	, , 0	nalidixic_acid JJ 0	, , 0	halogenated_salicylanilides VBZ B-verb.stative	( ( 0	bacteriostatic JJ B-adj.all	soaps NNS B-noun.artifact	) ) 0	, , 0	sulfonamides VBZ B-verb.motion	, , 0	tetracyclines NNS B-noun.artifact	, , 0	thiazides NNS B-noun.person	, , 0	and CC 0	certain JJ B-adj.all	organic JJ B-adj.all	staining JJ B-adj.all	dyes NNS B-noun.state	such JJ 0	as IN 0	methylene_blue NN B-noun.food	, , 0	toluidine_blue NN 0	, , 0	rose VBD B-verb.motion	bengal JJ I-verb.motion	and CC 0	methyl NN B-noun.attribute	orange NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d702.s2	However RB 0	, , 0	the DT 0	co NN 0	__ CD 0	administration NN B-noun.quantity	of IN 0	SPIRIVA NNP 0	with IN 0	other JJ 0	anticholinergic JJ B-adj.all	__ IN 0	containing VBG B-verb.stative	drugs NNS I-verb.stative	( ( 0	e.g. UH 0	, , 0	ipratropium NN 0	) ) 0	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	and CC 0	is VBZ B-verb.stative	therefore RB 0	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d670.s6	Given VBN B-verb.possession	the DT 0	primary JJ B-adj.all	CNS NNP 0	effects NNS B-noun.phenomenon	of IN 0	paliperidone NN 0	, , 0	INVEGA NNP B-noun.group	___ CC 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	combination NN 0	with IN 0	other JJ B-adj.all	centrally_acting_drugs NNS B-noun.location	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d761.s1	Cyclosporine NNP B-noun.person	, , 0	Preliminary NNP B-noun.person	data NNS I-noun.person	from IN 0	a DT 0	XENICAL NNP B-noun.group	and CC 0	cyclosporine JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	study NN B-noun.artifact	indicate VBP B-verb.communication	a DT 0	reduction NN B-noun.act	in IN 0	cyclosporine JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.attribute	when WRB 0	XENICAL NNP B-noun.group	was VBD 0	coadministered VBN B-verb.contact	with IN 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d647.s1	Streptozocin NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	prolong VB B-verb.stative	the DT 0	elimination NN B-noun.artifact	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	doxorubicin NN B-noun.food	and CC 0	may MD 0	lead VB B-verb.cognition	to TO 0	severe JJ B-adj.all	bone NN 0	marrow NN 0	suppression NN 0	, , 0	. . 0
DDI-MedLine.d230.s2	The DT 0	purpose NN B-noun.attribute	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	assess VB B-verb.cognition	the DT 0	potential NN B-noun.person	of IN 0	neferine NN B-noun.person	, , 0	an DT 0	effective JJ B-adj.all	anti NNS B-noun.person	- : 0	pulmonary JJ B-adj.all	fibrosis NN B-noun.artifact	drug NN I-noun.artifact	isolated VBN B-verb.change	from IN 0	the DT 0	embryo NN B-noun.person	of IN 0	Nelumbo JJ B-adj.all	nucifera NN B-noun.group	Gaertner NNP B-noun.person	's POS 0	seeds NNS B-noun.plant	, , 0	to TO 0	alter VB B-verb.change	the DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	amiodarone NN 0	. . 0	. . 0
DDI-DrugBank.d659.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	TRENTAL NNP B-noun.group	and CC 0	theophylline PRP 0	- : 0	containing VBG B-verb.communication	drugs NNS B-noun.person	leads VBZ B-verb.stative	to TO 0	increased VBN B-verb.change	theophylline NN 0	levels NNS B-noun.attribute	and CC 0	theophylline JJ 0	toxicity NN B-noun.attribute	in IN 0	some DT 0	individuals NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d596.s4	The DT 0	elevation NN B-noun.act	of IN 0	prothrombin NN B-noun.person	time NN 0	induced VBN B-verb.creation	by IN 0	warfarin NN B-noun.communication	is VBZ B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	administration NN B-noun.time	of IN 0	Exelon NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d220.s6	Compared VBN B-verb.cognition	with IN 0	the DT 0	elimination NN B-noun.act	of IN 0	pure JJ B-noun.phenomenon	luteolin NN I-noun.phenomenon	and CC 0	apigenin RB 0	, , 0	the DT 0	elimination NN B-noun.act	of IN 0	luteolin NN B-noun.substance	and CC 0	apigenin NN B-noun.person	was VBD B-verb.stative	much RB 0	lower JJR B-adj.all	in IN 0	hydrolyzed JJ B-adj.all	Flos NNP B-noun.person	Chrysanthemi NNP I-noun.person	extract NN I-noun.person	( ( 0	FCE NNP 0	) ) 0	containing VBG B-verb.stative	comparable JJ B-adj.all	amounts NNS B-noun.quantity	of IN 0	luteolin NN B-noun.substance	and CC 0	apigenin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d572.s12	A DT 0	104-week JJ 0	dietary JJ B-adj.all	carcinogenicity NN B-noun.phenomenon	study NN B-noun.artifact	with IN 0	ezetimibe NN B-noun.person	was VBD B-verb.stative	also RB B-adv.all	conducted VBN B-verb.communication	in IN 0	mice NNS B-noun.animal	at IN 0	doses NNS B-noun.artifact	up IN 0	to TO 0	500 CD 0	mg PRP 0	/ ( 0	kg RB 0	/ JJ 0	day NN 0	( ( 0	> $ 0	150 CD 0	times NNS B-noun.event	the DT 0	human JJ B-adj.all	exposure NN B-noun.person	at IN 0	10 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	based VBN B-verb.cognition	on IN 0	AUC0 NN B-noun.act	- : 0	24hr JJ 0	for IN 0	total JJ B-adj.all	ezetimibe NN B-noun.act	) ) 0	. . 0	. . 0
DDI-DrugBank.d781.s11	Digoxin NNP B-noun.person	, , 0	A DT 0	controlled JJ B-adj.all	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	has VBZ 0	shown VBN B-verb.perception	no DT 0	effect NN B-noun.cognition	on IN 0	plasma NN 0	digoxin NN 0	concentrations NNS B-noun.attribute	when WRB 0	coadministered VBN B-verb.communication	with IN 0	ACEON NNP B-noun.group	___ POS 0	Tablets NNS B-noun.location	, , 0	but CC 0	an DT 0	effect NN B-noun.cognition	of IN 0	digoxin NN B-noun.person	on IN 0	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	perindopril NN B-noun.time	/ : 0	perindoprilat NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	excluded VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d616.s1	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	administering VBG B-verb.perception	ZADAXIN NNP I-verb.perception	therapy NN 0	in IN 0	combination NN 0	with IN 0	other JJ B-adj.all	immunomodulating_drugs NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d677.s0	Phenothiazines NNS B-noun.artifact	are VBP B-verb.stative	capable JJ B-adj.all	of IN 0	potentiating VBG B-verb.stative	CNS_depressants NNS I-verb.stative	( ( 0	e.g. UH 0	, , 0	barbiturates NNS B-noun.person	, , 0	anesthetics NNS B-noun.person	, , 0	opiates NNS B-noun.person	, , 0	alcohol NN B-noun.person	, , 0	etc FW 0	. . 0	) ) 0	. . 0
DDI-DrugBank.d578.s1	Mutual JJ B-adj.all	inhibition NN B-noun.attribute	of IN 0	metabolism NN B-noun.attribute	occurs VBZ B-verb.stative	with IN 0	concurrent JJ B-adj.all	use NN 0	of IN 0	cyclosporin NN B-noun.person	and CC 0	methylprednisolone NN B-noun.attribute	, , 0	. . 0
DDI-DrugBank.d689.s0	Vasopressors NNS B-noun.person	, , 0	particularly RB B-adj.all	metaraminol NN B-noun.person	, , 0	may MD 0	cause VB B-verb.communication	serious JJ B-adj.all	cardiac NN B-noun.artifact	arrhythmias NN B-noun.artifact	during IN 0	halothane NN 0	anesthesia NN 0	and CC 0	therefore RB 0	should MD 0	be VB 0	used VBN B-verb.consumption	only RB B-adv.all	with IN 0	great JJ B-adj.all	caution NN B-noun.event	or CC 0	not RB B-adv.all	at IN 0	all DT 0	. . 0	. . 0
DDI-DrugBank.d756.s7	Caffeine NNP B-noun.person	and/or NNP I-noun.person	stimulantes VBZ B-verb.communication	of IN 0	the DT 0	ephedrine NN B-noun.communication	/ : 0	amphetamine JJ B-adj.all	type NN B-noun.person	may MD 0	counteract VB B-verb.change	the DT 0	specific JJ B-adj.all	actions NNS B-noun.act	of IN 0	levomepromazine NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d703.s0	Interaction NN 0	with IN 0	Other JJ 0	Central_Nervous_System_Depressants NNS B-noun.location	, , 0	MEPERIDINE NNP B-noun.group	SHOULD MD 0	BE VB 0	USED VBN B-verb.consumption	WITH IN 0	GREAT JJ B-noun.group	CAUTION NN B-noun.group	AND CC 0	IN IN 0	REDUCED NNP B-noun.group	DOSAGE NNP B-noun.group	IN IN 0	PATIENTS NNPS B-noun.group	WHO WP 0	ARE VBP 0	CONCURRENTLY RB 0	RECEIVING VBG B-verb.communication	OTHER JJ 0	NARCOTIC_ANALGESICS NNS B-noun.person	, , 0	GENERAL NNP B-noun.group	ANESTHETICS NNPS B-noun.group	, , 0	PHENOTHIAZINES NNP B-noun.group	, , 0	OTHER JJ 0	TRANQUILIZERS NNS B-noun.group	, , 0	SEDATIVE NNP B-noun.group	- : 0	HYPNOTICS NNS B-noun.group	( ( 0	INCLUDING NNP B-noun.group	BARBITURATES NNP I-noun.group	) ) 0	, , 0	TRICYCLIC_ANTIDEPRESSANTS NNPS B-noun.person	AND CC 0	OTHER JJ 0	CNS_DEPRESSANTS NNS B-noun.substance	( ( 0	INCLUDING NNP B-noun.group	ALCOHOL NNP I-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d761.s12	Although IN 0	undercarboxylated JJ 0	osteocalcin NN 0	, , 0	a DT 0	marker NN B-noun.person	of IN 0	vitamin NN 0	K NNP 0	nutritional JJ B-adj.all	status NN B-noun.state	, , 0	was VBD B-verb.stative	unaltered JJ B-adj.all	with IN 0	XENICAL NNP B-noun.group	administration NN B-noun.time	, , 0	vitamin NN 0	K NNP 0	levels NNS B-noun.state	tended VBD B-verb.social	to TO 0	decline VB B-verb.change	in IN 0	subjects NNS B-noun.artifact	taking VBG 0	XENICAL NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d214.s0	[ . 0	Influence NNP B-noun.person	of IN 0	hemantane NN B-noun.person	and CC 0	doxycycline NN B-noun.person	on IN 0	MPTP NNP B-noun.group	- : 0	evoked JJ B-adj.all	behavior NN B-noun.attribute	violations NNS I-noun.attribute	in IN 0	C57BL/6 JJ B-adj.all	mice NNS B-noun.person	] : 0	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d645.s8	Terbinafine JJ B-adj.all	clearance NN B-noun.attribute	is VBZ B-verb.stative	unaffected JJ B-adj.all	by IN 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d189.s9	With IN 0	respect NN B-noun.act	to TO 0	toxicity NN B-noun.attribute	, , 0	the DT 0	order NN B-noun.group	of IN 0	CYP NNP 0	inhibitor NN 0	effectiveness NN 0	was VBD B-verb.stative	ABT NNP 0	> CC 0	diethyldithiocarbamate VB B-verb.change	~ PRP 0	tranylcypromine VB B-verb.cognition	> : 0	ketoconazole NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d209.s11	If IN 0	in IN 0	certain JJ B-adj.all	cases NNS B-noun.state	, , 0	an DT 0	antidepressant NN B-noun.attribute	is VBZ 0	considered VBN B-verb.cognition	necessary JJ B-adj.all	, , 0	it PRP 0	may MD 0	be VB B-verb.stative	advisable JJ B-adj.all	to TO 0	replace VB B-verb.social	tamoxifen VBN I-verb.social	with IN 0	anastrozole NN B-noun.group	. . 0	. . 0
DDI-DrugBank.d753.s2	Anticholinergics NNS B-noun.person	or CC 0	other JJ B-adj.all	medications NNS B-noun.person	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	when WRB 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	opioid_analgesics NNS B-noun.person	may MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	risk NN 0	of IN 0	urinary JJ B-adj.all	retention NN B-noun.act	and/or CC 0	severe JJ B-adj.all	constipation NN B-noun.feeling	, , 0	which WDT 0	may MD 0	lead VB B-verb.cognition	to TO 0	paralytic JJ B-adj.all	ileus NN B-noun.person	. . 0	. . 0
DDI-MedLine.d163.s0	In IN 0	vitro NN B-noun.animal	activity NN B-noun.process	of IN 0	minocycline NN 0	combined VBN B-verb.change	with IN 0	fosfomycin NN 0	against IN 0	clinical JJ B-adj.all	isolates NNS B-noun.time	of IN 0	methicillin NN B-noun.food	- : 0	resistant JJ B-verb.communication	Staphylococcus NNP B-noun.person	aureus NN I-noun.person	. . 0	_ PRP 0	. . 0
DDI-MedLine.d209.s9	It PRP 0	is VBZ B-verb.stative	better JJR B-adj.all	to TO 0	avoid VB B-verb.social	prescribing VBG B-verb.communication	isoenzyme NN B-noun.person	CYP NNP I-noun.person	2D6 CD I-noun.person	inhibitors NNS I-noun.person	to TO 0	women NNS B-noun.person	treated VBN B-verb.social	with IN 0	tamoxifen NNS B-noun.person	for IN 0	breast NN 0	cancer NN B-noun.person	, , 0	especially RB B-adj.all	SSRI_antidepressants NNS B-noun.event	such JJ 0	as IN 0	paroxetine NN B-noun.person	and CC 0	fluoxetine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d679.s0	Preliminary JJ B-adj.all	evidence NN B-noun.communication	suggests VBZ B-verb.communication	that IN 0	cimetidine JJ B-adj.all	inhibits NNS B-noun.attribute	mebendazole JJ B-adj.all	metabolism NN B-noun.attribute	and CC 0	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	mebendazole NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d212.s8	After IN 0	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	colchicine NN B-noun.person	( ( 0	8 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	in IN 0	the DT 0	form NN B-noun.attribute	of IN 0	either CC 0	the DT 0	nanoemulsion NN B-noun.communication	or CC 0	in IN 0	free JJ B-adj.all	colchicine NN B-noun.person	solution NN B-noun.person	, , 0	the DT 0	relative JJ B-adj.pert	bioavailability NN B-noun.cognition	of IN 0	nanoemulsion NN B-noun.person	and CC 0	eugenol NN B-noun.act	- : 0	nanoemulsion NN B-noun.person	were VBD 0	enhanced VBN B-verb.change	by IN 0	about IN 0	1.6- CD 0	and CC 0	2.1-fold JJ B-noun.artifact	, , 0	respectively RB B-adv.all	, , 0	compared VBN B-verb.cognition	with IN 0	free JJ B-noun.person	colchicine NN I-noun.person	solution NN B-noun.person	. . 0	. . 0
DDI-MedLine.d179.s6	Although IN 0	single JJ 0	or CC 0	concurrent JJ B-adj.all	use NN 0	of IN 0	sunitinib NN B-noun.food	and CC 0	docetaxel NN B-noun.person	has VBZ B-verb.possession	some DT 0	anti NNS B-noun.person	- : 0	proliferative JJ B-adj.all	effects NNS B-noun.phenomenon	, , 0	the DT 0	sequential JJ B-adj.all	administrations NNS B-noun.person	of IN 0	both DT 0	drugs NNS B-noun.artifact	remarkably RB B-adv.all	enhanced VBN B-verb.change	anti NNS B-noun.person	- : 0	tumor NN B-noun.animal	activity NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d776.s35	Short JJ B-noun.body	- : 0	acting_Benzodiazepines NNS B-noun.person	, , 0	Following VBG 0	oral JJ B-adj.all	administration NN B-noun.time	of IN 0	midazolam NN B-noun.food	, , 0	fluconazole NN B-noun.person	resulted VBD B-verb.communication	in IN 0	substantial JJ B-adj.all	increases NNS B-noun.event	in IN 0	midazolam NN B-noun.animal	concentrations NNS I-noun.animal	and CC 0	psychomotor NN B-noun.person	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d659.s4	TRENTAL NNP B-noun.group	has VBZ 0	been VBN 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	antihypertensive_drugs NNS B-noun.object	, , 0	beta_blockers NNS B-noun.person	, , 0	digitalis NN B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	antidiabetic_agents NNS B-noun.location	, , 0	and CC 0	antiarrhythmics NNS B-noun.person	, , 0	without IN 0	observed JJ B-adj.all	problems NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d591.s2	In IN 0	vivo NN B-noun.animal	, , 0	the DT 0	plasma NN B-noun.plant	clearance NN B-noun.attribute	of IN 0	ropivacaine NN B-noun.person	was VBD 0	reduced VBN B-verb.change	by IN 0	70 CD B-adj.all	% NN 0	during IN 0	coadministration NN B-noun.person	of IN 0	fluvoxamine NN B-noun.substance	( ( 0	25 CD B-adj.all	mg NN B-noun.quantity	bid NN B-noun.food	for IN 0	2 CD B-adj.all	days NNS B-noun.act	) ) 0	, , 0	a DT 0	selective JJ B-noun.person	and CC 0	potent JJ B-noun.person	CYP1A2 JJ I-noun.person	inhibitor NN I-noun.person	. . 0	. . 0
DDI-DrugBank.d597.s19	Lithium NNP B-noun.person	, , 0	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	NSAIDs NNP B-noun.person	have VBP 0	produced VBN B-verb.creation	an DT 0	elevation NN B-noun.act	of IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	a DT 0	reduction NN B-noun.act	in IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d227.s8	At IN 0	the DT 0	same JJ B-adj.all	time NN B-noun.time	, , 0	the DT 0	locomotor NN B-noun.location	inhibitory JJ B-adj.all	effect NN B-noun.cognition	of IN 0	dexmedetomidine NN B-noun.person	was VBD 0	counteracted VBN B-verb.communication	by IN 0	ephedrine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d600.s1	Concurrent JJ B-adj.all	use NN 0	of IN 0	alcohol NN B-noun.food	and CC 0	other JJ B-adj.all	CNS_depression NN B-noun.act	- : 0	producing_drugs NNS B-noun.time	may MD 0	increase VB B-verb.change	the DT 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	methyprylon NN B-noun.attribute	or CC 0	these DT 0	other JJ 0	medications NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d652.s2	The DT 0	finding NN B-noun.act	that IN 0	metoclopramide NN B-noun.person	releases VBZ B-verb.body	catecholamines NNS B-noun.animal	in IN 0	patients NNS B-noun.person	with IN 0	essential JJ B-adj.all	hypertension NN B-noun.person	suggests VBZ B-verb.communication	that IN 0	it PRP 0	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	, , 0	if IN 0	at IN 0	all DT 0	, , 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	monoamine_oxi NN B-noun.person	- : 0	dase_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d704.s4	Therefore RB 0	, , 0	FLOMAX NNP B-noun.group	capsules NNS B-noun.artifact	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	combination NN 0	with IN 0	cimetidine NN B-noun.person	, , 0	particularly RB B-adv.all	at IN 0	doses NNS B-noun.location	higher JJR B-adj.all	than IN 0	0.4 CD 0	mg NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d611.s0	Other JJ 0	beta_adrenergic_aerosol_bronchodilators NNS 0	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	Alupent NNP B-noun.person	___ NNP I-noun.person	( ( 0	metaproterenol_sulfate JJ B-adj.all	USP NNP B-noun.group	) ) 0	because IN 0	they PRP 0	may MD 0	have VB B-verb.change	additive JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d700.s7	Cholestyramine NN B-noun.person	and CC 0	Drugs NNP B-noun.person	that IN 0	Bind NNP B-noun.group	Bile NNP I-noun.group	Acids NNP I-noun.group	, , 0	These DT 0	drugs NNS B-noun.artifact	interrupt JJ B-adj.all	enterohepatic JJ B-adj.all	recirculation NN B-noun.act	and CC 0	reduce VB B-verb.change	MPA NNP 0	exposure NN B-noun.communication	when WRB 0	coadministered VBN B-verb.communication	with IN 0	mycophenolate_mofetil NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d596.s7	Population NNP B-noun.group	PK NNP 0	analysis NN 0	with IN 0	a DT 0	database NN B-noun.time	of IN 0	625 CD 0	patients NNS B-noun.person	showed VBD B-verb.communication	that IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	rivastigmine NN B-noun.location	were VBD B-verb.stative	not RB B-adv.all	influenced VBN B-verb.communication	by IN 0	commonly RB B-adv.all	prescribed VBN B-verb.communication	medications NNS B-noun.person	such JJ 0	as IN 0	antacids NNS B-noun.person	( ( 0	n=77 NNP 0	) ) 0	, , 0	antihypertensives NNS B-noun.person	( ( 0	n=72 NN 0	) ) 0	, , 0	calcium_channel_blockers NNS B-noun.person	( ( 0	n=75 NN 0	) ) 0	, , 0	antidiabetics NNS B-noun.person	( ( 0	n=21 JJ 0	) ) 0	, , 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_drugs NNS B-noun.cognition	( ( 0	n=79 NN 0	) ) 0	, , 0	estrogens VBZ B-verb.social	( ( 0	n=70 JJ 0	) ) 0	, , 0	salicylate_analgesics NNS B-noun.person	( ( 0	n=177 NNP 0	) ) 0	, , 0	antianginals NNS B-noun.person	( ( 0	n=35 NNP 0	) ) 0	, , 0	and CC 0	antihistamines NNS B-noun.attribute	( ( 0	n=15 NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d710.s1	When WRB 0	a DT 0	single JJ 0	100 CD 0	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	rimantadine_HCl NNP B-noun.person	was VBD 0	administered VBN B-verb.possession	one CD 0	hour NN 0	after IN 0	the DT 0	initiation NN B-noun.act	of IN 0	Cimetidine NNP B-noun.location	( ( 0	300 CD 0	mg IN 0	four CD 0	times NNS B-noun.event	a DT 0	day NN 0	) ) 0	, , 0	the DT 0	apparent JJ B-adj.all	total JJ B-adj.all	rimantadine JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	this DT 0	single JJ B-adj.all	dose NN B-noun.communication	in IN 0	normal JJ B-adj.all	healthy JJ B-adj.all	adults NNS B-noun.location	was VBD 0	reduced VBN B-verb.change	by IN 0	18 CD B-adj.all	% NN 0	( ( 0	compared VBN 0	to TO 0	the DT 0	apparent JJ B-adj.all	total JJ B-adj.all	rimantadine JJ B-adj.all	clearance NN B-noun.attribute	in IN 0	the DT 0	same JJ B-adj.all	subjects NNS B-noun.person	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	cimetidine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d765.s1	For IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ketoconazole NN B-noun.communication	or CC 0	other JJ B-adj.all	potent JJ B-noun.person	CYP3A4 JJ I-noun.person	inhibitors NNS I-noun.person	such JJ 0	as IN 0	other JJ 0	azole_antifungals NNS B-noun.person	( ( 0	eg UH 0	, , 0	itraconazole NN B-noun.person	, , 0	miconazole NN B-noun.location	) ) 0	or CC 0	macrolide_antibiotics NNS B-noun.person	( ( 0	eg UH 0	, , 0	erythromycin NN B-noun.person	, , 0	clarithromycin NN 0	) ) 0	or CC 0	cyclosporine NN B-noun.state	or CC 0	vinblastine NN B-noun.location	, , 0	the DT 0	recommended VBN B-verb.communication	dose NN B-noun.quantity	of IN 0	DETROL_LA NNP B-noun.person	is VBZ B-verb.stative	2 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d773.s1	Patients NNS B-noun.person	studied VBD B-verb.cognition	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.cognition	of IN 0	TNKase NNP B-noun.person	were VBD B-verb.stative	routinely RB B-adv.all	treated VBN B-verb.change	with IN 0	heparin NN B-noun.person	and CC 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d732.s0	CHEMET NNP B-noun.group	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	to TO 0	interact VB B-verb.contact	with IN 0	other JJ 0	drugs NNS B-noun.artifact	including VBG B-verb.change	iron NN B-noun.artifact	supplements NNS B-noun.artifact	, , 0	. . 0
DDI-DrugBank.d776.s39	however RB 0	, , 0	in IN 0	some DT 0	patients NNS B-noun.person	there EX 0	were VBD 0	decreases VBZ B-verb.change	up RP I-verb.change	to TO 0	47 CD 0	% NN 0	and CC 0	33 CD 0	% NN 0	of IN 0	ethinyl_estradiol NN B-noun.food	and CC 0	levonorgestrel NN B-noun.state	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d578.s4	Drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.emotion	hepatic JJ B-adj.all	enzymes NNS B-noun.event	such JJ 0	as IN 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	, , 0	and CC 0	rifampin NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	methylprednisolone NN B-noun.attribute	and CC 0	may MD 0	require VB B-verb.communication	increased VBN B-verb.change	in IN 0	methylprednisolone NN 0	dose NN 0	to TO 0	achieve VB B-verb.social	the DT 0	desired VBN B-verb.emotion	response NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d201.s5	We PRP 0	elucidated VBD B-verb.motion	the DT 0	expression NN B-noun.communication	of IN 0	HB NNP 0	- : 0	EGF NN B-noun.group	in IN 0	T NNP 0	- : 0	ALL DT 0	cell NN B-noun.body	lines NNS B-noun.communication	, , 0	and CC 0	evaluated VBD B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	CRM197 NN B-noun.food	on IN 0	these DT 0	cells NNS B-noun.body	alone RB B-adv.all	or CC 0	in IN 0	combination NN 0	with IN 0	anticancer_agent JJ B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d739.s12	These DT 0	medications NNS B-noun.communication	included VBD B-verb.stative	thyroid_hormones NNS 0	, , 0	sedative_hypnotics NNS B-noun.person	, , 0	non RB 0	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_agents NNS B-noun.person	, , 0	benzodiazepines NNS B-noun.person	, , 0	and CC 0	decongestants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d742.s2	Drugs NNP B-noun.person	Affecting NNP I-noun.person	Hepatic NNP I-noun.person	Metabolism NNP I-noun.person	The DT 0	metabolism NN B-noun.artifact	and CC 0	pharmacokinetics NNS B-noun.person	of IN 0	REMERON_SolTab JJ B-adj.all	___ NN 0	( ( 0	mirtazapine NN 0	) ) 0	Orally NNP B-noun.group	Disintegrating NNP I-noun.group	Tablets NNPS I-noun.group	may MD 0	be VB 0	affected VBN B-verb.change	by IN 0	the DT 0	induction NN B-noun.act	or CC 0	inhibition NN B-noun.attribute	of IN 0	drug NN B-noun.person	- : 0	metab NN B-noun.person	- : 0	olizing JJ B-adj.all	enzymes NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d654.s0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.communication	200 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	increased VBD B-verb.change	retapamulin NN B-noun.communication	geometric JJ B-adj.all	mean JJ B-adj.all	AUC(0 JJ B-noun.group	- : 0	24 CD B-adj.all	) ) 0	and CC 0	Cmax NNP B-noun.person	by IN 0	81 CD 0	% NN 0	after IN 0	topical JJ B-adj.all	application NN B-noun.act	of IN 0	retapamulin NN B-noun.relation	ointment NN I-noun.relation	, , 0	1 CD B-adj.all	% NN 0	on IN 0	the DT 0	abraded JJ B-adj.all	skin NN B-noun.person	of IN 0	healthy JJ B-adj.all	adult NN B-noun.person	males NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d776.s28	Astemizole NNP B-noun.person	, , 0	The DT 0	use NN 0	of IN 0	fluconazole NN B-noun.substance	in IN 0	patients NNS B-noun.person	concurrently RB B-adv.all	taking VBG B-verb.change	astemizole JJ B-adj.all	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	metabolized VBN B-verb.change	by IN 0	the DT 0	cytochrome NN 0	P450 NN 0	system NN B-noun.substance	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	elevations NNS B-noun.person	in IN 0	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d629.s0	Oral JJ B-adj.all	metronidazole NN B-noun.attribute	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	potentiate VB B-verb.communication	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	coumarin NN B-noun.food	and CC 0	warfarin NN B-noun.act	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	prolongation NN B-noun.person	of IN 0	prothrombin NN B-adj.all	time NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d633.s9	When WRB 0	phenytoin NN B-noun.state	or CC 0	other JJ 0	hepatic JJ B-adj.all	enzyme NN B-noun.person	inducers NNS I-noun.person	such JJ 0	as IN 0	rifampin NN B-noun.person	and CC 0	phenobarbital NN B-noun.artifact	have VBP 0	been VBN 0	taken VBN 0	concurrently RB B-adv.all	with IN 0	Mexitil NNP B-noun.person	__ NNP I-noun.person	, , 0	lowered VBD B-verb.motion	Mexitil NNP B-noun.person	___ NNP I-noun.person	plasma NN I-noun.person	levels NNS I-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d589.s0	Concomitant JJ B-adj.all	glucocorticoid NN B-noun.person	therapy NN 0	may MD 0	inhibit VB B-verb.change	the DT 0	response NN B-noun.communication	to TO 0	Geref VB B-verb.change	__ PRP 0	. . 0	There EX 0	was VBD B-verb.stative	no DT 0	evidence NN B-noun.attribute	in IN 0	the DT 0	controlled VBN B-verb.social	studies NNS B-noun.act	of IN 0	Geref NNP B-noun.person	__ NNP I-noun.person	's POS 0	interaction NN B-noun.act	with IN 0	drugs NNS B-noun.artifact	commonly RB B-adv.all	used VBN B-verb.consumption	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	routine JJ B-adj.all	pediatric JJ B-adj.pert	problems NNS B-noun.communication	/ : 0	illnesses NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d604.s0	Thalidomide IN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	enhance VB B-verb.change	the DT 0	sedative JJ B-adj.all	activity NN B-noun.process	of IN 0	barbiturates NNS B-noun.location	, , 0	alcohol NN B-noun.person	, , 0	chlorpromazine NN 0	, , 0	and CC 0	reserpine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d737.s7	CYP NNP B-noun.person	interactions NNS I-noun.person	, , 0	Inhibitors NNP B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 NN I-noun.person	enzymes NNS B-noun.person	would MD 0	not RB B-adv.all	be VB 0	expected VBN B-verb.cognition	to TO 0	affect VB B-verb.change	pramipexole JJ B-adj.all	elimination NN B-noun.act	because IN 0	pramipexole NN B-noun.communication	is VBZ B-verb.stative	not RB B-adv.all	appreciably RB B-adv.all	metabolized VBN B-verb.change	by IN 0	these DT 0	enzymes NNS B-noun.act	in IN 0	vivo NN B-noun.animal	or CC 0	in IN 0	vitro NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d596.s8	Use NN 0	with IN 0	Anticholinergics NNPS B-noun.person	, , 0	Because IN 0	of IN 0	their PRP$ 0	mechanism NN B-noun.attribute	of IN 0	action NN B-noun.person	, , 0	cholinesterase_inhibitors NNS B-noun.person	have VBP B-verb.stative	the DT 0	potential NN B-noun.person	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	activity NN B-noun.process	of IN 0	anticholinergic_medications NNS B-noun.object	. . 0	. . 0
DDI-MedLine.d227.s9	We PRP 0	concluded VBD B-verb.cognition	that IN 0	the DT 0	combined VBN B-verb.change	administration NN B-noun.time	of IN 0	dexmedetomidine NN B-noun.person	with IN 0	ephedrine NN B-noun.person	may MD 0	have VB B-verb.stative	beneficial JJ B-adj.all	effects NNS B-noun.phenomenon	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	pain NN B-noun.person	without IN 0	causing VBG B-verb.creation	sedation NN B-noun.act	, , 0	which WDT 0	limits VBZ B-verb.change	the DT 0	use NN 0	of IN 0	dexmedetomidine NN B-noun.act	as IN 0	an DT 0	analgesic NN B-noun.person	in IN 0	humans NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d641.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	substances NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	also RB B-adv.all	tubularly RB B-adv.all	secreted VBN B-verb.contact	( ( 0	e.g. UH 0	, , 0	probenecid NN 0	) ) 0	could MD 0	potentially RB B-adv.all	result VB B-verb.stative	in IN 0	delayed JJ B-adj.all	clearance NN B-noun.person	of IN 0	ALIMTA NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d776.s31	Rifabutin NNP B-noun.person	, , 0	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	uveitis NN B-noun.food	in IN 0	patients NNS B-noun.person	to TO 0	whom WP 0	fluconazole NN B-noun.person	and CC 0	rifabutin NN B-noun.person	were VBD 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d634.s0	Anticoagulants NNS B-noun.person	( ( 0	oral JJ 0	) ) 0	, , 0	The DT 0	activity NN B-noun.process	of IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.object	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	anti NNS B-noun.person	- : 0	vitamin NN B-noun.person	- : 0	K NN 0	activity NN 0	attributed VBD B-verb.stative	to TO 0	methimazole NN B-noun.attribute	. . 0	___ NNP B-noun.person	. . 0
DDI-DrugBank.d680.s5	There EX 0	have VBP 0	been VBN 0	postmarketing VBG B-verb.communication	reports NNS B-noun.communication	of IN 0	increased VBN B-verb.change	INR NNP 0	and CC 0	prothrombin NN B-noun.person	time NN B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	proton_pump_inhibitors NNS B-noun.person	, , 0	including VBG B-verb.change	pantoprazole NN B-noun.communication	, , 0	and CC 0	warfarin NN B-noun.location	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d627.s0	Pilocarpine NN B-noun.person	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	beta_adrenergic_antagonists NNS B-noun.act	because IN 0	of IN 0	the DT 0	possibility NN B-noun.state	of IN 0	conduction NN B-noun.act	disturbances NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d161.s9	Our PRP$ 0	data NNS B-noun.cognition	demonstrate VBP B-verb.communication	that IN 0	chronic JJ B-adj.all	treatment NN B-noun.plant	with IN 0	the DT 0	metabotropic NN B-noun.attribute	glutamate NN I-noun.attribute	receptor NN B-noun.communication	5 CD B-adj.all	antagonist NN B-noun.person	, , 0	3-[(2-methyl-1,3-thiazol-4-yl)_ethynyl]_pyridine JJ 0	, , 0	significantly RB B-adv.all	reduces VBZ B-verb.change	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine JJ B-adj.all	toxicity NN B-noun.attribute	towards IN 0	dopaminergic NN B-noun.act	and CC 0	noradrenergic JJ B-adj.all	cell NN B-noun.body	groups NNS B-noun.group	in IN 0	non NN B-noun.person	- : 0	human JJ B-adj.all	primates NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d189.s8	Of IN 0	the DT 0	isoform NN B-noun.attribute	- : 0	specific JJ B-adj.all	CYP NNP B-noun.group	inhibitors NNS B-noun.person	tested VBN B-verb.social	for IN 0	an DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	precocene_I JJ B-adj.all	metabolite NN B-noun.attribute	profile NN B-noun.quantity	, , 0	only RB B-adv.all	tranylcypromine NN B-noun.act	was VBD B-verb.stative	noticeably RB B-adv.all	effective JJ B-adj.all	, , 0	indicating VBG B-verb.communication	a DT 0	role NN B-noun.attribute	of IN 0	CYPs NNP B-noun.person	2A6 NNP I-noun.person	, , 0	2C9 NNP B-noun.person	, , 0	2Cl9 NNP B-noun.person	, , 0	and CC 0	2E1 NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d214.s5	Acute NNP B-noun.person	administration NN I-noun.phenomenon	of IN 0	hemantane NN B-noun.state	or CC 0	doxycycline NN B-noun.person	failed VBD B-verb.social	to TO 0	influence VB B-verb.emotion	locomotion NN I-verb.emotion	in IN 0	mice NNS B-noun.animal	, , 0	while IN 0	their PRP$ 0	combination NN B-noun.event	normalized JJ B-adj.all	motor NN B-noun.person	activity NN B-noun.process	. . 0	. . 0
DDI-MedLine.d231.s0	Interaction NNP B-noun.act	study NN B-noun.artifact	of IN 0	moxifloxacin NN B-noun.person	and CC 0	lomefloxacin NN B-noun.person	with IN 0	co SYM 0	- : 0	administered VBN B-verb.possession	drugs NNS B-noun.artifact	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d591.s5	Possible JJ B-adj.all	interactions NNS B-noun.motive	with IN 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	be VB 0	metabolized VBN B-verb.cognition	by IN 0	CYP1A2 JJ 0	via IN 0	competitive JJ B-adj.all	inhibition NN B-noun.attribute	such JJ 0	as IN 0	theophylline PRP 0	and CC 0	imipramine NN B-noun.act	may MD 0	also RB 0	occur VBP B-verb.stative	. . 0	. . 0
DDI-DrugBank.d776.s38	Fluconazole JJ B-adj.all	tablets NNS B-noun.artifact	coadministered VBN B-verb.contact	with IN 0	ethinyl_estradiol- JJ 0	and CC 0	levonorgestrel NN B-noun.attribute	- : 0	containing VBG B-verb.stative	oral JJ B-adj.all	contraceptives NNS B-noun.person	produced VBD B-verb.creation	an DT 0	overall JJ B-adj.all	mean JJ B-adj.all	increase NN B-noun.event	in IN 0	ethinyl_estradiol NN 0	and CC 0	levonorgestrel NN B-noun.state	levels NNS B-noun.state	, , 0	. . 0
DDI-DrugBank.d573.s0	Interaction NN 0	with IN 0	Guanethidine NNP B-noun.person	, , 0	Although IN 0	minoxidil NN B-noun.time	does VBZ 0	not RB B-verb.change	itself PRP 0	cause VB B-verb.creation	orthostatic JJ B-adj.all	hypotension NN B-noun.act	, , 0	its PRP$ 0	administration NN B-noun.time	to TO 0	patients NNS B-noun.person	already RB B-adv.all	receiving VBG B-verb.communication	guanethidine NN B-noun.person	can MD 0	result VB B-verb.stative	in IN 0	profound JJ B-adj.all	orthostatic JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
